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The information available on in vitro release testing for controlled release parenteral 
formulations is limited. Thus investigating the effect of different media components 
and hydrodynamic setups in order to develop an in vitro release test that could predict 
the in vivo performance of parenteral formulations is needed. 
The aim of this thesis was to develop an in vitro release test that coupled with in silico 
modeling could predict the in vivo release of a parenteral drug formulation 
administered intravenously [using Amphotericin B liposomal formulation 
(Ambisome®) as formulation model)]. Amphotericin B is a poorly soluble and highly 
protein bound drug, therefore the effect of albumin on Amphotericin B solubility, 
degradation and microbiological activity was investigated. Biorelevant and clinically 
relevant media were developed and used with two hydrodynamics setups for the in 
vitro release testing of Ambisome®. Compartmental pharmacokinetic (PK) and 
physiologically-based pharmacokinetic (PBPK) modeling were performed in data 
from healthy subjects receiving Ambisome® in order to relate the in vitro release 
profiles to the in vivo release profile. The PBPK model was extrapolated to a 
hypoalbuminaemic population and used to evaluate the antifungal effect of 
Amphotericin B on Candida albicans. Albumin was of high importance in the test 
media as it increases the solubility and degradation rate of Amphotericin B, while it 
decreases its microbiological activity. In vitro release tests in biorelevant media with 
the sample and separate setup was successful to predict in vivo AmB release, assessed 
with the use of PK modeling. Prediction of the AmB liposomal and released plasma 
concentrations was achieved with the development of a PBPK model in which the in 
vitro release profiles in the developed media (clinically relevant media with 
biorelevant surfactants) were used. In the simulated hypoalbuminaemic population, 
the PBPK/PD model developed revealed that the microbiological activity of 
Amphotericin B was increased due to a decrease in albumin concentration (leading to 
more drug available to exert a pharmacological effect).  
This thesis provides an overview of how relevant media components and 
hydrodynamics affect the release of drug from an intravenously administered 
parenteral formulation and linked with either PK or PBPK modeling could predict the 
in vivo behaviour of the formulation and the released drug. This could be a starting 
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Aims and Objectives 
The general aim of this thesis is to develop clinically relevant in vitro release tests for 
parenteral formulations (using Ambisome®, a liposomal formulation of Amphotericin 
B, as formulation model) by investigating how medium components and 
hydrodynamics affect the release of the drug from the formulation and by using PK 
and PBPK modeling to establish the relationship with the in vivo data and how this 
modeling could be applied to predict the antifungal activity of the drug (PBPK/PD). 
The specific objectives of each chapter are: 
Chapter 1: A general overview of the current experimental setups for in vitro release 
testing for parenteral formulations, media proposed, physiological conditions that 
could be simulated in an in vitro test and the challenges to simulate these conditions. 
The limited information for the development of in vitro release tests for parenteral 
formulations are described. 
Chapter 2: The aim of this chapter was to investigate the solubility, degradation rate, 
dissolution and antifungal activity of Amphotericin B in simulated plasma with 
albumin concentrations representing healthy subjects and hypoalbuminaemic patients, 
and to develop a mathematical model to describe and simulate all the processes 
involved in AmB dissolution, in order to be the basis for the development of 
biorelevant dissolution testing of Amphotericin B formulations. 
Chapter 3: The aim of this chapter was to investigate the impact of different media 
components on the solubility of Amphotericin B in order to develop media where the 
AmB plasma solubility (clinically relevant solubility) could be matched and to 
evaluate the media developed for their suitability for compendial and clinically 
relevant in vitro release testing for parenterals.  
Chapter 4: The aims of this chapter were to investigate how synthetic surfactants, 
type of buffer and protein content (albumin concentration) along with hydrodynamics, 
affect the release of Amphotericin B from Ambisome® liposomes and how the in vitro 
release profiles, coupled with compartmental pharmacokinetic modeling can be used 
to predict the release from Ambisome® in vivo. 
Chapter 5: The aims of this chapter were: i. to investigate how the presence of 
albumin in clinically relevant media containing physiological surfactants (bile salts – 
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phospholipids), combined with biorelevant hydrodynamics, impact on the release of 
Amphotericin B from Ambisome®, and ii to link the in vitro release tests and with a 
novel PBPK model, in order to guide the development of a biopredictive release test 
for the liposomal Amphotericin B formulation Ambisome®. The extrapolation of the 
PBPK model to a hypoalbuminaemic population to build a PBPK/pharmacodynamics 





Chapter 1. In vitro release testing for parenteral 
formulations: current state and challenges 
Abstract 
In vitro release testing is commonly used for quality control purposes. Biorelevant in 
vitro release testing in which the in vivo conditions are simulated could assist 
formulation development and prediction of in vivo performance. For controlled release 
parenterals, the information is limited. There are different types of parenteral 
formulations which are mainly administered intravascularly, intramuscularly and 
subcutaneously. Three categories of in vitro release testing have been reported in the 
literature for parenterals but there are only few compendial release methods. 
Biorelevant release testing coupled with mathematical modeling of in vitro release 
profiles and observed in vivo data could be used to establish a correlation between the 
in vitro and in vivo release. The aim of this chapter is to describe the current state of 
release testing for controlled release parenteral formulations, the characteristics to be 
incorporated in the in vitro tests in order to improve their biorelevance and the use of 
mathematical modeling in the development of correlations and relations between the 






In vitro release testing is conducted to ensure adequate performance of controlled 
release parenteral formulations (parenterals) (Table 1.1). In vitro release tests used for 
quality control will not necessarily reflect the performance of parenterals in vivo as 
many of these tests do not attempt to simulate in vivo conditions. The in vitro release 
could be associated with the in vivo release in order to find a relationship between 
them. An in vitro in vivo correlation/relation (IVIVC/IVIVR) is a tool that can relate 
an in vitro parameter (e.g. percent released) to an in vivo parameter (e.g. area under 
the curve, maximum plasma concentration). Having a meaningful in vitro release test 
or an IVIVC/IVIVR could lead to faster development of new parenterals and reduce 
animal and human studies. This chapter will focus on describing the methods that have 
been used to assess the release of parenterals, the physiological characteristics of main 
parenteral administration routes (intravenous, intramuscular, subcutaneous and drug-
eluting stents) and the use of mathematical modeling on the development of IVIVC/ 
IVIVR. 
Table 1.1. Parenteral formulations used in therapeutics [1-3]. 
Formulation Description 
Microspheres Polymeric spherical particles in the micron size range. Drug 
can be entrapped in these particles either in the form of 
microcapsules with a polymer coating surrounding a drug 
core or in the form of micromatrices with the drug dispersed 
throughout the polymer. 
Nanoparticles Submicron-sized particles (3-200 nm), devices or systems 
that can be made using a variety of materials including 
polymers, lipids and even organometallic compounds. 
Liposomes Liposomes consist of one or more phospholipid bilayers with 
an enclosed aqueous phase.  
Emulsions Emulsions are formed by mixing of two or more immiscible 
liquids with limited mutual solubility; mixing is performed 
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via high energy conditions such as via ultra-sonication, 
homogenization, or micro fluidization. 
Hydrogels Aqueous gels 
Dendrimers Dendrimers are synthetic highly branched polymers with a 
central core with sizes in the nanometre range. i.e. VivaGel®. 
(astodrimer sodium) 
Drug Eluting Stents Devices designed to be implanted into the human body. 
Typically, a stent consists of a tubular mesh structure onto 
which the drug is deposited (eg. by polymer coating). 
 
1.2. In vitro release testing for parenterals: current state 
1.2.1. Release media 
Usually, the release medium is selected according to the solubility, stability and ease 
of assay of the drug analysed [4]. Currently, the release medium used for in vitro 
release testing is phosphate buffered saline (PBS) [5]. This medium just simulates 
plasma's pH and the osmolality.  
1.2.2. Release testing apparatus and operational conditions 
For parenteral formulations, there are three main methods that have been extensively 
reviewed in the literature [3, 4, 6-8]: 
 Dialysis 
 Continuous flow 
 Sample and separate 
Dialysis method (Figure 1.1): The sample (donor) is separated from the release 
medium (receptor) by a permeable membrane with an adequate molecular weight cut 
off (MWCO) that allows the drug to move freely until the concentrations of the donor 
and the receptor are equilibrated. Normal, reverse or side-by-side dialysis can be used 
[4, 8]. The sampling does not interfere with the formulation but particles might 
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aggregate, the released drug can be bound to the membrane and diffusion through the 
membrane may be a limiting factor for drug release [4, 6, 7]. 
 
Figure 1.1. Dialysis method to assess the in vitro release for parenteral formulations.  
 
Continuous flow (CF) method (Figure 1.2): A pump is used to induce release medium 
flow through a cell where the formulation is placed mixed within glass beads or 
immobilized with a special device. An appropriate pore size filter is used to prevent 
the escape of the formulation but filter clogging can be problematic [4]. The flow rate 
can be set depending on the kind of pump (e.g. peristaltic or piston pump). Samples 
can be taken from the release medium without interfering with the formulation [7] and 




Figure 1.2. Continuous flow method to assess the in vitro release for parenteral 
formulations.  
 
Sample and separate (SS) method (Figure 1.3): The formulation is placed in a 
container with the release medium at constant temperature with stirring or shaking. 
Samples are taken from the release medium and volume replacement can be made 
(when needed). During sampling, formulation is removed and samples are either 
filtered or centrifuged to separate the released drug from the formulation. The 
separation technique of the released drug should be investigated rigorously as some 
formulations may not sediment even with long ultracentrifugation times, and if the 
separation of released drug from the formulation is not performed quickly, a 
representative release profile cannot be obtained [6, 8, 9]. The test can be performed 
in a vial or in the paddle or basket apparatus, depending on the volume of the medium 





Figure 1.3. Sample and separate method to assess the in vitro release for parenteral 
formulations.  
 
For liposomes, the reverse dialysis has been recommended and for polymer 
nanoparticles the continuous flow method has been suggested due to possible 
aggregation with the SS method [7].  
Table 1.2 shows a list with the dissolution tests for parenteral formulations presented 
in 2015 by Cardot et al. [10] updated with the additions made by the FDA until January 
2019 [11]. 
 
Table 1.2. Dissolution methods published by the FDA for parenteral formulations 







USP 4 apparatus, 0.05% SLS pH 3.0, 





Test 1: USP 4 apparatus, 0.5 % SLS in 
water and  
Test 2: USP 2 apparatus, 0.35 % SLS in 







USP 4 apparatus, 0.55 % SLS, sampling 





USP 2 apparatus, 0.489% (w/v) 
Polysorbate 20 in 0.001 N HCl at 25.0°C, 
sampling times are indicated 
triptorelin palmoate Injectable 
suspension 
USP 2 apparatus, water-methanol (95:5); 
reconstitute vial in 2 mL water for 
Injection, add to 500 mL medium at 
37°C, sampling times are indicated 
aripiprazole Injectable 
suspension 
UPS 2 apparatus, 0.25% SDS, sampling 
times are indicated 
ciprofloxacin Otic injectable 
suspension 
USP 4 apparatus, 50 mM Acetate Buffer, 
pH 4.5 at 37°C [use glass beads; sample 
volume: 100 μL ], sampling times are 
indicated 
dantrolene sodium intravenous 
suspension 
USP 2 apparatus, 0.5% Benzalkonium 
Chloride in water, sampling times are 
indicated 
olanzapine pamoate intramuscular 
suspension 
USP 4 apparatus, 1% SLS in pH 6.8 






USP 2 apparatus, 0.3% SLS in 10 mM 
phosphate buffer, pH 7.2 + 0.02% 
sodium azide at 35°C 
leuprolide acetate Extended 
release 
injectable 










USP 2 or USP 4 apparatus are suggested 
naltrexone injectable 
suspension 
USP 2 or USP 4 apparatus are suggested. 
Phosphate buffered saline with 0.02% 
Tween 20 and 0.02% Sodium azide, pH 
7.4 (final osmolality should be 270 ± 20 
mOsm), or any other appropriate 
medium, at 37°C. The development of a 
release test is required. 
doxorubicin liposomes USP 2 or USP 4 apparatus are suggested. 
Develop a release medium starting at pH 
6.00 ± 0.05 and at 47ºC ± 0.5ºC. The 
development of a release test is required. 
azacitidine injectable 
suspension 




The development of a release test is 
required. 
















In terms of regulatory aspects for the assessment of release from parenteral 
formulations, the FDA has published two draft guidances on a) liposomal drug 
products [12] and b) drug products that contain nanomaterials [13]. Regarding the in 
vitro release testing for liposomal drug products, the following statement is made: "In 
vitro release of the drug substance from the liposome drug product under the 
stated/described experimental conditions with supportive data and information 
regarding the choice of those conditions" [12]. For assessment of the in vitro release 
of drug products with nanomaterials, the draft guidance states: "Detailed descriptions 
of the proposed dissolution/in vitro release test and the developmental parameters 
(selection of equipment/apparatus, media, agitation/rotation speed, pH, sink 
conditions, surfactant type and concentration) should be included in the submission" 
[13]. Recently (November 2018) an article on in vitro release tests for parenteral 
formulations was published [14]. In general, the compendial paddle [United States 
Pharmacopea (USP) apparatus 2] or the flow through cell apparatus (USP apparatus 
4) are recommended for the in vitro release testing of parenterals. The use of dialysis 
is also recommended for nanosuspensions, liposomes and microspheres. A release 
medium with physiological pH (7.4) and osmolality (275-300 mOsm/L) values is 
recommended. A surfactant or an organic solvent may be used in order to increase the 
solubility of the drug or to accelerate the release. For drug release from liposomal 
formulations the in vitro release tests should discriminate between different 
formulations and the in vivo conditions should be simulated to establish an IVIVC. 
The in vitro release for implants and drug eluting stents can be also assessed in the 
USP apparatus 7 [14]. 
1.3. Towards the development of biorelevant release testing for parenterals 
Understanding the factors affecting release enables identification of relevant 
characteristics of the in vivo environment for drug release as one of the goals for an in 
vitro release test is to predict the in vivo performance. In vivo critical factors affecting 
the release of the drug from the parenteral formulation should be identified for 
simulation in the in vitro release test in order to predict the in vivo performance [14, 
15]. Biorelevant release testing takes into consideration the hydrodynamics at the site 
of administration and the composition of the medium where drug will be released from 
the formulation [16]. 
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1.3.1. Release media 
1.3.1.1. Intravenous administration 
For intravenously administered parenterals, the relevant body fluid is plasma. Plasma 
contains ions, biomolecules and proteins (albumin, globulins and fibrinogen) [17], 
with albumin being the most relevant protein in terms of drug administration as it is 
able to bind acidic and lipophilic drugs [18]. Plasma albumin concentration in a 
healthy subject is 4 g/dL [19]. α1 acid glycoprotein is another plasma protein which 
can bind basic and neutral lipophilic drugs and its concentration in plasma is 0.1 g/dL 
[20]. These plasma components should be taken into account to develop a biorelevant 
release medium for intravenously administered parenterals. The composition of media 
attempting to simulate human plasma published in the literature is presented in Table 
1.2. 
Table 1.3. Composition of human plasma, Krebs Ringer buffer and simulated human 
plasma. 
Ion Concentration (mM) 




buffer [22, 23] 
HCO3
- 24.80 27.00 14.99 
K+ 4.60 5.00 4.56 
Cl- 99.00 103.00 127.32 
Na+ 150.00 142.00 136.17 
Ca2+ 4.70 2.50 1.00 
Mg2+ 1.60 1.50 0.49 
Inorganic phosphorus 1.51 1.00 2.00 
D-Glucose 5.6.0 - 10.00 
SO4





- 50.00 - 
HCl - 45.00 - 
Osmolality (mOsm/L) 289.00 - 285.00 
Viscosity 4.00 cP at 22°C, 
1.40 cP at 37°C 
[24] 
- - 
pH 7.40 7.25 7.30 – 7.40 
 
Simulated human plasma and Krebs – Ringer buffer take into account only the ionic 
components of plasma but the protein content is not considered. Performing release 
tests with simulated human plasma or Krebs Ringer buffer for a poorly soluble highly 
protein-bound drug could lead to an underestimation of the drug release. It has been 
reported that an increasing concentration of albumin increases itraconazole solubility 
[25] and the same trend was found for dicumarol [26]. Presence of albumin has been 
suggested in some simulated body fluids (i.e. simulated vaginal fluid, simulated semen 
solution [21], simulated uterine fluid [27]).  
1.3.1.2. Drug eluting stents 
Drug eluting stents are placed into coronary arteries to prevent re-occlusion, and the 
released drug has to exert a pharmacological action in the region where the stent has 
been implanted (local action) [28]. Alginate hydrogels and long term stable hydrogels 
have been employed in in vitro release testing to provide a matrix similar to the tissue 
present in the implantation site [3, 28]. 
1.3.1.3. Intramuscular and subcutaneous administration 
For these types of administration, the interstitial fluid (the liquid surrounding the 
tissue's cells), is the medium of interest. This fluid permeates from blood to muscle 
and the subctaneous enviroment and its composition has been measured indirectly 
from plasma, as it can be considered as a plasma ultrafiltrate (Table 1.3) [29]. A 
biorelevant release medium for both intramuscular and subcutaneous administration 
has not yet been developed. Simulated body fluid (SBF) has been employed to test the 
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activity of biomaterials to bind to bones [30] and its ionic composition is similar to 
interstitial fluid (Table 1.3), thus, it could be a good option to use for in vitro release 
tests for parenterals administered intramuscularly or subcutaneously.  
 
Table 1.4. Composition of interstitial fluid found in the human body and simulated 
body fluid used for bond binding tests. 
Ion 
Interstitial fluid [29] Simulated body fluid [30] 
Concentration (mM) 
Total calcium 1.6 2.7 
Total magnesium 0.7 1.5 
Total sodium 134.6 142.7 
Total potassium 3.2 5 
Total CO2 23.9 4.2 
Phosphate 0.6 1.0 
Albumin 0.2 (12.5 g/L) - 
Sulphate - 0.5 





1.3.2. Biorelevant hydrodynamics 
1.3.2.1. Intravenous administration and drug eluting stents 
The characteristics of the hydrodynamics in the bloodstream should be simulated to 
the in vitro release test. The cardiac output is approximately 5000 mL/min [31] and 
the flow rates present in the human body could seem too large and too diverse to be 
incorporated into a release test. The average linear velocities of blood in some blood 
vessels are 40 cm/s for the aorta, 15 cm/s for the vena cavae, 0.03 cm/s for capillaries 
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[32], 19 cm/s for arteries and 7.8 cm/s for veins [33]. The maximum flow rate that a 
flow through cell apparatus piston pump can achieve is 50 mL/min. If linear velocities 
are considered, utilizing a setup with the small cell (diameter = 12 mm) of the flow 
through cell apparatus and a flow rate of 50 mL/min, the linear velocity would be 0.74 
cm/s, which would only be enough to match the linear velocity in the capillaries; if the 
same setup is used to simulate aorta's linear velocity, a flow rate of 2700 mL/min 
would be needed. If the flow rate of blood vessels is considered, then the flow rate for 
arteries would be 26 mL/min, for veins 4.8 mL/min [33] and for the coronary artery 
35 mL/min [34], which could be simulated with the flow through cell apparatus' piston 
pump.  
Simulating the in vivo flow rate or linear velocity of plasma in the circulatory system 
might be important for drug eluting stents as they are immobilized and plasma passes 
through them at certain flow rate/linear velocity. For in vitro drug release testing from 
stents, a flow through cell was filled with hydrogel leaving an empty space in the 
centre where the stent was placed and the release medium was propelled by a 
peristaltic pump at a flow rate of 35 mL/min to simulate the coronary artery flow rate 
[3].  
For the administration of liposomes intravenously, the particles move with the fluid, 
provided adequate suspension and mixing of particles i.e. there is no static pool where 
particles aggregate and sediment, as this should not happen in vivo after intravenous 
administration. Hydrodynamic conditions need to facilitate dispersion of moving 
particles as it happens in vivo. The flow through cell apparatus could be adapted in 
order to allow free movement of particles in the whole setup of a flow through cell 
apparatus closed system but losing the advantages of having the particles trapped in a 
cell. 
1.3.2.2. Intramuscular and subcutaneous administration  
For intramuscular and subcutaneous administration, after the release from the 
formulation, the drug needs to travel to the bloodstream. There are theoretical critical 
steps before the absorption of drugs from intramuscular formulations and the relevant 
hydrodynamics are: the diffusion of water to the depot (site of injection), the diffusion 
away from the depot and the distance to the blood vessels and the blood flow [35].  
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The rate of fluid exchange between blood and the interstitium is influenced by the 
"Starling forces" (Equation 1.1): 
𝐽𝑣 =  𝐾𝑓[(𝑃𝑣 − 𝑃𝑡) − 𝜎 (𝜋𝑝 − 𝜋𝑡)] (Eq 1.1) [36, 37] 
where 𝐽𝑣 is the fluid exchange rate, 𝑃𝑣 and 𝑃𝑡 are the intravascular and tissue fluid 
hydrostatic pressures, respectively; 𝜋𝑝 and 𝜋𝑡 are the plasma and interstitial fluid 
colloid osmotic pressures, respectively; 𝐾𝑓 is the filtration coefficient that describes 
the hydraulic permeability of the barrier (permeability to bulk flow of water) and σ is 
the reflection coefficient for plasma proteins. σ could take values from 1 (a totally 
impermeable barrier) and 0 (a barrier that does not offer restriction to the protein 
movement). The Starling force balance and the local barrier permeability to water and 
protein dictate fluid exchange [36, 37]. Starling force calculations provide the rate of 
fluid entering into the administration site and a suitable flow rate or equivalent 
hydrodynamics should be incorporated to the in vitro release test or in a mathematical 
model. In addition, the hydrodynamics of blood passing through the muscles and skin 
should be considered in the biorelevant in vitro release testing development.  
For muscles, the blood flow rate would depend on their activity state (rest or active). 
The oxygen requirements in the resting state are low and thus blood flow rate ranges 
between 5 and 10 mL/min/100 g, while in the active state the blood flow rate reaches 
up to 80–100 mL/min/100 g as the demand for oxygen and substrates augments [38]. 
For subcutaneous formulations, the normal blood flow in skin ranges from 1.5 to 2.5 
mL/ 100 g/min, with the nocturnal period and change in posture increasing blood flow 
up to 200% and 30-40%, respectively [39]. The release and the absorption of drugs in 
the subcutaneous space are similar to those observed in the intramuscular space, 
involving the blood flow to the zone of administration, the drainage by the lymph and 
the distance to blood vessels [40].  
Other factors affecting the rate and the extent of absorption from intramuscular 
formulations, are the site that the formulation is administered (with higher absorption 
on the deltoids compared to the gluteus [41]), and the depth of the injection (as the 
needle needs to penetrate and reach the muscle, otherwise the administration would be 
in the adipose tissue [35]). In women, drug absorption from intramuscular 
formulations administered in the gluteus is slower than in men, as the adipose tissue 
layer in the gluteus is thicker in women, making gender a factor to take into account 
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for the development of in vitro release/dissolution tests for intramuscular administered 
formulations [35, 42]. All of these factors should be taken into account for the 
development of a biorelevant release test for a formulation intended for intramuscular 
administration and for the design of the in vivo study.  
To develop a release test for subcutaneous and intramuscular formulations, the same 
parameters should be considered. The CF methods could be used in this case as the 
flow through cell apparatus pump (piston or peristaltic pump) can provide a 10 
mL/min flow. Furthermore the dialysis method could be used, as the retention of the 
formulation in the dialysis bag could be exploited to mimic retention in muscle or 
subcutaneous tissue.  
1.3.3. Challenges for the development of biorelevant release testing for 
parenterals 
Some in vivo physiological processes might be difficult to incorporate into a 
biorelevant in vitro release test.  
For subcutaneous and intramuscular administration of parenteral formulations (Figure 
1.4a), there are two possible processes occurring simultaneously in the site of 
administration with the release of the drug. One is the degradation of the drug and the 




Figure 1.4. In vivo processes after administration of parenterals. a) Intramuscular and 




For intravenous formulations (Figure 1.4b) the situation could be more complex. The 
formulation is administered to the bloodstream and simultaneously, the release of the 
drug and the distribution and elimination of the formulation (through urine or feces) 
are taking place. If the formulation consists of particles (liposomes), these will be 
removed from the circulation by the Mononuclear Phagocytic System (MPS). Cells 
cannot identify particles alone but they can recognize proteins bound to their surface 
by van der Waals, electrostatic, ionic, hydrophobic and hydrophilic forces [43]. Owens 
et al define opsonization as the process by which a foreign organism or particle 
becomes covered with opsonin proteins, thereby making it more visible to phagocytic 
cells [43]. Circulating opsonins include: IgG, IgM, complement fragments (C3, C5), 
fibronectin, laminin [44], α2-macroglobulin, apolipoprotein H (β2-glycoprotein I) and 
E [45], C-reactive protein, type I collagene [43] and albumin that can act either as an 
opsonin [46] or as a disopsonin (the opposite of an opsonin) [47, 48]. However, this 
needs to be addressed carefully as it was found for poly (lactic-co-glycolic acid) 
microparticles that the degradation of the particles was twice as fast in vivo than in 
vitro, due to the immune response [49]. 
It would be difficult to incorporate into an in vitro test the inflammation process at the 
site of administration that will affect the release from formulations. Options could 
include a mechanism of simultaneous release and removal of the formulation (possibly 
only feasible in sample and separate setup for intravenous administered formulations) 
in case that the immune response is relevant (stealth liposomes are less likely to be 
subject to removal by the immune system). In this case, the in vivo immune removal 
rate would be required but it is difficult to be estimated. It was believed that the 
immune response was only responsible for encapsulating the formulations and 
preventing drug release but new evidence has shown that cellular infiltration augments 
drug release [15, 29].  
In the case of subcutaneous administration, the absorption of the drug is related to the 
molecular weight. Data from a goat model showed that small molecules are absorbed 
through the blood capillaries and large macromolecules through the lymph [50]. 
Studies performed in rats showed that molecules as large as albumin can be absorbed 
through blood capillaries [42]. 
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Drug eluting stents (Figure 1.4c) are implanted in people diagnosed with 
arteriosclerotic disease. In the vessel wall, there will be deposition of lipids, cells of 
the immune system and calcification. The vessel is likely to be damaged during the 
implantation of the stent which may result in more inflammation and in a large 
modification of a normal vessel wall leading to a decrease in the absorption of drug 
[9]. The endothelial changes, affecting the absorption of drug from the stent would be 
difficult to simulate in an in vitro test. 
1.4. Prediction of in vivo performance of parenterals 
An IVIVC establishes the relationship between an in vitro parameter and an in vivo 
response after the administration of a formulation [51]. The FDA defines an IVIVC as 
a predictive mathematical model describing the relationship between an in-vitro 
property of a dosage form and an in-vivo response [52]. Generally, the in vitro property 
is the rate or the endpoint of dissolution and the in vivo response is the concentration 
or the amount of drug in plasma as a function of time [53]. According to the FDA, an 
IVIVC must be able to predict the in vivo behaviour accurately and consistently [52]. 
The EMA has a similar section for IVIVC in the document "Guideline on quality of 
oral modified release products" [54]. There are successful cases for IVIVC of oral 
dosage forms that utilize biorelevant media to simulate the physiological fluids of the 
gastrointestinal tract (GI tract) and the hydrodynamics that can be provided by the 
paddle apparatus [55], the flow through cell apparatus [56] or special setups that can 
simulate more closely the hydrodynamics of the GI tract [57]. This is translated into 
faster development processes and cost reductions. Although these guidelines and 
definitions were set for extended release oral dosage forms, they can be extrapolated 
to parenteral formulations. The widespread use and development of IVIVC has not 
been accomplished yet for parenteral formulations and examples are limited. The FDA 
mentions IVIVC in its draft guidance for liposomal products stating: "Although few 
examples exist, we encourage you to establish an IVIVC for the liposome product. 
Some IVIVRs may be established even if a complete IVIVC is not feasible" [12] 






1.4.1. IVIVC examples of parenteral formulations 
Studies aiming to establish an IVIVC for parenteral formulations are presented in 
Table 1.4. It has to be noted that these studies are mainly for subcutaneous and 
intramuscular administrations. With respect to intravenous formulations, there are 
some examples of in vitro release tests that characterize the release of doxorubicin 
from liposomes (determining the residual drug remaining in the liposomes [58] or by 
dialysis methods [59, 60]) but these were not developed for predicting the in vivo 
behaviour and IVIVCs were not established. 
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5 mL of medium in the 
dialysis tube and 40 mL in 
the receptor chamber; 37°C 
phosphate buffer 
with sodium azide 







A linear relation was 
established between 
the in vitro and the in 
vivo drug released 
Rats 




Flow through cell apparatus 
small cell (diameter =12 
mm) packed with 1 mm 
glass beads; microparticles 
Phosphate buffer 




subtraction of the 
drug content in the 
degraded 
After performing a 
time scaling/shifting 
for the in vitro 




dispersed in the cell; 
volume: 250mL (closed 
mode); flow rate 20mL/min; 
37°C. 
microspheres from 
the total drug 
loaded into the 
microspheres 
in vivo release, a 
linear relation was 






Flow through cell apparatus 
small cell (diameter = 12 
mm) packed with 1 mm 
glass beads; microparticles 
dispersed in the cell; 
volume: 250 mL (closed 
system); flow rate 8mL/min. 
37, 45, 50 and 54.5°C. 
Phosphate buffer 





(from published in 
vivo data). 
A linear correlation 
was established for 
the release tests 
performed at 50 and 
54.5 °C 
Human 
Leuprolide osmotic implant/ 
subcutaneous [64] 
Peristaltic pump; volume 12 
mL (closed system); flow 
rate: 4mL/min.; 37°C. 
Phosphate buffer 
with 2 %w/v 
sodium azide. 
Calculated from the 
drug amount in the 
implant prior the 
implantation and 
after the 
A linear relation was 
established between 
the in vitro and the in 








Duration of study: 3, 6, 9 
and 12 months (in vivo 
study duration) 
explantation in the 
animals at 3, 6, 9 




Flow through cell apparatus 
small cell (diameter = 12 
mm) packed with 1 mm 
glass beads; microparticles 
dispersed in the cell; 
volume: 250 mL (closed 
system); flow rate 8mL/min. 
37°C. 
 
phosphate buffer Wagner–Nelson 
deconvolution 
method 
A linear relation was 
established between 
the in vitro and the in 
vivo drug released  
Rabbits 
Sample and separate methods 
Buserelin subcutaneours 
implants [66] 
Centrifuge tubes with 12 mL 
of medium; 37°C 
phosphate buffer 
pH = 7.4 with 





between the mean in 
vivo residence time 










Micro particles suspended in 
phosphate buffer and 
shacked in a water bath. 











Microspheres or one implant 
were suspended in 100 mL 
of medium with constant 
stirring (50 rpm) at 37°C 
Phosphate buffer 
pH=7.4 with 
0.001% Tween 80 
Numerical 
deconvolution  
A linear relation was 
established between 
the in vitro and the in 





micro centrifuge tube with 
1.5 mL of medium under 





A linear relation was 
established between 
the in vitro and the in 




It can be noticed that there are considerable differences among the techniques and 
conditions chosen for the release tests, animal models and mathematical data 
treatment. Furthermore there is a wide variety in the type of formulations (implants, 
microspheres and liposomes). The most utilized method to assess the in vitro release 
was SS followed by CF (Table 1.4). The release medium used in most examples is 
PBS pH = 7.4, with volumes of media used ranging from 1.5 to 250 mL.  
1.4.2. PBPK modeling 
Apart from the traditional approach, development of IVIVCs can be performed with 
the combination of in vitro release tests with advanced pharmacokinetic modeling 
approaches (i.e. physiologically based pharmacokinetic modeling (PBPK)) [68].  
Physiologically based pharmacokinetic modeling (PBPK) is defined as the 
mathematical description of relevant physiological, physicochemical and biochemical 
processes in order to explain the pharmacokinetic behaviour of a compound [69]. The 
input parameters for the models are i) drug dependent (e.g. pka, logP, solubility, 
fraction unbound to proteins) and ii) drug independent (e.g. blood flows, tissue 
volumes) [70-73]. Commercial PBPK modeling software is available (e.g. Gastro- 
Plus®, simCYP® or PK-Sim® [68]) and reference to PBPK modeling is increasing from 
regulatory agencies [74]. The FDA have published the “Physiologically Based 
Pharmacokinetic Analyses — Format and Content (Guidance for Industry) [75]” and 
the EMA the “Guideline on the qualification and reporting of physiologically based 
pharmacokinetic (PBPK) modelling and simulation [76]”. 
PBPK models for parenteral formulations have been developed for several types of 
nanoparticles as reviewed by Li et. al. [77] including: carbon nanoparticles [78], 
polylactic-glycolic acid (PLGA) nanoparticles [78], silver nanoparticles [79], 
dendrimer [80] and gold/dendrimer composite nanoparticles [81]. 
A PBPK model for a liposomal formulation of Amphotericin B (Ambisome®) has been 
published. The model was based on rat and mouse data that were extrapolated to 
healthy humans and both the liposomal and the released drug were simulated [82, 83]. 
In a PBPK model for copolymer modified liposomes of docetaxel in mice, the PK of 
total docetaxel was described but the PK of released drug or drug in the liposomes was 
not taken into account [84, 85].  
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PBPK modeling has been used to simulate PK of long acting formulations following 
intramuscular administration [86]. 
1.4.2.2. Input of in vitro release data to the model 
Mathematical models for in vitro release profiles can be divided into two main 
categories: empirical and mechanistic [87]. Mechanistic models include parameters 
related to the drug release mechanism from the dosage forms (e.g. Higuchi, Korsmeyer 
– Peppas [88]).  
Empirical models are based on fitting data to a specific model [4]. As some parenterals 
are in the form of solid particles in suspension, common approaches to dissolution 
modeling can be used for such parenteral formulations. Examples include approaches 
made with the Weibull probability function for modeling the release from leuprolide 
polylactide and polylactide-co-glycolide microspheres [89] (Eq 1.2). 
𝑥 = 1 − 𝑒−𝛼𝑡
𝛽
 Eq 1.2 
where 𝑥 is the fraction released at time 𝑡, 𝛼 is an apparent rate constant, 𝛽 is the shape 
factor of Weibull function and 𝑡 is the time. 
In cases where there is an initial burst in the release, the equation can be modified to 
Equation 1.3: 
𝑥 =  𝑥𝑏𝑢𝑟𝑠𝑡 + (1 − 𝑒
−𝛼𝑡𝛽) Eq 1.3 
where 𝑥𝑏𝑢𝑟𝑠𝑡 is the fraction releasedof the initial burst, 𝑥 is the fraction released at 
time 𝑡, 𝛼 is an apparent rate constant, 𝛽 is the shape factor of Weibull function and 𝑡 
is the time. It is important to notice that Weibull is a flexible probability function, so 
the release can easily fit to this equation, but it is not based in the mechanism that 
governs the release [89]. 
1.4.3. Challenges and points to consider for IVIVC for parenterals 
To increase the predictability of the in vitro tests, understanding the fate of the 
formulations and the released drugs in the organism (Figure 1.2) could help to improve 
the development of PBPK models for parenterals. These models could be useful for 
IVIVC establishment and furthermore carry the potential for use in the development 
of a Pharmacokinetics/Pharmacodynamics (PK/PD) model [73]. 
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A matter of the utmost importance is the fact that many of these parenteral 
formulations will be administered to patients whose disease may impact on the drug 
release; for example, the changes in protein concentration or the presence of 
inflammatory mediators could affect drug release [90]. The composition of the fluid 
at the administration site in a disease state must be considered to adapt the biorelevant 
release medium for simulation of this state. Currently, to the best of our knowledge, 
release media to simulate the disease state for parenterals are not available. 
Development of these types of release media would be important to predict the best 
clinical performance of the formulation in the target patients. 
1.5. Conclusions 
In vitro release testing can be a valuable tool during formulation development and 
assist prediction of in vivo behaviour. The tests might be modified in order to be 
biorelevant to obtain meaningful data that can be used in an IVIVC model. There are 
some promising results of IVIVC for parenteral formulations performed in animals 
but studies with humans are lacking. These limitations could be addressed through 
understanding of relevant in vivo factors at the site of administration and their 
application to in vitro testing through adjustment of test conditions, or alternatively 
judicious application of modeling techniques to reflect in vivo processes which are 
impossible to be replicated in vitro. 
There is still a lot of research to be performed in the field of parenteral 
release/dissolution testing for establishment of compendial and biorelevant in vitro 
release tests.  
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Chapter 2. Investigation and simulation of dissolution with 
concurrent degradation under healthy and 
hypoalbuminaemic simulated parenteral conditions- case 
example Amphotericin B 
 
Abstract 
Guidance on dissolution testing for parenteral formulations is limited and not often 
related to in vivo performance. Critically ill patients represent a target cohort, 
frequently hypoalbuminaemic, to whom certain parenteral formulations are 
administered. Amphotericin B (AmB) is a poorly soluble, highly protein-bound drug, 
available as lipid-based formulations and used in critical illness. The aim of this study 
was to develop media representing hypoalbuminaemic and healthy plasma, and to 
understand and simulate the dissolution profile of AmB in biorelevant media. 
Dissolution media were prepared with bovine serum albumin (BSA) in Krebs-Ringer 
buffer, and tested in a flow through cell apparatus and a bottle/stirrer setup. Drug 
activity was tested against Candida albicans. BSA concentration was positively 
associated with solubility, degradation rate and maximum amount dissolved, and 
negatively associated with dissolution rate constant and antifungal activity. In the 
bottle/stirrer setup, a biexponential model successfully described simultaneous 
dissolution and degradation, and increased in agitation reduced the discriminatory 
ability of the test. The hydrodynamics provided by the flow-through cell apparatus 
were not adequate to dissolve the drug. Establishing discriminating test methods with 
albumin present in the dissolution media, representing the target population, supports 










The parenteral administration route is utilized when a quick or a depot effect is needed, 
when the patient cannot take oral formulations for systemic therapy or when the 
physicochemical properties of the drug make it impossible to be delivered by any other 
route [1]. Formulations such as microspheres, liposomes, nanoparticles and emulsions 
(among others) have been developed to be able to meet the requirements of a long or 
a sustained exposure. The dissolution test is an in vitro test designed to characterize 
the dissolution/release of the drug from a formulation and hopefully, predict the 
behaviour of the drug in vivo. There are 3 main methods to assess dissolution/release 
from controlled release parenterals that have been described extensively in the 
literature: Sample and separate, Continuous flow and Dialysis methods [2-6].  
Several factors may influence the dissolution of a formulation in vivo. As the ultimate 
goal of the dissolution test is to ensure clinical performance, these factors should be 
reflected in the dissolution test [7]. Biorelevant dissolution testing takes into 
consideration the characteristics of the site of administration in vivo that may impact 
on the dissolution and release of a drug from a formulation. This involves the 
composition and the physicochemical properties of the medium and the 
hydrodynamics where the drug will be released [8]. 
For parenterals administered intravenously the release medium is blood, consisting of 
2 fractions, the cellular fraction and plasma. Plasma is a fluid that contains ions and 
biomolecules. Albumin is the major circulating protein in human plasma (up to the 
60% of plasma proteins). The normal reference value of plasma albumin for a healthy 
subject is 40 g/L ± 10% [9]. Albumin is the most relevant protein in terms of drug 
administration as it is a carrier for metals, ions, fatty acids, amino acids, bilirubin, 
enzymes and drugs [9].  
Several parenteral formulations, that are not simple aqueous solutions, can be 
administered in the clinical setting to patients that have significant morbidities such as 
cancer or critically illness. Hypoalbuminaemia is common in the critical ill patients 
(affecting approximately 50% of patients), and while there is no reference value for 
hypoalbuminaemia, it can be considered when the plasma albumin levels are lower 
than < 25 g/L [9]. Low levels of serum albumin may affect pharmacokinetics and 
pharmacodynamics of highly protein bound drugs. With a decrease in the protein 
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levels in plasma there is more unbound drug in circulation which would lead to an 
increased pharmacological effect. On the other hand, the free drug can penetrate into 
tissues with a corresponding increase in the volume of distribution and a subsequent 
decrease in the maximum plasma concentration [9, 10]. Release/dissolution of poorly 
soluble, highly protein bound drugs from parenteral formulations, and associated local 
drug concentrations are likely to be influenced by protein concentration at the site of 
release. Therefore, in vitro dissolution tests that simulate the in vivo environment are 
needed for parenteral formulations that are not aqueous solutions, which take into 
account the likely changes that arise in target patient groups, with particular reference 
to albumin concentration. 
One drug that is administered to critically ill patients is Amphotericin B (AmB), which 
is still one of the most effective therapies for systemic fungal infections. In clinical 
practice, AmB is administered as an infusion using a multidose scheme usually lasting 
for several days [11]. AmB is highly bound (>95%) to plasma proteins (Low Density 
Lipoproteins, albumin and α1 glycoproteins [12, 13]). The major drawback of AmB 
is its poor water solubility (reported values: 0.09 µg/mL [14], 1.38 µg/mL [15] and 6 
µg/mL [16] at pH = 7). To tackle this problem, several formulations have been 
developed, including Liposomal AmB (Ambisome®) and AmB in a lipid complex 
(Abelcet®), where AmB is within the lipid structures. Furthermore, a correlation has 
been observed between volume of distribution at steady state of total AmB following 
administration of Abelcet® and albumin concentration, in critically ill patients [17], 
illustrating the relevance of albumin concentration to AmB pharmacokinetics in the 
target patient cohort. 
The aim of this study was to investigate the solubility and the dissolution of AmB in 
simulated plasma with albumin concentrations representing healthy subjects and 
hypoalbuminaemic patients, and to develop a mathematical model to describe and 
simulate all the processes involved in its dissolution, in order to be the basis for the 





2.2. Materials and Methods 
2.2.1 Materials 
AmB analytical standard (87.8%), Methanol (MeOH) High Performance Liquid 
Chromatography (HPLC) grade, formic acid, Sabouraud Dextrose (SBD) Broth, 
NaOH, MgCl2, CaCl2, NHCO3 and NH4HCO2 were obtained from Sigma Aldrich 
(Germany); AmB active pharmaceutical ingredient (API) powder (85%) from Cayman 
Chemical (USA); BSA Protease Free Powder Fraction V, dimethyl sulfoxide 
(DMSO), dextrose, Na2HPO4, NaH2PO4, NaCl and KCl were obtained from Fisher 
Scientific (USA); Sabouraud dextrose (SBD) agar was obtained from Oxoid (UK), 25 
mL sterile universal culture tubes were obtained from Sterilin Thermo Scientific (UK); 
10 μL plastic loops from Microspec (UK); GF/D (pore size 2.7 μm, 25 mm diameter) 
and GF/F (pore size 0.7 μm, 25 mm diameter) filters were obtained from Whatman 
(UK) and regenerated cellulose (RC) filters 0.45 µm 13 mm diameter from Cronus 
(UK). The yeast strain used in the microbiology experiments was Candida albicans 
SC5314 [18]. 
2.2.2. Dissolution biorelevant media composition and characterization 
The dissolution media employed were Krebs-Ringer Buffer (KRB), supplemented 
with BSA at different concentrations according to the experiment: 1.5, 2.0, 3.0 or 4.0% 
w/v. The pH was adjusted to 7.2 – 7.3 with 0.1 M HCl using a Seven Compact pH 
meter (Mettler Toledo, China). The osmolality of the media with 2.0 and 4.0% w/v 
BSA was measured via the freezing-point depression method with a Micro-
Osmometer 3300 (Advanced Instruments, Massachusetts USA). Viscosity of all media 
was measured with a Bohlin Rheometer (Germany) with a shear rate 0.1 - 1.5 Pa 
(logarithmic scale), 20 integrations per measurement and with a delay time of 5 
seconds and an integration time of 20 seconds. The geometry was a 4° and 40 mm 
diameter (CP 4/40) cone parallel to a plate and the experiments were conducted at 
25°C in triplicate. The measurement at the closest value to the steady state was 





2.2.3. Chromatographic conditions for the analysis of AmB from biorelevant 
dissolution media samples 
The chromatographic method to quantify AmB was a modification of the method 
reported by Nilsson-Ehle et al [19]. Briefly, AmB was quantified by HPLC analysis 
using a Hewlett Packard Series 1100 equipped with an auto sampler, temperature 
regulated column compartment, quaternary pump and diode array detector (DAD 
detector) (Agilent Technologies). The column was a C18 Waters Sunfire Column 
(Ireland) 150 x 46 mm 5μm. The temperature of the column compartment was set at 
25°C. The mobile phase consisted of formate buffer (50 mM; pH = 3.2): MeOH 
(25:75, v/v); the flow rate was 1 mL/min and analysis was performed with the DAD 
detector at λ = 406 nm. The UV spectrum was recorded from 300 to 450 nm (where 
necessary for detection of the degradant). Quantification of AmB in samples was made 
based on calibration curves. Freshly prepared standard solutions (0.5 – 10 μg/mL) in 
the corresponding medium were prepared by appropriate dilution of a 500 μg/mL 
stock solution of AmB analytical standard in 1:1 MeOH: DMSO v/v. The 5 μg/mL 
standard solution in KRB – BSA 4% w/v was incubated at 37°C and was monitored 
every hour to check the stability of the samples for up to 24 h. The limit of detection 
and the limit of quantification were 0.12 and 0.37 μg/mL, respectively.  
2.2.4. Sample treatment of AmB in the biorelevant dissolution media 
Proteins were precipitated by adding 2 volumes of methanol to 1 volume of the sample 
followed by mixing in a vortex (Scientific Industry Inc., USA) for 30 seconds and then 
centrifuged for 10 minutes at 12000 rpm and 5°C (Eppendorf Heraeus Fresco 17 
centrifuge, Thermo Electron LED GmbH., Germany). The supernatant was filtered 
through a 0.45 μm RC filter before injected to the HPLC. 
2.2.5. Liquid chromatography – Mass Spectrometry (LCMS) studies 
The identification of the mass of the molecular structures detected as peaks in the 
HPLC chromatograms was performed by LCMS. An excess of AmB was added to the 
medium (KBR-BSA 4.0% w/v) and after stirring for 8 h at 130 rpm [Variomag 
multipoint stirring plate (Thermo Electron Corporation, Germany); 15 x 6 mm 
magnetic stirrers (Fisherbrand, UK)] at 37°C, the undissolved drug was removed by 
centrifugation [3000 rpm 5 min 5°C]. The supernatant was treated for protein 
precipitation (section 2.2.4) and analysed by LCMS [Ultimate 3000 UHPLC (Dionex, 
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USA); autosampler; quaternary pump; DAD detector; maXisHD Time-of-Flight Mass 
Spectrometer coupled with an electrospray source (ESI-TOF) (Bruker Daltonics, 
Germany)]. The conditions of the chromatography analysis were the same as 
previously described (section 2.2.3), with the exception of the injection volume being 
30 μL and a split flow post column before the mass spectrometry detector to a flow 
rate of 0.3 mL/min. In this case, the formate buffer (50 mM) was prepared with formic 
acid and ammonium formate, in order to make it suitable for Mass Spectrometry 
(absence of sodium ions). The samples were analysed in negative mode. Data was 
processed using external calibration with the Bruker Daltonics software 
(DataAnalysisTM) as part of the overall hardware control software (CompassTM). 
2.2.6. Degradation studies of AmB in the biorelevant dissolution media 
In order to characterise the degradation of AmB in the dissolution media, 
approximately 10 mg of AmB API powder was added to 50 mL of the dissolution 
media (KRB-BSA 1.5, 2.0, 3.0, or 4.0% w/v) and then stirred for 1 h at 130 rpm (in 
Variomag multipoint stirring plate) at 37°C. The samples were centrifuged for 5 
minutes at 3000 rpm and 4°C (Heraeus Biofuge Primo R Centrifuge, Thermo Electron 
LED GmbH. Germany), to remove the undissolved AmB and the supernatant was 
incubated at 37°C. Samples were taken at 0.5, 1.0, 1.5, 2.0, 3.0, 4.0, 5.0, 6.0 and 8.0 
h, injected to the HPLC after sample treatment (protein precipitation; section 2.2.4) 
and the concentration of AmB in the samples was calculated. All experiments were 
performed in triplicate. A linear fit was applied to the degradation data from 4 h to the 
last time point, after a natural logarithm transformation of the measured concentration 
(Excel 2013, Microsoft. USA) and the degradation rate constant (𝑘𝑑𝑒𝑔) was calculated 
from the slope of the line. 
2.2.7. Solubility studies of AmB in the biorelevant dissolution media 
Approximately 2.5 mg of AmB API powder were placed in a 100 mL glass bottle (56 
mm diameter/ 105 mm height; Duran, Germany) with 30 mL of KRB supplemented 
with BSA 1.5, 2.0, 3.0 or 4.0% w/v, stirred at 130 rpm (in Variomag multipoint stirring 
plate) and incubated at 37°C. The sampling times were 0.5, 1.0, 1.5, 2.0, 3.0, 4.0, 5.0, 
6.0, 8.0, 10.0, 12.0 and 24.0 hours. The undissolved AmB was removed by 
centrifugation (Eppendorf centrifuge 3000 rpm, 5 min, 5°C; following validation (data 
not shown) centrifugation was selected as a cost-effective alternative to filtration) and 
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after sample treatment (protein precipitation; section 2.2.4), the samples were injected 
to the HPLC and the concentration of AmB in the samples was calculated. All 
experiments were performed in triplicate. 
2.2.8 Mass balance studies of AmB in the biorelevant dissolution media 
The total undissolved, dissolved and degraded percentages of AmB in KRB-BSA 
2.0% and 4.0% w/v media were calculated. Approximately 0.3 mg of the AmB API 
powder were weighed on a micro balance (Sartorius SE 2-F connected to an Eliex 
E550 antistatic device). The AmB was placed in a 100 mL glass bottle containing 15 
mL of dissolution medium (KRB with 2.0 or 4.0% w/v BSA), and then stirred at 130 
rpm and incubated at 37°C. A 1 mL sample withdrawn at 24 h was centrifuged (3000 
rpm, 5 min, 5°C; removal of the undissolved AmB), and after addition of methanol for 
the protein precipitation (section 2.2.4), was injected to the HPLC and the AmB 
concentration (𝐴𝑚𝐵 𝑑𝑖𝑠𝑠𝑜𝑙𝑣𝑒𝑑 𝑎𝑡 24 ℎ) was calculated. The remaining AmB in the 
bottle was dissolved with methanol (protein precipitation procedure; section 2.2.4), 
analysed and the final concentration of AmB (𝐴𝑚𝐵 𝑓𝑖𝑛𝑎𝑙) was calculated. All 
experiments were performed in triplicate. The total undissolved (𝐴𝑚𝐵 𝑇𝑢𝑛𝑑𝑖𝑠𝑠𝑜𝑙𝑣𝑒𝑑: 
AmB undissolved powder in the bottle), the total dissolved (𝐴𝑚𝐵 𝑇𝑑𝑖𝑠𝑠𝑜𝑙𝑣𝑒𝑑: AmB in 
solution at 24 h and AmB degraded up to 24 h) and the total degraded 
(𝐴𝑚𝐵 𝑇𝑑𝑒𝑔𝑟𝑎𝑑𝑒𝑑 : AmB degraded up to 24 h) percentages of AmB were calculated 
based on Eq (2.1 – 2.3): 
𝐴𝑚𝐵 𝑇𝑢𝑛𝑑𝑖𝑠𝑠𝑜𝑙𝑣𝑒𝑑  = 𝐴𝑚𝐵 𝑓𝑖𝑛𝑎𝑙 − 𝐴𝑚𝐵 𝑑𝑖𝑠𝑠𝑜𝑙𝑣𝑒𝑑 𝑎𝑡 24 ℎ  Eq 2.1 
𝐴𝑚𝐵 𝑇𝑑𝑖𝑠𝑠𝑜𝑙𝑣𝑒𝑑  = 𝐴𝑚𝐵 𝑖𝑛𝑖𝑡𝑖𝑎𝑙 − 𝐴𝑚𝐵 𝑇𝑢𝑛𝑑𝑖𝑠𝑠𝑜𝑙𝑣𝑒𝑑   Eq 2.2 
where 𝐴𝑚𝐵 𝑖𝑛𝑖𝑡𝑖𝑎𝑙 is the mass (0.3 mg) placed into the reservoir initially (100%)  
𝐴𝑚𝐵 𝑇𝑑𝑒𝑔𝑟𝑎𝑑𝑒𝑑  = 𝐴𝑚𝐵 𝑇𝑑𝑖𝑠𝑠𝑜𝑙𝑣𝑒𝑑  −  𝐴𝑚𝐵 𝑑𝑖𝑠𝑠𝑜𝑙𝑣𝑒𝑑 𝑎𝑡 24 ℎ  Eq 2.3 
2.2.9. Antimicrobial activity assay of AmB in the biorelevant media: MIC and MFC 
determination 
2.2.9.1. Quantification of C. albicans.  
The strain was maintained on SBD agar plates. A new culture was started from a single 
colony in a culture tube with 5 mL of SBD broth and was incubated at 37°C overnight 
in a shaking incubator (Innova 44, New Brunswick Scientific, USA), after which the 
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optical density (OD) was measured at 600 nm (OD600). The Colony Forming Units 
(CFU) of the culture was determined by preparing serial dilutions from 10–1 to 10–6. 
100 μL of the suspensions were plated on SBD agar plates, incubated overnight at 
37°C, the number of colonies was counted and the relationship with the OD600 of the 
culture was established.  
2.2.9.2. MIC and MFC studies.  
The OD600 of an overnight culture of C. albicans was measured, and diluted to a final 
concentration of 105 CFU/mL. Minimum Inhibitory Concentration (MIC) studies were 
performed with the following concentrations of AmB: 0, 1.5, 3.0, 4.5, 6.0, 7.5, 9.0 and 
10.5 μg/mL for the experiments with BSA 2.0% w/v, and 0, 3.0, 4.5, 6.0, 7.5, 9.0, 10.5 
and 12.0 μg/mL for the experiments with BSA 4.0% w/v. Culture medium without 
BSA was set as the control for these experiments. The MIC was defined as the lowest 
concentration of AmB at which there was no visual turbidity in the liquid broth. The 
Minimum Fungicidal Concentration (MFC) experiments were performed by plating 
10 μL of the yeast cultures from the MIC assays on SBD agar plates and incubated for 
24 h at 37°C. The MFC was defined as the lowest concentration of AmB where there 
was no visible growth on the agar plates. The results are expressed as the intervals 
where the MIC and MFC were found. The experiments were performed in duplicate. 
2.2.10. Dissolution studies of AmB in biorelevant media 
2.2.10.1. Sample and separation method (bottle/stirrer) 
Dissolution studies were carried in a glass bottle with a similar setup as the solubility 
experiments (section 2.2.7). 0.5 mg of AmB API powder was weighed and placed into 
a 100 mL glass bottle with 30 mL of the dissolution medium. Two hydrodynamic 
conditions were tested: low agitation (130 rpm) for KRB – BSA 0, 1.5, 2.0, 3.0 and 
4.0% w/v and high agitation (380 rpm) for experiments with KRB – BSA 2.0% w/v 
and BSA 4.0% w/v. Samples were withdrawn up to 24 h were treated and analysed as 
previously described (sections 2.2.7 and 2.2.4) and the % AmB dissolved over time 





2.2.10.2. Continuous Flow method (flow through cell apparatus) 
The dissolution studies were carried out in a flow-through cell dissolution apparatus 
(Sotax CE7 smart connected to a Sotax piston pump CP7, Sotax, Switzerland) 
operated in the closed mode [20]. A 5mm ruby glass bead was positioned at the bottom 
of the cell (small cell:12 mm diameter; large cell: 22.6 mm diameter), the conical part 
of the cell was filled with 1 mm glass beads and 5 mg of AmB API powder were 
weighed and placed on top of the glass beads. Glass fibre filters (GF/D, GF/F) were 
positioned at the top of the cell. Two different hydrodynamic conditions were tested: 
i. small cell with a flow rate of 35 mL/min (high velocity) and ii. large cell with a flow 
rate of 16 mL/min (low velocity). 50 mL of the dissolution medium (KRB with BSA 
2.0% w/v or 4.0% w/v) were put in the reservoir under constant stirring. 0.5 mL 
samples were collected at specific time points up to 8 h and volume replacement with 
fresh medium was made. Dissolution experiments were also performed with 0.5 mg 
of AmB in the two media (KRB with BSA 2.0% w/v or 4.0% w/v) under both velocity 
conditions and with 5 mg of AmB API in water (HPLC grade) under high velocity 
conditions. The samples after treatment (protein precipitation; section 2.2.4) were 
injected to the HPLC and the % AmB dissolved over time was calculated. All 
experiments were performed in triplicate at 37°C. 
2.2.11. Treatment of dissolution data 
The AmB dissolution profiles were corrected for degradation using the corresponding 
degradation rate constants (section 2.2.6). The concentration over time accounting for 
degradation (Ccorrected) was calculated using Eq 2.4. 
𝐶𝑐𝑜𝑟𝑟𝑒𝑐𝑡𝑒𝑑 =  𝐶𝑡 +  𝑘𝑑𝑒𝑔 ∗  𝐴𝑈𝐶0−𝑡  Eq 2.4. 
Where Ct is the observed concentration at time t, AUC0-t is the Area Under the 
Observed Concentration – Time Curve from time 0 to time 𝑡 and 𝑘𝑑𝑒𝑔 is the 
degradation rate constant obtained from the degradation experiments. The corrected 
dissolution profiles were calculated based on 𝐶𝑐𝑜𝑟𝑟𝑒𝑐𝑡𝑒𝑑 and a first order curve fitting 
(Eq 2.5) was performed in order to obtain the dissolution rate constant (GraphPad 
Prism 6, GraphPad Software, Inc, USA). 
𝑋𝑐𝑜𝑟𝑟𝑒𝑐𝑡𝑒𝑑 =  𝑋𝑚𝑎𝑥 ∗ (1 − 𝑒
−𝑘𝑑𝑖𝑠𝑠𝑡)  Eq 2.5. 
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where 𝑘𝑑𝑖𝑠𝑠is the dissolution rate constant, 𝑋𝑐𝑜𝑟𝑟𝑒𝑐𝑡𝑒𝑑 is the corrected percent 
dissolved at time t and 𝑋𝑚𝑎𝑥 is the maximum corrected percent dissolved. The 
goodness of fit was assessed based on the correlation coefficient (R2) and the Akaike 
Information Criterion (AIC). Equation 2.6 was utilized to simulate the dissolution 
profiles (𝑋𝑠𝑖𝑚𝑢𝑙𝑎𝑡𝑒𝑑) in the bottle/stirrer accounting for degradation. The simulations 
were performed using GraphPad Prism 6. 
𝑋𝑠𝑖𝑚𝑢𝑙𝑎𝑡𝑒𝑑 =  
𝑋𝑚𝑎𝑥∗𝑘𝑑𝑖𝑠𝑠
𝑘𝑑𝑖𝑠𝑠−𝑘𝑑𝑒𝑔
(𝑒−𝑘𝑑𝑒𝑔𝑡 − 𝑒−𝑘𝑑𝑖𝑠𝑠𝑡)   Eq 2.6. 
Where 𝑋𝑚𝑎𝑥 is the maximum corrected percent dissolved, 𝑘𝑑𝑖𝑠𝑠 is the dissolution rate 
constant and 𝑘𝑑𝑒𝑔 is the degradation rate constant. 
2.2.12. Statistical analysis 
Data were analysed with one-way ANOVA and the Tukey test was selected in order 
to perform pair wise multiple comparison of all groups (significance p<0.05). A t- test 
was used to compare two experimental means (significance p < 0.05). The analyses 
were performed with Statgraphics Centurion XVII (Statpoint Technologies Inc, USA). 
2.3. Results and Discussion 
2.3.1. Biorelevant dissolution media simulating healthy and hypoalbuminaemic 
parenteral conditions 
The composition of KRB and its physicochemical properties are similar to human 
plasma (Table 2.1). The biorelevance of KRB supplemented with BSA is described in 
terms of composition, pH, osmolality and viscosity as compared with the 
corresponding properties of human plasma from healthy subjects (Table 2.1) [21-24]. 
A small variation in pH is observed due to the pH adjustment before the addition of 
the proteins. The addition of BSA marginally increases the viscosity of the medium 
(p<0.01) whereas the increase of the osmolality is not statistically significant (p > 
0.05). The BSA concentration in the medium (1.5 – 4.0 % w/v) reflects the albumin 
levels in the plasma of a critically ill patient and of a healthy subject [9]. A 76% 
sequence identity between Human Serum Albumin (HSA) and BSA has been 
measured [25], justifying the use of BSA as a substitute for HSA. In addition, an in 
silico analysis utilizing molecular modeling, predicted only one favourable binding 
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site in both HSA and BSA for AmB B [26], further supporting the biorelevance of 
KRB supplemented with BSA.  
Table 2.1. Composition and physicochemical properties of healthy human plasma and 
KRB; Mean ± SD of measured physicochemical properties with different 
concentrations of BSA (n = 3). 
Ion 
Healthy Human Plasma KRB 
Composition (Concentration (mM); [21-23]) 
HCO3
- 24.80 14.99 
K+ 4.60 4.56 
Cl- 99.00 127.32 
Na+ 150.00 136.17 
Ca2+ 4.70 1.00 
Mg2+ 1.60 0.49 
Inorganic phosphorus 1.51 2.00 
D-Glucose 5.60 10.00 
 Physicochemical properties 
pH 7.40 [21] 
7.34 ± 0.03 (+BSA 1.5% w/v) 
7.35 ± 0.03 (+BSA 2.0% w/v) 
7.34± 0.03 (+BSA 3.0% w/v) 
7.36 ± 0.01 (+BSA 4.0% w/v) 
Osmolality (mOsm/L) 289.0 [21] 
298.0 ± 10.4 (+BSA 2.0% w/v) 
308.7 ± 2.5 (+BSA 4.0% w/v) 
Viscosity (cps) 3.8 – 4.7 cP at 22°C [24] 
Measurement at 25°C 
3.70 ± 0.03 (+BSA 1.5% w/v) 
3.79 ± 0.03 (+BSA 2.0% w/v) 
3.88 ± 0.02 (+BSA 3.0% w/v) 





2.3.2. Identification of the AmB degradation product 
During the development of the AmB quantification method, an extra peak in AmB 
chromatograms with a shorter retention time was noted. When the sample was 
incubated at 37°C, the area of this unknown peak increased with time and the AmB 
peak area decreased. The UV spectra of the two peaks are broadly similar with a main 
difference in the λmax [λmax for AmB: 406 nm; λmax for unknown compound: 380 nm 
(Figure 2.1)], suggesting that the unknown compound is related to AmB. 
 
Figure 2.1. Representative UV spectra of AmB and deg-AmB. 
 
LCMS experiments revealed that the mass spectrum of the unknown compound has a 





Figure 2.2. Mass spectra of AmB and deg-AmB in KRB-BSA 4% w/v obtained by 
LCMS in negative mode. 
 
Based on these studies, this unknown compound is more polar than AmB (due to its 
shorter retention time) and it can be suggested that it is AmB’s degradation product 
(deg-AmB). It has been reported that AmB auto–oxidates in the presence of oxygen 
with formation of free radicals and epoxidation is the most probable route of 
degradation (but the epoxidation products have not yet been characterized) [27-29]. A 
degradation product has not been reported previously in studies where AmB was 
quantified. This could be due to the specific ion transition followed by the multiple 
reaction monitoring [30-33] and the elution of the more polar AmB degradation 
product in the washing step of the solid phase extraction used for the purification of 
the sample [31, 34-36] in these methods. Furthermore, plasma components could 
potentially prevent/alter the rate of AmB degradation. 
2.3.3. Degradation studies of AmB in the biorelevant media 
The degradation of AmB in dissolution media with different concentrations of BSA 
was assessed in order to enable the quantification of the actual AmB dissolved in the 
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dissolution studies. Degradation data and degradation rate constants of AmB in the 
studied media are presented in Figure 2.3 and Table 2.2, respectively. 
 
Figure 2.3. ln AmB concentration as a function of time in KRB with BSA 1.5 – 4.0 
%w/v with the bottle/stirrer set up (130 rpm) at 37°C (degradation study; Mean ± SD; 
n = 3). 
 
The concentration of BSA in the medium has a statistically significant effect on the 
degradation rate constants of AmB (p<0.01). The increasing concentration of BSA 
results in an increase in the degradation rate constant of AmB, with the degradation 
rate constant being 3 times higher in the media with 4.0% w/v BSA compared to the 
one in media with BSA 1.5% w/v. 
Table 2.2. AmB degradation rate constants (𝑘𝑑𝑒𝑔) and solubility values in KRB with 
different BSA concentrations (Mean ± SD; n = 3). 
KRB-BSA (%w/v) 𝑘𝑑𝑒𝑔 (h
–1) Solubility (μg/mL) 
1.5 0.03 ± 0.01 13.03 ± 1.09 
2.0 0.07 ± 0.00 13.80 ± 1.40 
3.0 0.07 ± 0.00 15.28 ± 0.78 





2.3.4. Solubility studies of AmB in the biorelevant media 
The AmB solubility data for 24 h in KRB with different concentrations of BSA are 
presented in Figure 2.4. 
 
Figure 2.4. AmB concentration as a function of time in KRB with BSA 1.5 – 4.0 %w/v 
with the bottle/stirrer set up (130 rpm) at 37°C (solubility study; Mean ± SD; n = 3). 
 
The solubility of AmB in the biorelevant media increases with an increase in BSA 
concentration in the medium. While drug loss through degradation facilitates further 
solubilisation, as the dissolution rate is faster than the degradation rate, the AmB 
solubility saturation value is considered to be the point at which the concentration 
reaches a plateau, generally at around 10 h – 12 h (3 – 5 h for KRB BSA 1.5% w/v) 
(Table 2.2) and after this point, the AmB concentration is decreased due to degradation 
being the dominant process at this time when there is no longer the same excess of the 
drug. The deg-AmB peak was present in all samples’ chromatograms and its area 
increased with increased mass dissolved. The increase in drug solubility mediated by 
albumin has been reported for another anti-fungal drug, Itraconazole, illustrating the 
importance of BSA concentration in the medium for poorly soluble, highly protein 
bound drugs [37]. These solubility values should be taken into account when 
developing biorelevant test conditions for an AmB formulation, with a view to 
developing an in vivo / in vitro correlation. As the patients who are going to receive 
AmB therapy may present with hypoalbuminaemia, albumin concentration could 
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impact on the observed mass dissolved/released from the formulation, which will be 
reflected in the pharmacokinetics of the drug.  
2.3.5. Mass Balance studies of AmB in the biorelevant media 
The results of the mass balance studies of AmB in KRB with BSA 2.0% w/v and KRB 
with BSA 4.0% w/v are presented in Table 2.3. The 𝐴𝑚𝐵 𝑑𝑖𝑠𝑠𝑜𝑙𝑣𝑒𝑑 𝑎𝑡 24 ℎ is 
similar for both concentrations of BSA (2.0% w/v and 4.0% w/v) in the medium, but 
the 𝐴𝑚𝐵 𝑇𝑑𝑖𝑠𝑠𝑜𝑙𝑣𝑒𝑑 in which the degradation of AmB is taken into account is higher 
in the medium with BSA 4.0% w/v, as the AmB degradation is higher in this BSA 
concentration. This supports the results in sections 2.3.3 and 2.3.4, implying that BSA 
has a critical effect on the degradation and solubility of AmB in the medium, 
confirming the faster degradation and increased mass dissolved in medium with higher 
BSA concentration. 
Table 2.3. Percentage of AmB in mass balance studies in KRB – BSA media after 24 
h at 37°C (Mean ± SD; n = 3). 
 KRB BSA 2.0% w/v KRB BSA 4.0% w/v 
𝐴𝑚𝐵 𝑑𝑖𝑠𝑠𝑜𝑙𝑣𝑒𝑑 𝑎𝑡 24 ℎ 39.43 ± 11.09 34.46 ± 4.29 
𝐴𝑚𝐵 𝑓𝑖𝑛𝑎𝑙 76.61 ± 7.98 59.21 ± 2.15 
𝐴𝑚𝐵 𝑇𝑢𝑛𝑑𝑖𝑠𝑠𝑜𝑙𝑣𝑒𝑑 37.18 ± 3.11 24.75 ± 6.20 
𝐴𝑚𝐵 𝑇𝑑𝑖𝑠𝑠𝑜𝑙𝑣𝑒𝑑 62.82 ± 3.11 75.25 ± 6.20 
𝐴𝑚𝐵 𝑇𝑑𝑒𝑔𝑟𝑎𝑑𝑒𝑑 23.39 ± 7.98 40.79 ± 2.15 
 
2.3.6. Antimicrobial activity of AmB in the biorelevant media 
In order to assess the effect of BSA in the activity of AmB against Candida albicans, 
MIC and MFC values were determined (Table 2.4). A marked effect of BSA on the 
activity of AmB is shown. The results for the control experiments are in agreement 
with what is reported in the literature for the MIC of AmB against C. albicans (0.06 – 
1 mg/L) [36-39]. When BSA was added to the culture media, the MIC increased 10-
fold in the medium with BSA 2.0% w/v and approximately 20-fold in the medium 
with BSA 4% w/v. In the absence of BSA, the MFC was fairly close to the MIC values, 
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indicating that AmB is fungicidal. However, in the presence of BSA, the MFC was 
higher than the highest concentration of AmB that was tested, suggesting a fungistatic 
activity instead. The increase in the concentration of AmB to exert its antifungal 
activity has been reported before in studies where the source of albumin was HSA 
(human serum albumin) [40]. This could be explained by the fact that AmB is highly 
bound to proteins, and only the free fraction can exert a pharmacological effect. If 
there is more albumin in the medium, more drug will be bound to it and the 
concentration required to have the same efficacy will be higher. In vivo, AmB can also 
be bound to α1-acid glycoprotein [12, 13], but as this protein’s blood concentration is 
only 0.1% w/v (24 μM) compared to the 2.0 – 4.0% w/v BSA (300 – 600 μM) (that is 
used to substitute HSA) its effect can be considered negligible for the purposes of this 
study. 
Table 2.4. MIC and MFC (μg/mL) of AmB against Candida albicans in SBD broth 











Control 0.2 – 0.4 












AmB > 10.5 > 12.0 > 10.5 > 12.0 






2.3.7. Dissolution studies of AmB in biorelevant media  
2.3.7.1. Sample and separation method (bottle/stirrer) 
The AmB dissolution profiles in biorelevant media (KRB with the addition of BSA 
1.5 – 4.0 %w/v) obtained with the bottle/stirrer setup are presented in Figure 2.5. 
 
Figure 2.5. % AmB dissolved in KRB with different concentrations of BSA (%w/v) 
with the bottle/stirrer set up at 37°C a) and b) dissolution profiles before correction for 
degradation; c) and d) dissolution profiles after correction for degradation. (Mean ± 
SD; n = 3) [LA: low agitation; HA: high agitation]. 
 
Dissolution studies were performed in KRB without BSA, however neither the AmB 
dissolution nor the AmB degradation could be quantified due to the very low 
solubility, and hence minimal dissolution, of the drug in this medium. The AmB 
dissolution with its degradation occurring simultaneously is similar at both agitation 
levels with a plateau value ranging from 18.55% – 23.14% (low agitation) and 16.21% 
– 20.50% (high velocity). A drop in the % dissolved is observed at 24 h due to the 
degradation, with this being higher for the low agitation conditions and the low levels 
of BSA (1.5% w/v and 2% w/v) (Figure 2.5a and 2.5b). When the dissolution profiles 
are corrected for the degradation (Figure 2.5c and 2.5d) the continuous dissolution of 
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AmB in the media with high levels of BSA (3.0% w/v and 4.0% w/v) in both agitation 
conditions can be observed. At low agitation conditions and at low levels of BSA in 
the medium the % dissolved from 12 h to 24 h is decreased (5.49% in the medium 
with 1.5% w/v BSA) or remains unchanged (in the medium with 2.0% w/v BSA). The 
dissolution of AmB corrected for degradation is described by a first order process and 
the calculated dissolution rate constants are presented in Table 2.5. There is a 
statistically significant decrease in dissolution rate constant (𝑘𝑑𝑖𝑠𝑠) between the same 
levels of BSA (2.0% w/v) in high agitation conditions compared to low agitation 
conditions (p = 0.033). While there is a trend towards a decrease in 𝑘𝑑𝑖𝑠𝑠 with increase 
in BSA concentration in the medium in low agitation conditions, the differences in 
𝑘𝑑𝑖𝑠𝑠 between each medium in the same agitation conditions were not statistically 
significant (p > 0.05). The maximum % AmB dissolved (𝑋𝑚𝑎𝑥) is statistically similar 
between the same levels of BSA in the two agitation conditions (p > 0.05). 𝑋𝑚𝑎𝑥 
increases with a higher concentration of BSA in the medium, with this increase being 
statistically significant only for the low level of BSA (1.5% w/v) when compared to 
the other three levels of BSA under low agitation (p < 0.05) (in agreement with the 
mass balance studies). For the different levels of BSA under high agitation statistically 
significant differences in 𝑋𝑚𝑎𝑥 were not observed (p > 0.05). These results suggest 
that agitation rate is of greater relevance when using media with lower albumin 
concentrations probably due to the better powder dispersal and its exposure to the 
albumin that is present. When the high agitation is applied, the discriminatory ability 
of the test is reduced. The simulated dissolution profiles of AmB in media with 
different levels of BSA and under both agitation conditions in the bottle/stirrer setup 




Figure 2.6. Simulated and observed % AmB dissolved as a function of time [lines: 
simulated profiles (obtained with Eq 6); points observed values (Mean ± SD; n=3)] 
 
The use of a biexponential function in which the dissolution (𝑘𝑑𝑖𝑠𝑠) and degradation 
rate (𝑘𝑑𝑒𝑔) constants were incorporated results in successful prediction of AmB 
dissolution. Dissolution modeling could be a valuable tool to provide a mechanistic 
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understanding of drug dissolution in cases where other processes, such as degradation, 
occur simultaneously with dissolution. 
Table 2.5. Dissolution rate constants (𝑘𝑑𝑖𝑠𝑠), maximum corrected AmB % dissolved 
(𝑋𝑚𝑎𝑥) and goodness of fit parameters (first order curve fitting; R
2, AIC) for the 







-1) 𝑿𝒎𝒂𝒙 (%) R
2 AIC 
1.5 Low 0.46 ± 0.10 26.73 ± 1.52 0.93 ± 0.01 28.93 ± 1.56 
2.0 Low 0.30 ± 0.13 34.85 ± 3.29 0.98 ± 0.01 20.20 ± 3.62 
3.0 Low 0.25 ± 0.10 38.33 ± 2.81 0.95 ± 0.02 32.16 ± 4.28 
4.0 Low 0.20 ± 0.03 40.05 ± 3.98 0.95 ± 0.02 33.53 ± 8.04 
2.0 High 0.16 ± 0.02 36.54 ± 1.25 0.99 ± 0.00 13.71 ± 2.20 
4.0 High 0.16 ± 0.02 37.20 ± 5.43 0.95 ± 0.01 28.71 ± 4.57 
R2: correlation coefficient, AIC: Akaike Information Criterion. 
 
2.3.7.2. Continuous Flow method (flow through cell apparatus) 
AmB dissolution profiles in KRB with BSA 2.0% w/v and BSA 4.0% w/v under low 







Figure 2.7. % AmB dissolved in KRB with different concentrations of BSA (%w/v) 
with the flow through cell apparatus at 37°C (Mean ± SD; n = 3) [LV: low velocity; 
HV: high velocity]. 
 
The dissolution of AmB was very low in all cases, with the maximum % dissolved 
being 3.10 ± 0.08 % dissolved in the medium with BSA 4% w/v under low velocity 
after 8h and the samples’ concentrations did not reach the corresponding AmB 
solubility in the medium (Figure 2.4). A low % AmB dissolved was also observed in 
the case where a lower amount of AmB was used (0.5mg; data not shown) revealing 
that the low dissolution does not relate to the AmB amount in the cell. The AmB 
dissolution with the flow through set up was lower than the AmB dissolution with the 
bottle/stirrer set up (Figure 2.5). The theoretical average linear velocities, based on 
flow rate and cell diameter, employed in the flow through cell apparatus were 0.07 
cm/s (low velocity) and 0.52 cm/s (high velocity) while the outer edge of the stirrer in 
the bottle had a rotational linear velocity of 10.2 cm/s (low agitation) and 29.5 cm/s 
(high agitation). With the lowest velocity in the bottle/stirrer setup being at least 20 
times greater than the highest velocity of the flow-through cell apparatus, the reduced 
AmB power dispersal leading to aggregation in the flow through cell compared to the 
bottle/stirrer set up is evident. As the AmB binding to BSA is a dynamic process, 
selection of appropriate hydrodynamics which facilitate interaction between BSA and 
solute, which in this case is a poor soluble compound with wetting issues [41], is 
essential. 
2.4. Conclusions 
AmB is used for the treatment of systemic fungal infections and it is highly bound to 
plasma proteins, including albumin. In clinical practice, AmB is used in patient 
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cohorts that frequently exhibit hypoalbuminaemia. As hypoalbuminaemia is known to 
affect pharmacokinetics of highly protein bound drugs, AmB is a useful model 
compound to explore the development of dissolution tests that closely simulate in vivo 
conditions for parenteral therapies. In this work, we have developed biorelevant 
dissolution media with BSA concentrations representing hypoalbuminaemic patients 
and healthy subjects. BSA was shown to be a critical component in the media as the 
solubility and the degradation rate constant of AmB were dependent on the 
concentration of BSA. Accounting for concurrent degradation, dissolution over time 
could be modeled and simulated with the proposed approach (Equation 2.4 – 2.6), 
facilitating calculation of the total amount of AmB dissolved. The results of the two 
different setups for dissolution showed that the AmB powder needed a strong agitation 
(in terms of average linear velocity) for dissolution. Following correction of AmB 
dissolution to account for degraded AmB, a difference can be observed between the 
dissolution profiles (dependent on the BSA concentration), which is reflected in the 
values of the dissolution rate and maximum amount dissolved. Conversely, in the high 
agitation conditions, there was reduced discrimination between dissolution profiles 
following correction of dissolution for degraded AmB. Furthermore, the 
microbiological studies support the observation that the AmB is solubilised by binding 
to BSA, reducing the free fraction for activity and increasing the observed MIC. 
Establishing discriminating test methods with BSA present in the dissolution media 
supports future development of both biorelevant and clinically relevant tests for 
parenteral formulations. For biorelevant dissolution testing for poorly soluble, highly 
protein bound drugs such as AmB, protein concentration should be considered as a 
medium component and the concentration used is critical, particularly given the 
relevance of the concentrations to target patient populations. Going forward it is 
important to include this element in biorelevant dissolution test development for 
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Chapter 3: In vitro conditions for performance evaluation of 
products for intravascular administration: Developing 
appropriate test media using Amphotericin B as a model 
drug 
Abstract 
Currently, there are no compendial in vitro release tests specifically indicated for 
parenteral formulations. Consideration of biorelevant and clinically relevant test 
media represents a valuable approach for the development of in vitro tests that ideally 
can provide information on the formulation performance in vivo. The aim of this study 
was to investigate the effect of different media components on the solubility of 
Amphotericin B (a poorly soluble highly protein-bound drug) in order to develop 
biorelevant and clinically relevant media for future in vitro release testing from its 
liposomal formulation. Three categories of media were considered in the development 
approach: Category 1 media: effect of albumin concentration; category 2 media: effect 
of biorelevant concentrations of plasma components (bile salts, phospholipids, 
cholesterol, albumin); category 3 media: attaining clinically relevant solubility with 
biorelevant and synthetic surfactants with and without albumin and setting the basis 
for the development of a simulated hypoalbuminaemic's plasma medium. All the 
surfactants tested increased Amphotericin B solubility while the simultaneous 
presence of albumin had a negative effect on solubility. Clinically relevant media with 
the use of biorelevant, synthetic surfactants and albumin were developed. One medium 
in which the solubility of Amphotericin B was reduced was identified as potential 
candidate medium to simulate hypoalbuminaemic patients' plasma. The development 
of biorelevant and clinically relevant media and understanding the effect of media 
components and their interactions, supports future development of meaningful in vivo 
predictive release tests for parenteral formulations. 
 
Keywords: 




Recently, the development of parenteral formulations (for low water soluble and toxic 
drugs) has grown as they are a suitable alternative to tackle drug related issues or to 
increase the duration of the pharmacological effect. 
Currently, there is not an in vitro compendial method specifically assessing how 
changes to formulations might result in a change in in vivo performance of a parenteral 
drug product [1-5]. The in vitro dissolution/release testing used in quality control does 
not provide information about the dissolution/release of the drug in the environment 
where the formulations will be administered (such as the intravenous, intramuscular 
and subcutaneous routes [1]).  
Biorelevant dissolution testing refers to an attempt to mimic the conditions of the in 
vivo environment in terms of the composition and physicochemical characteristics of 
the in vivo fluids and the hydrodynamics at the site of administration [6]. Recently, 
clinically relevant dissolution testing has been defined: the term “clinically relevant” 
implies the establishment of a link between a drug product quality attribute (e.g. 
solubility) and in vivo performance (e.g. in vivo solubility) [7, 8]. This terminology 
has been agreed in a workshop organised by US FDA and the International Consortium 
for Innovation and Quality in Pharmaceutical Development (IQ) [8]. This approach 
enables dissolution testing to establish safe boundaries and reject drug product batches 
falling outside of the established safe range enabling the method to become clinically 
relevant [8]. 
Another aspect that is not usually covered in compendial in vitro release testing in 
terms of the media composition is the variation in in vivo physiological conditions 
induced by illness. In addition to simulating the fluid where the formulation will be 
administered, these physiological changes should, when appropriate, be reflected in 
the test medium. 
From previous studies, our group has developed a biorelevant test medium that 
simulates plasma (using Krebs Ringer Buffer (KRB) for the ionic content and bovine 
serum albumin (BSA) to represent the human serum albumin) which was used to 
evaluate the impact of albumin concentration on the solubility and degradation of 
Amphotericin B (AmB) [9]. AmB, a highly protein-bound (including to albumin and 
lipoproteins [10-12]) and poorly soluble drug [13], was selected as a model drug as it 
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is commerically available as parenteral lipid-based formulations (including 
Ambisome® and Abelcet®) for intravenous administration. AmB formulations can be 
used in patients suffering from severe systemic fungal infections. The presentation of 
sepsis in critically ill patients can include hypoalbuminaemia, possibly caused by 
reduced albumin synthesis but also by increased vascular permeability during the 
inflammatory response to sepsis. Thus, hypoalbuminaemia is a common feature of the 
vascular fluid into which AmB is administered in vivo. 
The aim of this chapter was to investigate the impact of different media components 
on the solubility of AmB to develop media able to target AmB plasma solubility 
(clinically relevant solubility) and to evaluate if the composition of a medium is 
suitable for future compendial in vitro release testing. Media were developed based on 
three categories (Figure 3.1). Category 1 media: biorelevant media, investigating the 
impact of concentration of albumin. Category 2 media: Biorelevant media, 
investigating the impact of biorelevant concentrations of plasma components to which 
AmB binds in vivo [cholesterol, bile salts, phospholipids with and without BSA]. 
Category 3 media: Clinical relevant media; category 3a media, attaining clinically 
relevant solubility with surfactants found in plasma (bile salts and phospholipids); 
Category 3b media, attaining clinically relevant solubility with synthetic surfactants 
(SLS, CTAB or Tween 80); Category 3c media, potential for category 3b media to be 
used as a basis to develop media for solubility and release studies simulating 
hypoalbuminaemic patients. The development of biorelevant and clinically relevant 
test media (based on the active pharmaceutical ingredient (API)) is a primary step 
towards the development of biorelevant and clinically relevant release testing of 




Figure 3.1. Categories of media development. 
 
3.2. Materials and Methods 
3.2.1. Materials 
AmB analytical standard (87.8%), methanol (MeOH) high performance liquid 
chromatography (HPLC) grade, formic acid mass spectrometry grade, NaOH, MgCl2, 
CaCl2, hexadecyltrimethylammonium bromide (CTAB), NHCO3 and NH4HCO2 were 
obtained from Sigma Aldrich (Germany); ethylenediaminetetracetic acid anhydrous 
(EDTA) from Sigma Aldrich (USA); AmB API powder (85%) from Cayman 
Chemical (USA); BSA protease free powder fraction V, dimethyl sulfoxide (DMSO), 
dextrose, sodium dodecyl sulphate (SLS), Na2HPO4, NaH2PO4, KH2PO4, NaCl and 
KCl from Fisher Scientific (USA); Tween 80 from Amresco (USA); 
phosphatidylcholine from egg from Lipoid GmbH (Germany); sodium taurocholate 
from Prodotti Chimici e Alimentaria (Italy); GF/D (pore size 2.7 μm, 25 mm diameter) 
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and GF/F (pore size 0.7 μm, 25 mm diameter) filters from Whatman (UK) and 
regenerated cellulose (RC) filters 0.45 µm 13 mm diameter from Cronus (UK). 
3.2.1.1. Human plasma collection 
Blood was drawn from healthy volunteers (having given informed consent) by median 
cubital vein venipuncture by a trained phlebotomist following local ethics committee 
approval (EIRA1, Issue 3, 11/5/2010). To act as anticoagulant, 2 mL of an EDTA 50 
mg/mL solution were added to a final volume of 50 mL of blood, for a final 
concentration of 2 mg/mL. Plasma was separated from blood cells by centrifugation 
for 10 min at 2000 x g (Heraeus Biofuge Primo R Centrifuge, Thermo Electron LED 
GmbH. Osterode, Germany) and the supernatant was separated into aliquots and kept 
at -80°C.  
3.2.2. Sample treatment of AmB in plasma and test media 
The sample treatment method was described previously [9]. Briefly, proteins were 
precipitated by adding 2 volumes of methanol to 1 volume of the sample followed by 
mixing in a vortex mixer and centrifuged for 10 minutes at 12000 rpm at 5°C. The 
supernatant was filtered through a 0.45 μm RC filter before injection to the HPLC. 
3.2.3. Chromatographic conditions for the analysis of AmB from plasma samples 
and test media 
The chromatographic method to quantify AmB was described previously [9]. Briefly, 
AmB was quantified by HPLC with a C18 Waters Sunfire column (Ireland) 150 x 46 
mm 5 μm at 25°C. The mobile phase was formate buffer (50 mM; pH = 3.2): MeOH 
(25:75, v/v); the flow rate was 1 mL/min and AmB was detected at λ = 406 nm. The 
UV spectrum was recorded from 300 to 450 nm. Quantification of AmB in samples 
was based on standard curves. Freshly prepared standard solutions (0.5 – 15 μg/mL) 
in the corresponding medium were prepared by appropriate dilution of a 500 μg/mL 
stock solution of AmB analytical standard in 1:1 MeOH: DMSO v/v. The limit of 






3.2.4. Test media for evaluation of performance of parenteral drug products 
Media were developed following the scheme of the 3 categories of development 
(Figure 3.1).  
3.2.4.1. Category 1 media: investigating the impact of albumin concentration 
Category 1 media consisted of KRB with varying biorelevant albumin concentrations 
and were developed and characterized as previously described [9].  
3.2.4.2. Category 2 media: investigating the effect of biorelevant concentrations 
of plasma components on AmB solubility 
Plasma components with the potential to affect the solubility of AmB in vivo, were 
added to KRB in biorelevant concentrations: bile salts 12.0 μM (mean value of highest 
concentrations reported in literature [14-16]); phosphoslipids 2.5 mM [17, 18] and CH 
4.5 mM [19]. For media preparation bile salts [sodium taurocholate was used as source 
of bile salts (BS)] were weighed and dissolved in KRB and then phospholipids 
[phosphatidylcholine from egg was used as source of phospholipids (PL)] from a stock 
solution of 100 mg/mL (dissolved in dichloromethane) were added; afterwards, where 
relevant, CH dissolved in chloroform (3.5 mg/mL) was added to the medium. Organic 
solvents were evaporated with a rotary evaporator consisting of a Büchi Waterbath B-
480 set at 40°C and a Büchi Rotovapor R-114 (Büchi Labotechnik. Flawil, 
Switzerland) attached to a vacuum pump unit PC 2001 Vario (Vacuubrand GMBH. 
Wertheim, Germany). The pressure was decreased from 650 mbar in steps of 70 mbar 
every two minutes to 100 mbar, where the pressure was maintained for 10 minutes. 
When included in the medium, BSA was added after the evaporation of the organic 
solvents. The composition of the media is listed in Table 3.2 (Category 2 media). 
Osmolality, viscosity, pH and buffer capacity of these media were measured (section 
3.2.5) and AmB solubility studies (section 3.2.7) were also performed in these media. 
3.2.4.3. Category 3 media: investigating the impact of biorelevant and synthetic 
surfactants to achieve clinically relevant AmB solubility  
Media were developed to achieve clinically relevant solubility values of AmB by using 
surfactants found in plasma (BS and PL) and synthetic surfactants (SLS, CTAB, 
Tween 80), the effect of BSA was also evaluated (media with and without BSA 4.0% 
86 
 
w/v). Media with synthetic surfactants was investigated for potential use for the 
simulation of hypoalbuminaemic patients' plasma. 
3.2.4.3.1. Category 3a: Biorelevant surfactants 
Attaining clinically relevant solubility with surfactants found in plasma (BS and PL), 
with and without BSA. In order to evaluate the impact of concentration of BSA and 
biorelevant surfactants on AmB solubility; media with BS, PL and BSA were 
prepared. The use of PBS as a simpler buffer solution than KRB was also investigated 
as a basis for media development. A 2 level factorial design of experiments (DoE) was 
used to identify which factors had a significant effect on AmB solubility. Factors 
investigated were type of buffer: PBS or KRB; BS concentration: 3.0 or 10.0 mM; and 
PL concentration: 0.2 or 3.0 mM. The BS concentration was selected in order to have 
a higher concentration than the biorelevant concentration and be studied in a wide 
range. The PL concentration was set in order that the PL (BS+PL) molar fraction was 
below than 0.6, which is the necessary for mixed micelles formation [20]. 8 
experimental setups resulted from the combination of these factors, and BSA 4.0% 
w/v was added to all media. Solubility studies were performed in the 8 media and 
AmB solubility values were used as the response for the DoE in order to predict the 
composition of a dissolution medium in each buffer able to produce a clinically 
relevant AmB solubility value. After the identification of the statistical significant 
factors affecting AmB solubility, the composition of clinically relevant media were 
predicted with the DoE (section 3.2.10), targeting the AmB solubility in plasma, and 
AmB solubility studies were conducted in these media for comparison with AmB 
plasma solubility values to validate the prediction. To investigate how BSA affects 
AmB solubility in the presence of the biorelevant surfactants, the predicted media were 
also prepared without BSA. Media characterization, AmB degradation and solubility 
studies were performed in the developed media with and without BSA (section 3.2.5, 
3.2.6 and 3.2.7). 
3.2.4.3.2. Category 3b: Synthetic surfactants 
Attaining clinically relevant solubility with synthetic surfactants (SLS, CTAB or 
Tween 80) with and without BSA, KRB and PBS were tested with 3 different types of 
surfactants: SLS (anionic surfactant), CTAB (cationic surfactant) and Tween 80 (non-
ionic surfactant). The critical micelle concentration (CMC) of charged surfactants was 
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determined in PBS and KRB by conductimetry (Conductivity Meter, WPA CMD 500, 
Scientific Laboratory Supplies Ltd, UK) to assure that the concentrations selected 
were above the CMC. 1 mL of a 10.0 mM solution of the surfactant in the 
corresponding buffer was added to either 20 mL (for SLS) or 50 mL (for CTAB) of 
the same buffer and the conductivity recorded. Conductivity was plotted against the 
surfactant concentration and the CMC was established when there was a change in the 
slope. Measurements were performed in triplicate. 
To study the effect of the surfactants on AmB solubility, the surfactant concentrations 
investigated were 5.0, 50.0 and 100.0 mM with and without BSA 4.0 %w/v. Single 
point AmB solubility experiments were conducted in all the media following the 
procedure described in section 2.7, with 1 mg of AmB API powder added in 10 mL of 
medium and sampling at 12 h (solubility plateau value was reached around 12 h in 
previous solubility determinations [9]). The media with the surfactant resulting in an 
AmB solubility value closer to the AmB plasma solubility, with and without BSA, 
were selected to develop the clinically relevant media. Surfactant concentrations, in 
the range where media comprised the clinically relevant AmB solubility value, were 
investigated in order to obtain the surfactant concentration to produce clinically 
relevant AmB solubility [5.0 - 50.0 mM with BSA and 0.1 - 4.0 mM without BSA]. 
Media characterization, degradation and solubility studies (section 3.2.5, 3.2.6 and 
3.2.7) were performed in the developed media. 
3.2.4.3.3. Category 3c: Potential media to simulate hypoalbuminaemic patients. 
Potential for media with synthetic surfactants and BSA, to be used as a basis to develop 
media simulating hypoalbuminaemic patients. 
In order to identify conditions that could direct future hypoalbuminaemic medium 
development, clinically relevant medium in PBS from category 3b was used as a base. 
For these studies there was no target solubility value as a reference AmB solubility in 
hypoalbuminaemic plasma is not available. In order to mimic hypoalbuminaemic 
plasma, the use of PBS was explored with a) 2.0 % w/v BSA and the corresponding 
concentration of surfactant developed as clinically relevant medium in category 3b, b) 
2.0% w/v BSA with half of the concentration of surfactant from category 3b media 
and c) 4.0% w/v BSA with half of the concentration of surfactant from category 3b 
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media. Media characterization, degradation studies (section 3.2.5 and 3.2.6) and single 
point solubility studies as described in section 3.2.4.3.2 were performed in the media. 
3.2.5. Test media characterization 
Media characterization methodology was described previously [9]. Briefly, pH was 
measured in all the media following addition of all components. Osmolality was 
measured via the freezing-point depression method with a Micro-Osmometer 3300 
(Advanced Instruments, Massachusetts USA). Viscosity of all media was measured 
with a Bohlin Rheometer (Germany) at 25°C in triplicate. The measurement at the 
value closest to steady state was recorded as the viscosity value. Buffer capacity was 







𝑎𝑣𝑒𝑟𝑎𝑔𝑒 𝑣𝑜𝑙𝑢𝑚𝑒 𝑜𝑓 𝑠𝑎𝑚𝑝𝑙𝑒
 𝑜𝑣𝑒𝑟 𝑟𝑎𝑛𝑔𝑒 𝑖𝑛𝑣𝑜𝑙𝑣𝑒𝑑
)(∆𝑝𝐻)




 is the buffer capacity, [𝐻𝐶𝑙] is the concentration of hydrochloric acid and 
∆𝑝𝐻 is the pH increment. The measurement was performed in triplicate. 
3.2.6. Degradation studies of AmB in plasma and in test media 
The degradation study methodology was described previously [9]. Briefly, 3 mg of 
AmB API powder was added to 20 mL of plasma and then stirred for 1 hour at 130 
rpm at 37°C. Samples were centrifuged for 5 minutes at 3000 rpm at 4°C and the 
supernatant incubated at 37°C. Samples were taken at 0.5, 1.0, 1.5, 2.0, 3.0, 4.0, 5.0, 
6.0, 8.0 and 24.0 hours, injected to the HPLC after sample treatment and the 
concentration of AmB in the samples was determined. For dissolution media, the same 
procedure was followed with 10 mg of AmB API powder added to 50 mL of 
dissolution media and monitored for 8 hours. All experiments were performed in 
triplicate. A linear fit was applied to the degradation data from 4 h to the last time 
point, after a natural logarithm transformation of the measured concentration (Excel 
2013, Microsoft. USA) and the degradation rate constant (𝑘𝑑𝑒𝑔) was calculated from 





3.2.7. Solubility studies of AmB in plasma and in test media 
Solubility study methodology was described previously [9]. Briefly, approximately 
2.5 mg of AmB API powder were placed in a 100 mL glass bottle with 30 mL of the 
corresponding dissolution media, stirred at 130 rpm and incubated at 37°C. The 
sampling times were 0.5, 1.0, 1.5, 2.0, 3.0, 4.0, 5.0, 6.0, 8.0, 10.0, 12.0 and 24.0 hours. 
The undissolved AmB was removed by centrifugation and after protein precipitation, 
samples were injected to the HPLC and the concentration of AmB in the samples was 
calculated. Solubility studies in plasma were performed with 1.5 mg of AmB in 10 mL 
of plasma. The AmB solubility saturation value was considered when the 
concentration reached a plateau value. An AmB solubility value in the dissolution 
media similar to the AmB plasma solubility was considered "clinically relevant". All 
experiments were performed in triplicate. 
3.2.8. Dissolution studies of AmB in clinically relevant media from category 3a 
and 3b, and category 3c media, with the flow through-cell dissolution apparatus 
Dissolution studies were carried out in a flow-through cell dissolution apparatus 
(Sotax CE7 smart connected to a Sotax piston pump CP7, Sotax, Switzerland) 
operated in the closed mode [21]. Tests were carried in category 3 clinically relevant 
media (3a and 3b) and in media from category 3c. A 5mm ruby glass bead was 
positioned at the bottom of the cell (small cell: 12 mm diameter; large cell: 22.6 mm 
diameter). 0.5 mg of AmB API powder was weighed and mixed with 6.0 g or 0.75 g 
of 1 mm glass beads, for the large or small cell, respectively, and were placed into the 
cell filling the conical part. Glass fibre filters (GF/D, GF/F) were positioned at the top 
of the cell. Two different hydrodynamic conditions were tested: i. small cell with a 
flow rate of 35 mL/min (high velocity: 0.52 cm/s) and ii. large cell with a flow rate of 
16 mL/min (low velocity: 0.07 cm/s). 50 mL of test medium were placed into the 
reservoir under constant stirring at 37°C. 0.5 mL samples were collected at specific 
time points up to 8 hours and volume was replaced with fresh medium. Dissolution 
studies were also performed with 5 mg (high dose) of AmB in category 3b PBS 
medium without BSA under both velocity conditions. Samples were injected to the 
HPLC after sample treatment and AmB concentration was quantified in order to 




3.2.9. Treatment of dissolution data 
Treatment of dissolution data was described previously [9]. Briefly, AmB dissolution 
profiles were corrected for degradation using the corresponding degradation rate 
constants with Equation 3.2. 
𝐶𝑐𝑜𝑟𝑟𝑒𝑐𝑡𝑒𝑑 =  𝐶𝑡 +  𝑘𝑑𝑒𝑔 ∗  𝐴𝑈𝐶0−𝑡  Eq 3.2 
where 𝐶𝑡 is the observed concentration at time 𝑡, 𝐴𝑈𝐶0−𝑡 is the Area Under the 
Observed Concentration – Time Curve from time 0 to time 𝑡 and 𝑘𝑑𝑒𝑔 is the 
degradation rate constant obtained from the degradation experiments.  
The corrected dissolution profiles were calculated based on 𝐶𝑐𝑜𝑟𝑟𝑒𝑐𝑡𝑒𝑑 and a first order 
curve fitting (Eq 3.3) was performed in order to obtain the dissolution rate constant 
(GraphPad Prism 7, GraphPad Software, Inc, USA). 
𝑋𝑐𝑜𝑟𝑟𝑒𝑐𝑡𝑒𝑑 =  𝑋𝑚𝑎𝑥 ∗ (1 − 𝑒
−𝑘𝑑𝑖𝑠𝑠𝑡)  Eq 3.3 
where 𝑘𝑑𝑖𝑠𝑠is the dissolution rate constant, 𝑋𝑐𝑜𝑟𝑟𝑒𝑐𝑡𝑒𝑑 is the corrected percent 
dissolved at time t and 𝑋𝑚𝑎𝑥 is the maximum corrected percent dissolved. 
3.2.10. Statistical analysis 
Equation 3.4 was used to analyse the DoE of the category 3a clinical relevant media 
development. 
𝑦 =  𝜇 + 𝐴 + 𝐵 + 𝐶 + 𝐴 ∗ 𝐵 + 𝐴 ∗ 𝐶 + 𝐵 ∗ 𝐶  Equation 3.4 
where 𝑦 is the response (AmB solubility), 𝜇 is the total mean; 𝐴, 𝐵 and 𝐶 are the main 
factors (buffer, BS concentration and PL concentration, respectively); 𝐴 ∗ 𝐵, 𝐴 ∗ 𝐶 
and 𝐵 ∗ 𝐶 are the 2 level interactions. Buffer type was represented by a value of -1 for 
PBS and +1 for KRB. The coefficient of each term was determined by analysing the 
DoE and the substituted equation was used to calculate the composition of clinically 
relevant media (targeting AmB solubility plasma values). 
To evaluate the effect of surfactants and BSA on AmB solubility, the in category 3a 
and 3b clinically relevant media, estimated and the standardized effects for surfactants 
(BS-PL, SLS, CTAB and Tween 80), BSA presence and its interaction, were 
calculated and used to construct a Pareto chart. A factor was significant when the 
standardized effect (bars) was larger than the line for statistical significance level (α = 
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0.05) (vertical line). To compare degradation rate constants, a t-test was used to 
compare two experimental independent means and a paired t-test to compare two 
experimental related means (significance p < 0.05). Data analysis and the DoE (design 
and analysis) were performed with the statistical software Statgraphics Centurion 
XVII (USA).  
3.3. Results and discussion 
3.3.1. Determination of solubility and degradation rate constant of AmB in 
human plasma from healthy volunteers 
AmB solubility in plasma reached a plateau between 3 – 12 h at a concentration of 
32.52 ± 0.98 µg/mL (Figure 3.2) and the AmB degradation rate constant in plasma 
was 0.033 ± 0.002 h–1 (Table 3.1). 
 
 
Figure 3.2. Solubility study of AmB in category 2 media: AmB concentration as a 
function of time in plasma and category 2 media (Mean ± SD; n= 3). KRB BSA 4.0 






Table 3.1. Degradation rate constants of AmB in plasma, category 1 and 3 media. 
(Mean ± SD; n = 3). 
Type of medium Medium 𝒌𝒅𝒆𝒈 (h
-1) 
Plasma Plasma 0.033 ± 0.002  
Category 1 
KRB BSA 1.5% w/v 0.026 ± 0.000 
[9] 
KRB BSA 2.0% w/v 0.065 ± 0.005 
[9] 
KRB BSA 3.0% w/v 0.065 ± 0.021 
[9] 





KRB BS 20.0 mM PL 4.0mM 0.023 ± 0.010  
KRB BS 20.0 mM PL 4.0 mM BSA 4.0% 
w/v 
0.060 ± 0.008 
PBS BS 19.8 mM PL 7.9 mM 0.048 ± 0.006 
PBS BS 19.8 mM PL 7.9 mM BSA 4.0% 
w/v 
0.097 ± 0.021 
3b 
KRB SLS 1.5mM 0.009 ± 0.007 
KRB SLS 30.0mM BSA 4.0% w/v 0.038 ± 0.001 
PBS SLS 1.4 mM 0.005 ± 0.003 
PBS SLS 60.0 mM BSA 4.0% w/v 0.052 ± 0.015 
3c 
PBS SLS 30.0 mM BSA 2.0% w/v 0.062 ± 0.014 
PBS SLS 30.0 mM BSA 4.0% w/v 0.082 ± 0.015  




3.3.2. Test media development for evaluation of performance of parenteral drug 
products  
3.3.2.1. Category 1 media 
AmB solubility values in category 1 media, obtained in our previous study, were lower 
(13.03 - 17.56 µg/mL) than the one observed in plasma and the degradation rate 
constants were not statistically similar to the one observed in plasma (Figure 3.2, Table 
3.1) [9]. 
3.3.2.2. Category 2 media 









Vis (cPs) pH 
BC HCl 
(mEq/L/pH) 
Plasma Plasma 275 - 300 [22] 3.5 [23] 
7.34 ± 0.04 
[24] 
16.1 ± 0.9 [25] 
Category 1 KBR BSA 4.0% w/v 308 [9] 4.0 ± 0.0 [9] 7.36 [9] 12.0 ± 1.2 
Category 2 
KRB BS 12.0 μM PL 2.5 mM 278 5.0 ± 0.1 8.64 1.5 ± 0.0 
KRB BS 12.0 μM PL 2.5 mM CH 4.5 mM 273 5.0 ± 0.1 8.79 1.5 ± 0.1 
KRB BS 12.0 μM PL 2.5 mM BSA 2.0% 
w/v 
314 5.2 ± 0.1 7.79 7.8 ± 0.0 
KRB BS 12.0 μM PL 2.5 mM CH 4.5 mM 
BSA 4.0% w/v 
306 5.0 ± 0.1 7.80 7.5 ± 0.2 
KRB BS 12.0 μM PL 2.5 mM BSA 8.0% 
w/v 
351 5.2 ± 0.0 7.65 7.7 ± 0.0 
Category 3 3a KRB BS 20.0 mM PL 4.0 mM 310 4.8 ± 0.1 8.25 1.7 ± 0.0 
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PBS BS 19.8 mM PL 7.9 mM 330 4.7 ± 0.1 7.36 6.1 ± 0.1 
KRB BS 20.0 mM PL 4.0 mM BSA 4.0% 
w/v 
415 5.0 ± 0.1 8.50 5.2 ± 0.1 
PBS BS 19.8 mM PL 7.9 mM BSA 4.0% 
w/v 
425 4.9 ± 0.1 7.18 14.2 ± 0.8 
3b 
KRB SLS 1.5 mM 289 4.6 ± 0.1 8.54 1.2 ± 0.0 
PBS SLS 1.4 mM 280 4.4 ± 0.1 7.43 5.6 ± 0.1 
KRB SLS 30.0 mM BSA 4.0% w/v 350 5.0 ± 0.1 7.84 7.9 ± 0.1 
PBS SLS 60.0 mM BSA 4.0% w/v 325 5.2 ± 0.1 7.56 10.3 ± 0.2 
3c 
PBS SLS 30.0 mM BSA 2.0% w/v 300 4.8 ± 0.0 7.10 9.3 ± 0.2 
PBS SLS 30.0 mM BSA 4.0% w/v 297 4.6 ± 0.0 7.18 9.6 ± 0.6 
PBS SLS 60.0 mM BSA 2.0% w/v 302 4.9 ± 0.1 7.04 11.6 ± 0.3 
Osm: Osmolality, Vis: Viscosity, BC HCl: buffer capacity determined with HCl.  
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On the other hand pH is only similar to plasma in the media with BSA but the buffer 
capacity was not as high as in plasma. BSA increased the osmolality and the buffer 
capacity, and kept the pH at ~7.5. However, when any other component apart from 
BSA was added, an increase in the pH and a decrease in the buffer capacity were 
observed (Table 3.2).  
Addition of BSA, in a concentration range from 1.5 to 4.0 % w/v in KRB buffer 
(category 1 biorelevant media), was reported to increase AmB solubility [9]. The 
addition of biorelevant plasma components, to which AmB is bound in vivo, to the 
medium would be expected to increase AmB solubility bringing it closer to its plasma 
solubility. AmB concentration profiles in category 2 media show a decrease in AmB 
solubility compared to its solubility in KRB BSA 4.0% w/v (category 1 media) and 
plasma (Figure 3.2). In the concentrations utilized for media development, PL and CH 
are not soluble [26, 27]; this might be counterproductive to AmB solubilisation, as the 
components are needed to be in solution in order to dissolve AmB. When CH or BS-
PL are present in the media without BSA (Table 3.2), the AmB solubility values are 
the lowest of all the values measured in all the tested media (Figure 3.2). In the media 
where BSA is present along with BS-PL or BS-PL CH, regardless of its concentration, 
AmB solubility is slightly higher than in these media without BSA, but lower than the 
solubility values measured in media with only BSA (Figure 3.2). It has been reported 
that BSA is capable of binding bile salts [28-30], cholesterol [31, 32] and 
phospholipids [33]. The results suggest that, rather than CH or BS-PL having an 
additive effect to BSA on the solubility of AmB, BSA is hindering solubilisation by 
biorelevant components added to the medium leading in their inability to bind/dissolve 
AmB while at the same time the biorelevant components are reducing the solubilising 
effect of BSA on AmB. Only in the category 2 medium with the highest BSA 
concentration, (KRB BS PL BSA 8.0% w/v) AmB solubility was increased, but still 
it was lower than in the medium with only BSA 4.0% w/v (category 1 biorelevant 
medium). As category 2 media failed to produce better solubility values than category 






3.3.2.3.1. Category 3a media 
The concentration of BS and PL in the medium were the only significant factors on 
the analysis of AmB solubility for the development of category 3a media (Figure 3.3). 
 
 
Figure 3.3. Pareto chart for the standardized effects of the main factors and 2 level 
interactions of the analysis of AmB solubility in media with BS, PL and different types 
of buffer. The black horizontal line represents the significance threshold for the 
effects. The factors with an effect (bar) larger than the threshold are statistically 
significant. 
 
Equation 3.5 was obtained from the DoE analysis and was used to predict the 
concentrations of BS and PL in both KRB and PBS to produce AmB solubility values 
similar to the ones observed in plasma (clinically relevant).  
𝑆𝑜𝑙𝑢𝑏𝑖𝑙𝑖𝑡𝑦 (𝜇𝑔/𝑚𝐿) = 5.56 − 2.09 ∗ 𝐵𝑢𝑓𝑓𝑒𝑟 + 0.33 ∗ 𝐵𝑆(𝑚𝑀) + 0.04 ∗
𝑃𝐿(𝑚𝑀) + 0.29 ∗ 𝐵𝑢𝑓𝑓𝑒𝑟 ∗ 𝐵𝑆(𝑚𝑀) + 0.81 ∗ 𝐵𝑢𝑓𝑓𝑒𝑟 ∗ 𝑃𝐿(𝑚𝑀) + 0.18 ∗
𝐵𝑆(𝑚𝑀) ∗ 𝑃𝐿(𝑚𝑀) (Eq 3.5). 
The predicted concentrations of BS and PL were BS 20.0 mM PL 4.0 mM for KRB 
BSA 4.0% w/v and BS 19.7 mM PL 7.9 mM for PBS BSA 4.0%w/v. The media 
characterization showed that the presence of BSA increases the buffer capacity, the 
osmolality and the pH (in KRB); similar to the effects noted in category 2 media (Table 
3.2). Osmolality was similar to the one of plasma only for the media prepared without 
BSA (the concentration of BS-PL had a high impact on the osmolality and when BSA 
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was added, the osmolality increased up to 425 mOsm/L). The pH value was only 
similar to the one of plasma for the medium prepared in PBS. The buffer capacity 
statistically similar to the plasma value only in PBS BS 19.8 mM PL 7.9 mM BSA 
4.0% w/v. Degradation rate constants were not statistically similar to the one observed 
in plasma except in the KRB BS 20.0 mM PL 4.0 mM medium (Table 3.1). In KRB, 
the presence of BSA resulted in faster degradation of AmB than in the medium without 
BSA; in PBS this effect is not observed. The higher AmB degradation rate constant 
values in these media could be due to the absence of certain plasma components which 
could reduce the AmB degradation. 
AmB solubility in these media was lower than the one observed in plasma, but in these 
media without BSA, AmB solubility values were similar to the ones observed in 
plasma (clinically relevant) (Figure 3.4).  
 
 
Figure 3.4. Solubility study of AmB in category 3a media: AmB concentration as a 
function of time in category 3a media with and without BSA (Mean ± SD; n= 3). Solid 
lines represent media with BSA 4.0% w/v and dotted lines media without BSA. AmB 
plasma solubility was added for comparison purposes.  
 
The predicted BS and PL concentrations were much higher than the initial exploration 
ranges, and the effects of BS - PL on solubilising potential of BSA and vice versa, 
were not captured in the media as the equation was not suitable for extrapolation. 
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However, the effect of BSA in the first place seems to have been immaterial in 
equation 3.5, as clinical relevant solubility was achieved without any BSA. 
3.3.2.3.2. Category 3b: clinically relevant media 
The CMC of SLS and CTAB in water is 8.1 mM and 1.0 mM, respectively [34]. The 
CMC of surfactants tends to decrease in a medium where the ionic strength is high, 
such as in saline buffers like PBS and KRB [35]. The CMC of SLS in PBS and KRB 
was 1.3 ± 0.0 mM and 1.4 ± 0.2 mM, respectively and the CMC of CTAB in PBS and 
KRB was 0.9 ± 0.0 mM and 0.2 ± 0.0 mM, respectively. The surfactant concentrations 
selected for the solubility studies were above of their CMC. CTAB was not soluble at 
100.0 mM and KRB CTAB 50.0 mM BSA 4.0%w/v medium gelatinized, thus, AmB 
solubility could not be measured in these media. Figure 3.5 shows the AmB solubility 
in the different media with and without BSA. 
 
Figure 3.5. Solubility study of AmB in media with surfactants for the development of 
category 3b media: AmB concentration in PBS or KRB with 5.0, 50.0 and 100.0 mM 
concentrations of SLS, CTAB or Tween with and without BSA 4.0% w/v at 12 h 
(Mean ± SD; n= 3). Black horizontal line represents the AmB solubility value in 
human plasma from healthy subjects. 
 
The apparent limit on AmB concentration, even with the highest surfactant 
concentration, was due to the AmB amount added ~ 1.0 mg, hence, concentration 
could not be higher than ~100.0 μg/mL and this value cannot be considered as the 
AmB solubility value. The charged surfactants (anionic and cationic) solubilised more 
AmB than the non-ionic surfactant despite the fact that AmB is a 
hydrophobicmolecule (log P 0.8 [36]). AmB, as an amphoteric molecule with two pKa 
values (pKa1 = 5.5, pKa2 = 10.0) will be charged at pH 7, thus, the interaction between 
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its charges and those of the surfactant would promote contact of the molecules leading 
to solubilisation of the drug. Similar to category 2 and 3a media observations, BSA 
presence in the media decreased AmB solubility. It has been reported that BSA binds 
to SLS, CTAB and Triton X-100 (non-ionic surfactant) with with the weakest binding 
observed for Triton X-100 [37-39]. Figure 3.6 shows the effect of surfactants (in both 
category 3a and 3b media) and BSA on AmB solubility. 
 
Figure 3.6. Pareto charts for the standardized effects of the main factors and 2 level 
interactions of the analysis of AmB solubility in media with surfactants and BSA 4.0% 
w/v. The black horizontal line represents the significance threshold for the effects. The 
factors with an effect (bar) larger than the threshold are statistically significant. 
 
The surfactant presence has a statistically significant positive effect on AmB 
solubility, whereas BSA and the interaction between BSA and surfactant have a 
negative effect. The results suggest that the presence of BSA and the surfactant alone 
in the medium, solubilise AmB [9], but when both are in the medium, they interfere 
with each other preventing AmB solubilisation and leading to a decrease in the 
solubility compared to the solubility reached in the medium with the surfactant alone. 
The ability of BSA to interfere with several types of molecules (BS, PL, CH, SLS, 
CTAB, Tween 80, as found in this study) has to be taken into account when a 
biorelevant or clinically relevant medium, incorporating BSA, is developed. The 
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required concentration of other components with surfactant/solublising activity could 
be under-estimated due to protein-surfactant interactions, leading to an unintended 
reduction in API solubility. Among the media with the different surfactants tested, the 
presence of SLS in the medium was the only one to produce clinically relevant 
solubility values of AmB in KRB and PBS, with and without BSA. 
The composition of media based on either KRB or PBS with BSA were calculated to 
target an AmB clinically relevant solubility value. The calculated compositions of the 
media to reach AmB solubility values similar to the observed in plasma were KRB 
SLS 30.0 mM BSA 4.0%w/v and PBS 60.0 mM BSA 4.0%w/v. The media 
composition without BSA could not be obtained directly by just removing BSA from 
the media as AmB solubility would be extremely high (Figure 3.5). Therefore, lower 
concentrations of SLS (0.1 – 4.0 mM) were tested in PBS and KRB to find the 
appropriate concentration for clinically relevant AmB solubility values without BSA. 
The SLS concentrations where the AmB solubility was similar to the one observed in 
plasma were 1.5 mM for KRB and 1.4 mM for PBS. In the clinically relevant media 
developed with SLS, the presence of BSA did not affect the viscosity but increased 
the buffer capacity and the osmolality as in category 3a media (Table 3.2). AmB 
degradation rate constants were not statistically similar to the one observed in plasma. 
AmB degradation rate constants were the lowest in media composed of SLS alone in 
buffer solution, which can be considered minimal (Table 3.1), and the AmB 
degradation rate constant in media with BSA were significantly higher than in the 
medium with SLS only. This effect could be related to observations found in category 
1 media (Table 3.1) where an increasing BSA concentration had a positive effect on 
the degradation rate constant. The results of the solubility studies in the developed 
category 3b media with and without BSA are presented in Figure 3.7. It can be 






Figure 3.7. Solubility study of AmB in category 3b media: AmB concentration as a 
function of time in the category 3b clinically relevant media with and without BSA 
(mean ± SD; n= 3). AmB plasma solubility was added for comparison purposes. The 
BSA concentration is in %w/v units. 
 
3.3.2.3.3. Category 3c: clinically relevant media 
As solubility data in plasma was only available from plasma obtained from healthy 
subjects, a target solubility value for hypoalbuminaemic patients was not available. 
This section therefore represents characterisation of media evolved from category 3b 
as potential candidates for further patient-centric media development. The 
composition of the media was the following: a) PBS SLS 60.0 mM BSA 2.0 % w/v, 
b) PBS SLS 30.0 mM BSA 2.0% w/v to reflect the reduced inhibition of BSA on SLS 
(observed during category 2 and 3a and 3b media development) when the lower BSA 
concentration was used and c) PBS SLS 30.0 mM BSA 4.0% w/v to explore the 
reduced potential for SLS solubilisation which might better reflect a potentially lower 
solubility in hypoalbuminaemia. These 3 media had characteristics similar to healthy 
plasma (Table 3.2) apart from a reduced buffer capacity and slightly lower pH. The 
AmB degradation rate constants in media with BSA 4.0% w/v are apparently higher 
than the ones obtained in media with BSA 2.0% w/v but the difference was not 
statistically significant. All the degradation rate constants were statistically different 
to the one observed in plasma. The results of the single point AmB solubility studies 
in these media were: a) PBS SLS 60.0 mM BSA 2.0 % w/v = 65.57 ± 4.98 µg/mL, b) 
PBS SLS 30.0 mM BSA 2.0% w/v = 25.84 ± 0.97 µg/mL, c) PBS SLS 30.0 mM BSA 
4.0% w/v = 19.77 ± 0.29 µg/mL. This supports the hypothesis that BSA interferes with 
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the action of the surfactants, in this case SLS, as in the medium with SLS 60.0 mM 
and BSA 2.0% w/v concentrations, the AmB concentration at 12 h was the highest and 
in the medium with SLS 30.0 mM and BSA 4.0% w/v, was the lowest.  
3.3.2.4. Summary and evaluation of the test media 
Table 3.3 presents a summary and an evaluation of the media in terms of 
biorelevance/clinically relevance of the media developed in comparison with the 
parameters obtained from plasma. Although category 1 media [9] was not clinically 
relevant for solubility or degradation, this media could be useful to investigate the 
impact of the albumin concentration on poorly soluble and highly – bound to proteins 
drugs as it was shown for AmB on its solubility, degradation and pharmacological 
activity [9]. Clinically relevant AmB solubility values are achieved by using 
biorelevant surfactants in category 3a media without BSA. These media could be used 
for in vitro release tests of AmB lipid-based formulations and also, these media with 
BSA could be used in order to identify an effect of BSA on the formulation even if it 
is not clinically relevant. Clinically relevant AmB solubility values were achieved in 
all the category 3b media developed. Category 3b media without BSA, as it is easier 
to prepare and the degradation of the drug is minimal (Table 3.1) it could be the base 
towards the development of appropriate media for compendial release tests. For 
category 3c media the AmB there was no reference values for solubility, degradation 
and media characterization due to the unavailability of hypoalbuminaemic plasma. 
PBS SLS 30.0 mM BSA 4.0% w/v it is a good candidate towards the development of 
simulated hypoalbuminaemic plasma as the AmB solubility at 12 h in this medium 
was lower than the clinically relevant value.  
Neither the solubility nor the degradation rate constant could be related to any of the 
properties of media characterization (Table 3.2). Solubility was found to be highly 
related to the concentration of BSA and of the surfactants in the medium (Figure 3.6), 




Table 3.3. Overall evaluation of biorelevance, clinically relevance and easiness of preparation of the media developed. The values of media 
characterization were compared against the values reported in the literature for plasma and the AmB solubility found in plasma. NA = not 
determined due to data unavailable for comparison,  = not biorelevant,  = biorelevant. Easiness of preparation (EoP) received values from 1 to 
4, being 1 to the easiest and 4 the most difficult to prepare. 
Category Medium CRS CRD Osm Vis pH BC HCl EoP 
Category 1 KRB BSA 4.0% w/v [9] No No     1 
Category 3a 
KRB BS 20.0 mM PL 4.0 mM Yes Yes     4 
PBS BS 19.8 mM PL 7.9 mM Yes No     3 
KRB BS 20.0 mM PL 4.0 mM BSA 4.0% w/v No No     4 
PBS BS 19.8 mM PL 7.9 mM BSA 4.0% w/v No No     3 
Category 3b 
KRB SLS 1.5 mM Yes No     2 
PBS SLS 1.4 mM Yes No     1 
KRB SLS 30.0 mM BSA 4.0% w/v Yes No     2 
PBS SLS 60.0 mM BSA 4.0% w/v Yes No     1 
Category 3c PBS SLS 30.0 mM BSA 2.0% w/v ND ND ND ND ND ND 1 
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PBS SLS 30.0 mM BSA 4.0% w/v ND ND ND ND ND ND 1 
PBS SLS 60.0 mM BSA 2.0% w/v ND ND ND ND ND ND 1 
CRS: AmB clinically relevant solubility, CRD: AmB clinically relevant degradation rate constant, Osm: osmolality, Vis: viscosity, BC HCl: buffer 




3.3.4. Dissolution studies of AmB with the flow through cell apparatus in 
clinically relevant media 
Dissolution studies were performed in clinically relevant media from category 3a and 
3b, and in each of the media explored in category 3c (Figure 3.8).  
 
Figure 3.8. %AmB dissolved as a function of time in the category 3a and 3b clinically 
relevant media and in category 3c media with the flow through cell apparatus at 37°C 
(mean ± SD; n= 3). High dose = 5 mg of AmB. BSA concentration is in %w/v units. 
Points represent observed data and the lines the first order (Eq 3.3) equation fittings. 
 
Clinically AmB solubility values were obtained in PBS and in KRB, but the media 
with PBS were selected for dissolution studies due to their easiness of preparation 
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(compared to KRB). First order equation parameters of AmB for corrected for 
degradation dissolution profiles fitted to Eq 3.3, are listed in Table 3.4  
Dissolution profiles in PBS BS 19.8 mM PL 7.9 mM could not be modeled using Eq 
3.3 in either low or high velocity conditions. In the low velocity environment, the % 
AmB dissolved reached a maximum value of 44.93 ± 2.89% at 3.0 h and then started 
to decrease until the end of the experiment (8 h). This could indicate that mixed 
micelles of BS – PL need a stronger agitation (as in the bottle/stirrer setup of solubility 
and degradation studies) to be able to have a steady effect on AmB solubility and not 
only for one part of the test. There was not reduction of the AmB percent dissolved 
when the test was conducted at high velocity, however in this situation there was no 
discernible plateau and rather a very gradual increase in % dissolved over time, 
prohibiting fitting of Eq 3.3 to the data. In summary, AmB is dissolved better under 
the high velocity conditions in the clinical relevant category 3a medium (Figure 3.8). 
There was a statistically significant negative effect of velocity in dissolution rate 
constant for the 0.5 mg dose and a positive effect on maximum % dissolved on the 5 
mg dose, however these differences were of low practical significance and possibly 
reflect process variability.  
The % AmB dissolved in the  experiment with the high dose of AmB reached a plateau 
value of around 30%, due to the solubility of AmB in this medium (~30 µg/mL), 
(Figure 3.8). In category 3b media with BSA, with respect to velocity, the low and 




Table 3.4. Parameters obtained after fitting (Eq 3.3) of %AmB dissolution profiles in category 3b clinically relevant media and 3c media with the 
flow through cell apparatus (Mean ± SD, n = 3). 
Type of medium Medium Flow/velocity 𝒌𝒅𝒊𝒔𝒔  (h
-1) 𝑿𝒎𝒂𝒙 (%) R
2 AIC 
Category 3b 
PBS SLS 1.4 mM Low 
dose 
Low 2.39 ± 0.13 36.28 ± 0.59 0.94 ± 0.00 50.03 ± 0.29 
PBS SLS 1.4 mM High 
dose 
Low 2.98 ± 0.74 16.75 ± 1.16 0.91 ± 0.01 38.77 ± 2.28 
PBS SLS 60.0 mM 
BSA 4.0% w/v 
Low 3.65 ± 1.59 52.79 ± 5.52 0.91 ± 0.05 63.05 ± 3.77 
PBS SLS 1.4 mM Low 
dose 
High 1.88 ± 0.26 38.66 ± 2.08 0.93 ± 0.02 53.94 ± 4.06 
PBS SLS 1.4 mM High 
dose 
High 2.50 ± 0.40 19.47 ± 0.81 0.92 ± 0.01 40.40 ± 1.32 
PBS SLS 60.0 mM 
BSA 4.0% w/v 




PBS SLS 30.0 mM 
BSA 2.0% w/v 
Low 4.21 ± 0.96 53.38 ± 9.94 0.96 ± 0.05 50.47 ± 9.28 
PBS SLS 30.0 mM 
BSA 2.0% w/v 
High 2.33 ± 0.35 63.07 ± 3.48 0.94 ± 0.01 63.20 ± 1.21 
PBS SLS 30.0 mM 
BSA 4.0% w/v 
High 7.66 ± 5.39 37.22 ± 8.20 0.89 ± 0.04 57.06 ± 3.45 
PBS SLS 60.0 mM 
BSA 2.0% w/v 
High 6.43 ± 2.87 78.38 ± 0.50 0.96 ± 0.01 63.08 ± 3.31 
 





In the velocity regimes in the flow through apparatus, both of which are low overall 
in comparison to the bottle/stirrer set up (low velocity: 0.07, high velocity: 0.52, 
bottle/stirrer:10.2 cm/s), a faster dissolution and a higher % AmB dissolved is 
observed in the category 3b medium with BSA compared to the one observed in the 
medium without BSA. This could be attributed to increased wetting/dispersion from 
either the BSA or the SLS. PBS SLS 1.4 mM is suggested as a simplified medium that 
could be used in compendial dissolution testing of AmB parenteral formulation, as 
clinically relevant AmB solubility values were obtained in this medium.  
In category 3c media, the %AmB dissolved in PBS SLS 60.0 mM BSA 2.0% w/v 
started to decrease before the 1.5 h sample in the low velocity conditions. The results 
suggest that the agitation required to keep SLS, BSA and AmB in solution at these 
concentrations was higher as the decrease was not observed when the high velocity 
conditions were used.  The highest %AmB dissolved was observed in PBS SLS 60.0 
mM BSA 2.0% w/v and the lowest in PBS SLS 30 mM BSA 4.0% w/v, supporting 
the hypothesis that BSA binds the surfactants and prevents their interaction with AmB. 
The AmB dissolution profiles in PBS SLS 30.0 mM BSA 2.0% w/v and PBS SLS 60 
mM BSA 4.0% w/v were similar, probably due to the same ratio of SLS/BSA in these 
two media. Velocity had a negative effect only on the dissolution rate of AmB in PBS 
SLS 30.0 mM BSA 2.0% w/v whereas this was not observed in the AmB dissolution 
in the other category 3c media. It could be hypothesized that for this specific medium, 
this difference could be due to that with the low velocity setup (large cell and a flow 
rate of 16/mL), the powder is in contact with a larger volume of medium and for a 
longer period of time than with the high velocity which could help to dissolve the 
powder faster. The results suggest that the most suitable clinically releavant medium 
to simulate hypoalbuminaemic conditions is PBS SLS 30 mM BSA 4.0% w/v; 
confirmation with solubility studies in plasma from hypoalbunaemic patients would 
be needed. This is only based on the hypothesis that in plasma from 
hypoalbuminaemic patients, AmB solubility values will be lower than in healthy 
subjects as a decreasing concentration of albumin decreases AmB solubility. As the 
dissolution profiles were calculated based on concentrations corrected accounting for 
AmB degradation, the degradation rate constant was not a factor to be considered in 
the analysis, as it was already taken into account in the profiles. AmB had clinically 
relevant solubility values in the media used for the dissolution studies (~ 30 µg/mL) 
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and with the amount of AmB and the volume of medium used in the studies, in case 
of the 100% dissolution of AmB the maximum concentration that could be obtained 
was 10 µg/mL which is the third part of the solubility value, thus, the solubility could 
not be a factor affecting the dissolution. Only in category 3c media, where the 
solubility values were different, the differences of AmB percent dissolved could be 
accounted to the solubility.  
3.4. Conclusions 
AmB is an antifungal drug that is highly bound to plasma proteins, including albumin 
and lipoproteins. It is administered to patients intravenously as lipid-based 
formulations. Therefore, a test medium to assess the release profile of the drug from 
its lipid-based parenteral formulations that can provide clinically relevant results is 
desirable. 
In this study we have developed biorelevant media based on plasma composition 
(which was not useful) and clinically relevant dissolution media based on the solubility 
of AmB in plasma. This was achieved by using saline buffers, surfactants (biorelevant 
and synthetic) and BSA. It was shown that addition of BSA in the medium generally 
induces a faster degradation of AmB. Another role of BSA in the media is the 
capability to interfere with the solubilizing activity of almost all of the components 
that were added to the media. Instead of resulting in an improved AmB solubility by 
combining surfactants with BSA, the opposite effect was observed. This has to be 
taken into consideration for development of in vitro test media where the protein 
binding is an important feature. From the dissolution studies, it can be concluded that 
PBS SLS 1.4 mM could be a good option for future release tests of AmB formulations, 
as the degradation in this medium is minimal. This medium was the easiest to prepare 
suggesting its potential suitability for routine use in compendial testing. For the 
simulated hypoalbuminaemic media, PBS SLS 30 mM BSA 4.0% w/v is suggested as 
a potential candidate medium for further (patient centric) medium development, 
although future experiments with hypoalbuminaemic plasma are needed to confirm 
the effect of hypoalbuminaemia on solubility. Development of clinically relevant 
media is a first step for developing clinically relevant dissolution/ release tests with a 
view to obtaining in vitro data predictive of the in vivo behaviour of the formulation 
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Chapter 4: In vitro in vivo relations for the parenteral 
liposomal formulation of Amphotericin B. Part 1: A 
biorelevant and clinically relevant approach 
Abstract 
There is limited information of how to perform in vitro release tests for intravenously 
administered parenteral formulations and how to relate the in vitro release with an in 
vivo pharmacokinetic parameter after the administration of the formulation. In this 
study, the effect of hydrodynamics (sample and separate and continuous flow) and 
medium components (synthetic surfactants, albumin and buffers) on the release of 
Amphotericin B from the liposomal Ambisome® formulation were investigated. 
Pharmacokinetic modeling of plasma concentration profiles from healthy subjects 
administered with Ambisome® was used to estimate the in vivo release rate constant 
of drug from the formulation in order to compare them with the in vitro release 
profiles. With the estimated in vivo release rate constant and with the in vitro release 
rate constant, release concentrations profiles were calculated and percent release 
profiles calculated. Two approaches were followed: comparison of release rate 
constants and comparison of the area under the curve of the percent release. Albumin 
was found to be most critical factor for the release of the drug by having a negative 
effect on the amount of Amphotericin B released. The release profiles obtained with 
the sample and separate setup in Krebs Ringer buffer - albumin 4.0% w/v and the 
release profile in Krebs Ringer buffer - albumin 2.0% w/v medium with the continuous 
flow setup at low velocity were similar to the in vivo release profiles in healthy 
subjects. Determining the factors affecting drug release from parenteral formulations 
and relating the release profiles to a pharmacokinetic parameter in vivo could lead to 
the development of in vitro in vivo correlations and relations. 
 
Keywords: 





The timescale of therapeutic effect of parenterals can be controlled, to a certain extent, 
by the type of the formulation (e.g. microparticles, nanoparticles, suspensions, 
liposomes). Liposomes, the focus of this study, are vesicles formed by one or more 
phospholipid bilayers with an internal aqueous phase and a size ranging from 25 nm 
to 2500 nm that could encapsulate or integrate drugs in their structure [1]. There is a 
lack of regulatory guidance with specific release tests conditions for in vitro release 
tests for liposomes. Shah et. al. [2] provide some recommendations for the release 
testing: the use of the flow through cell dialysis adapter in the flow through cell 
apparatus. The FDA guideline for liposomal products only states that a validated 
release test should be performed with a suitable release medium (plasma, simulated 
physiological or a non-physiological medium) and with suitable agitation [3]. In vitro 
release from liposomes has been studied using several methods including dialysis and 
sample and separate methods [4-7]. In sample and separate methods, a critical step is 
the separation of the released drug from the liposomes. Ultracentrifugation can be 
used, but the long times required to pellet small liposomes makes this technique 
unsuitable to capture a snapshot of drug release for construction of a release profile 
[8-13]. Solid phase extraction (SPE) provides a quicker separation and the drug still 
entrapped in the liposomes can also be quantified; making it possible to calculate the 
release based on how much drug remains in the formulation (particularly suitable if 
the released drug has degradation or solubility issues) [14, 15].  
For the development of an in vitro release test for liposomes the first step is to consider 
selection of relevant conditions: a suitable release medium based on the 
physicochemical properties of the drug, suitable hydrodynamics and an adequate 
dialysis membrane with an appropriate molecular weight cut-off (MWCO) if needed. 
In vitro hydrodynamics would relate to the agitation applied in the form of 
predominantly rotational flow, provided by e.g. a magnetic stirrer, or by a 
predominantly linear flow e.g. the flow through cell apparatus [2]. 
Amphotericin B (AmB) is a polyene anti-fungal antibiotic, which is highly protein 
bound in vivo [16]. Ambisome® is a commercially available liposomal parenteral 
formulation of AmB. Ambisome® liposomes have a diameter less than 100 nm and 
consist of a unilamellar bilayer with AmB intercalated within the membrane, where 
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the drug is an integral part of the liposomal structure [17]. Ambisome® is administered 
by intravenous infusion to patients with suspected or proven systemic fungal 
infections [18]. Such patients can be critically ill and frequently exhibit 
hypoalbuminaemia. 
The release of polydiacetylene, a colorimetric compount, from liposomes has been 
reported, with the same charge and made of similar components as Ambisome® 
(negative charged liposomes of dimyristoylphosphatidycholine and polymerized 10, 
12-pentacosadiynoic), using CTAB (cationic surfactant), SLS (anionic surfactant) and 
Triton 100X (non-ionic surfactant) [19]. CTAB produced the fastest release followed 
by Triton 100X. The release with SLS was minimal but the addition of NaCl increased 
the amount released; as for charged surfactants, an increase in the ionic strength 
decreased the critical micellar concentration (CMC), while non-ionic surfactants were 
not affected [20]. Therefore, the buffer used in the release test is another factor to 
investigate. Mechanistically, it has been reported that surfactant monomers partition 
into the surface of the liposomes, then surfactant-saturated vesicles and lipid-saturated 
micelles start to coexist followed by the lipids forming mixed micelles with the 
surfactants eventually leading to liposomal disruption [21-23].  
Whereas in vitro release tests are frequently conducted for quality control purposes, in 
vitro release test conditions which reflect the in vivo prefromance are desirable. For 
parenteral formulations administered intravenously such as liposomes, 
pharmacokinetic (PK) models of formulated and released drug circulating 
concurrently could be exploited to estimate the in vivo release profile, in order to guide 
in vitro release test development.  
In previous studies, biorelevant media representing the plasma albumin concentration 
(Category 1 media [24] Chapter 3]) and media able to provide clinically relevant AmB 
solubility values using synthetic surfactants (Category 3b media [Chapter 3]) have 
been developed. These media were developed based on the AmB active 
pharmaceutical ingredient (API) and tests are needed to investigate how these media 
will affect the release from the liposomal formulation. Ambisome® liposomes are 
negatively charged [17] and this will define how surfactants, depending on their 
charge, will interact with them.  
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The aims of this study were a) to investigate how media composition including 
synthetic surfactants, buffers and protein content (bovine serum albumin (BSA) 
concentration); and hydrodynamic conditions affect the release of AmB from 
Ambisome® liposomes and b) using PK modelling of published data of AmB plasma 
concentration from healthy subjects to estimate in vivo release rates and area under the 
curve of the percent released profile, in order to identify clinically relevant in vitro test 
conditions for a parenteral liposomal formulation using Ambisome® as model 
formulation.  
4.2. Materials and Methods 
4.2.1. Materials 
AmB analytical standard (87.8%), methanol (MeOH) high performance liquid 
chromatography (HPLC) grade, formic acid mass spectrometry grade, NaOH, MgCl2, 
CaCl2, hexadecyltrimethylammonium bromide (CTAB), NaHCO3 were obtained from 
Sigma Aldrich (Germany); AmB API powder (85%) from Cayman Chemical (USA); 
BSA protease free powder fraction V, dimethyl sulfoxide (DMSO), dextrose, sodium 
dodecyl sulphate (SLS), Na2HPO4, NaH2PO4, KH2PO4, NaCl and KCl from Fisher 
Scientific (USA); Tween 80 from Amresco (USA); GF/D (pore size 2.7 μm, 25 mm 
diameter) and GF/F (pore size 0.7 μm, 25 mm diameter) filters from Whatman (UK); 
regenerated cellulose (RC) filters 0.45 µm 13 mm diameter from Cronus (UK); 
cellulose ester dialysis tubing of 300 kDa MWCO from Spectrum Labs® (USA) and 
Sep – Pak® Vac 3cc (500 mg) tC18 SPE column from Waters (Massachusetts, USA).  
4.2.2. Sample treatment of AmB from release media 
The SPE method to separate liposomal AmB from released AmB was a modification 
of the method reported by Egger et al [15]. Briefly, the SPE column was conditioned 
with 1.0 mL of MeOH followed by 1.0 mL of water. 1.0 mL of sample was passed 
through the column and the eluate was collected in a clean vial (liposomal AmB), the 
column was washed with 2.0 mL of water and collected in the same tube (remaining 
liposomal AmB in the column). 1.0 mL of methanol was passed through the column 
to elute the AmB retained in the column (released AmB). In the case of samples with 
proteins, samples were treated as described previously [24]. Briefly, proteins were 
precipitated by adding 2 volumes of methanol to 1 volume of the sample followed by 
mixing in a vortex for 30 seconds and then centrifuged for 10 minutes at 12000 rpm 
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and 5°C in an Eppendorf centrifuge. Supernatant was filtered through a 0.45 μm RC 
filter before injection to the HPLC. 
4.2.3. Chromatographic conditions for the analysis of AmB from release media 
The chromatographic method to quantify AmB was described previously [24]. Briefly, 
AmB was quantified by HPLC with a C18 Waters Sunfire column (Ireland) 150 x 46 
mm 5μm at 25°C. The mobile phase was formate buffer (50 mM; pH = 3.2): MeOH 
(25:75, v/v); the flow rate was 1 mL/min and AmB was detected at λ = 406 nm. The 
UV spectrum was recorded from 300 to 450 nm. Quantification of AmB in samples 
was made based on calibration curves. Freshly prepared standard solutions (0.5 – 15 
μg/mL) in the corresponding medium were prepared by appropriate dilution of a 500 
μg/mL stock solution of AmB analytical standard in 1:1 MeOH: DMSO v/v. The limit 
of detection and the limit of quantification were 0.12 and 0.37 μg/mL, respectively. 
4.2.4. In vitro release studies of AmB from Ambisome® formulation 
The factors investigated for the development of the in vitro release studies were: i. the 
composition of the release media: type of buffer, BSA concentration and synthetic 
surfactants concentration, and ii. the hydrodynamic conditions in terms of the 
apparatus used i.e. sample and separate (bottle/stirrer) or continuous flow (flow 
through cell apparatus).  
4.2.4.1. Sample and separate method (bottle/stirrer setup) 
Ambisome® powder (0.5 mg AmB) was placed into a 100 mL glass bottle (56 mm 
diameter/ 105 mm height; Duran, Germany) with 30 mL of release medium and stirred 
with a magnetic stirrer (in a Variomag multipoint stirring plate) at 37°C. Release 
studies were performed based on a two level factorial design of experiments (DoE) 
(section 4.2.9). The composition of release media and agitation conditions used in the 
DoE are shown in Table 4.1, the combination of all the factors resulted in 8 







Table 4.1. Levels and factors investigated with the sample and separate setup for the 
release studies of AmB from Ambisome®. 
Factors in KRB (no synthetic surfactants added) 
Level BSA %w/v Buffer Agitation (rpm) 
-1 2.0 PBS 130 (Low Agitation) 
+1 4.0 KRB 380 (High Agitation) 
Factors in media with synthetic surfactant (SLS) 
Level BSA %w/v Buffer Agitation (rpm) 
- 1 0.0 PBS 130 (Low Agitation) 
+ 1 4.0 KRB 380 (High Agitation) 
 
The agitation rates in the bottle/stirrer setup were selected based on the linear velocity 
of the stirrer edge, which at 130 rpm (10.2 cm/s) is comparable to the veins and at 380 




Table 4.2. In vivo (bloodstream) and in vitro (flow through cell apparatus with the 




(flow through cell 
apparatus) 








Arteries 3.0 - 26.0 4.9 - 19.0 3.0 - 26.0 0.01 - 0.11 
Veins 1.2 - 4.8 1.50 - 7.80 1.2 - 4.8 0.00 - 0.02 
Coronary artery 35.0 - 35.0 0.15 
Capillaries - 0.03 7.0 0.03 
Aorta - 30.0- 40.0 9655.0 40.00 
Vena cave - 15.00 3620.0 15.00 
 
The concentration of SLS was as described previously [Chapter 3] to produce 
clinically relevant AmB solubility values (PBS SLS 1.4 mM, KRB SLS 1.5 mM, PBS 
SLS 60.0 mM BSA 4.0% w/v and KRB SLS 30.0 mM BSA 4.0% w/v). In addition to 
the experimental conditions described in Table 4.1, release studies were also 
performed in KRB with CTAB and Tween 80 without BSA at low agitation. The 
concentration selected was the CMC + 5% CMC of the surfactant in KRB (CTAB 
CMC = 0.2 mM [Chapter 3], Tween 80 = 10.0 µM [28]) being 0.2 mM for CTAB and 
10.5 µM for Tween 80 the concentrations tested. Sampling times were 1, 2, 4, 6, 8, 
and 12 h and after sample treatment (SPE and protein precipitation; section 4.2.3), 
samples were injected to the HPLC and the % AmB release over time was calculated. 
All experiments were performed in triplicate.  
4.2.4.2. Continuous flow (flow through cell apparatus) 
AmB release studies were carried out in a flow-through cell dissolution apparatus 
(Sotax CE7 smart connected to a Sotax piston pump CP7, Sotax, Aesch, Switzerland) 
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operated in the closed mode [29]. A 5mm ruby glass bead was positioned at the bottom 
of the cell (large cell: 22.6 mm diameter). The dialysis membrane was placed onto the 
flow through cell apparatus dialysis adapter and Ambisome® powder (0.5 mg AmB) 
was placed into the membrane with 1.0 mL of the release medium. Glass fibre filters 
(GF/D, GF/F) were positioned at the top of the cell. 
Release studies were performed considering a) biorelevant conditions and b) 
conditions using synthetic surfactants. The biorelevant release studies were based on 
a two level factorial DoE, where the velocity [low velocity: 8 mL/min, high velocity: 
35 mL/min; at 8 mL/min, has linear velocity comparable to capillary linear velocities 
and at 35 mL/min, a flow rate comparable to the coronary artery (Table 4.2)] and BSA 
concentration in KRB (2.0 and 4.0% w/v, representing hypoalbuminaemic and healthy 
subjects, respectively) were the factors investigated. 36 mL of release medium were 
used in order to simulate the equivalent volume available on administration of 1 mg/kg 
of AmB as Amphotericin B® to a 70 kg subject (assuming 5 L of blood volume).  
For studies performed in media with synthetic surfactants PBS SLS 1.4 mM was the 
release medium and the effect of velocity was investigated [medium velocity: 16 
mL/min, high velocity: 35 mL/min] and 50 mL of medium were used in order to 
achieve sink conditions (3x saturation solubility) [Chapter 3].  
Samples were taken for up to 12 h and, after sample treatment (if necessary), were 
injected to the HPLC and the %AmB release over time was calculated. All 
experiments were performed in triplicate at 37°C.  
4.2.5. Release data treatment 
Data treatment was previously described [24]. Briefly, for the studies with the sample 
and separate method, %AmB released over time was calculated based on the percent 
of AmB still entrapped in the liposomes at the time of sampling (%𝐴𝑚𝐵𝑙𝑖𝑝𝑜𝑠𝑜𝑚𝑎𝑙) 
(Equation 4.1) to construct the calculated %𝐴𝑚𝐵𝑟𝑒𝑙𝑒𝑎𝑠𝑒𝑑 profile. 
%𝐴𝑚𝐵𝑟𝑒𝑙𝑒𝑎𝑠𝑒𝑑 = %𝐴𝑚𝐵𝑖𝑛𝑖𝑡𝑖𝑎𝑙 − %𝐴𝑚𝐵𝑙𝑖𝑝𝑜𝑠𝑜𝑚𝑎𝑙   (Equation 4.1)  
where %𝐴𝑚𝐵𝑖𝑛𝑖𝑡𝑖𝑎𝑙 is the mass of AmB placed into the reservoir initially (100%) and 
%𝐴𝑚𝐵𝑟𝑒𝑙𝑒𝑎𝑠𝑒𝑑 is the calculated AmB percent released at time 𝑡. There was no 
correction for degradation for these profiles as the AmB still in the liposome cannot 
be subject of degradation. 
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For the studies with the continuous flow method, %AmB released over time was 
corrected for degradation using the degradation rate constant [Chapter 3] with 
Equation 4.2 to construct the calculated %𝐴𝑚𝐵𝑟𝑒𝑙𝑒𝑎𝑠𝑒𝑑 profile. 
%𝐴𝑚𝐵𝑟𝑒𝑙𝑒𝑎𝑠𝑒𝑑 = %𝐴𝑚𝐵𝑟𝑒𝑙𝑒𝑎𝑠𝑒𝑑(𝑜𝑏𝑠) + 𝑘𝑑𝑒𝑔 ∗ 𝐴𝑈𝐶0−𝑡   (Equation 
4.2) 
where %𝐴𝑚𝐵𝑟𝑒𝑙𝑒𝑎𝑠𝑒𝑑 is the corrected AmB percent released accounting for 
degradation, %𝐴𝑚𝐵𝑟𝑒𝑙𝑒𝑎𝑠𝑒𝑑(𝑜𝑏𝑠) is the AmB percent released at time t, 𝐴𝑈𝐶0−𝑡 is the 
Area Under the Curve of the observed concentration – time curve from time 0 to time 
𝑡  and 𝑘𝑑𝑒𝑔 is the degradation rate constant obtained from the degradation experiments 
[Chapter 3]. 
First order curve fitting (Eq 4.3) was performed on the %𝐴𝑚𝐵𝑟𝑒𝑙𝑒𝑎𝑠𝑒𝑑 profiles in order 
to obtain the release rate constant (𝑘𝑟𝑒𝑙) (GraphPad Prism 7, GraphPad Software, Inc, 
USA). 
%𝐴𝑚𝐵𝑟𝑒𝑙𝑒𝑎𝑠𝑒𝑑 = %𝐴𝑚𝐵𝑟𝑒𝑙𝑒𝑎𝑠𝑒𝑑𝑚𝑎𝑥 ∗ (1 − 𝑒
−𝑘𝑟𝑒𝑙𝑡) Eq 4.3. 
where 𝑡 is time and %𝐴𝑚𝐵𝑟𝑒𝑙𝑒𝑎𝑠𝑒𝑑𝑚𝑎𝑥 is the maximum AmB amount released. The 
coefficient of determination (R2) and Akaike information criterion (AIC) were 
calculated. 
𝐴𝑈𝐶0−12ℎ was calculated for all the %𝐴𝑚𝐵𝑟𝑒𝑙𝑒𝑎𝑠𝑒𝑑 profiles. 
4.2.6. Atomic Force Microscopy (AFM) 
To further investigate the effect of proteins and surfactants on the liposomes, AFM 
studies were performed. Ambisome® liposomes were incubated in the following 
media: KRB, KRB BSA 4.0% w/v, KRB SLS 1.5 mM BSA 4.0% w/v (for 30 minutes) 
and in KRB CTAB 0.2 mM, KRB Tween 10.0 µM and KRB SLS 1.5 mM (for 5 
minutes; a shorter period of incubation was set in order to reflect the fast release of 
AmB from the liposomes observed in the absence of BSA). After the incubation, 
samples were centrifuged for 30 minutes at 13,300 rpm in an Eppendorf centrifuge, 
the supernatant was discarded and the pellet was dried under vacuum. The pellets were 
diluted with 1 mL of HPLC water, and then 10 µL of the liposomal solution was placed 
on a freshly cleaved mica surface (1.5 cm × 1.5 cm; G250-2 Mica sheets 1″ × 1″ × 
0.006″; Agar Scientific Ltd., Essex, UK). The sample was then air-dried for ∼30 min 
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and imaged immediately by scanning the mica surface in air under ambient conditions 
using a Bruker MultiMode 8 Scanning Probe Microscope (Digital Instruments, Santa 
Barbara, CA, USA) operated on Peak Force QNM mode. The AFM measurements 
were obtained using ScanAsyst-air probes; the spring constant was calibrated by 
thermal tune (Nominal 0.4 N m−1) and the deflection sensitivity calibrated using a 
silica wafer. AFM scans were acquired at a resolution of 512 × 512 pixels at scan rate 
of 1 Hz, and produced topographic images of the samples in which the brightness of 
features increases as a function of height. The surface roughness (Ra) of each substrate 
was determined by using Nanoscope Analysis’ algorithm to analyse several scans of 
the surface from different locations (n = 20). AFM images were collected from random 
spot surface sampling (at least four areas).  
4.2.7. PK modeling for the estimation of the in vivo AmB release rate constant 
from plasma concentration profiles 
4.2.7.1. Data for PK modeling of Ambisome® following administration to healthy 
subjects  
Published data of plasma concentration profiles from healthy subjects administered 
with Fungizone® (AmB deoxycholate formulation, molar fractions: sodium 
deoxycholate and AmB, 0.7 and 0.3 respectively [30,31]) and Ambisome®, where the 
liposomal and released AmB were quantified, were digitalized with Webplot 
digitalizer 3.8 software (Table 4.3). 
Table 4.3. In vivo studies of administration of AmB formulations (Fungizone® and 
Ambisome®) to healthy subjects. 
Population Healthy subjects 
Formulation Fungizone® Ambisome® 
# of subjects 5 5 
Dose 0.6 mg/kg 2.0 mg/kg 
Infusion time 2.0 h 2.0 h 




4.2.7.2. Workflow for PK modeling and estimation of in vivo release profile 
The workflow for the PK modeling to estimate the in vivo release rate constant of 
AmB from Ambisome® (𝑘𝑟𝑒𝑙−𝑖𝑣) and for model optimization are shown in Figures 4.1 
and 4.2, respectively. 
 
Figure 4.1. Workflow for the PK modeling of free AmB (Fungizone® administration) 
and liposomal AmB (Ambisome® administration) in order to estimate 𝑘𝑟𝑒𝑙−𝑖𝑣 (in vivo 




Figure 4.2. Compartmental PK modeling of liposomal AmB and free AmB for the 
estimation of 𝑘𝑟𝑒𝑙−𝑖𝑣.  
Compartmental modeling was performed with the excel add-in PKSolver [34] and the 
estimation of 𝑘𝑟𝑒𝑙−𝑖𝑣, the optimization of the models and the simulations were 
performed with Berkeley Madonna® 8.3.23 software. The R2 was obtained from 
observed plasma concentration profiles vs predicted plasma concentration profiles of 
both liposomal and released AmB . The in vivo elimination rate constant from 
liposomal AmB models (𝑘𝑒𝑙𝐿) comprised the sum of the rate constants of liposomal 
AmB elimination (𝑘10𝐿) and in vivo AmB release (𝑘𝑟𝑒𝑙−𝑖𝑣), i.e. 𝑘𝑒𝑙𝐿 = 𝑘10𝐿 + 𝑘𝑟𝑒𝑙−𝑖𝑣.  
4.2.8. Evaluation of the in vitro tests using the PK model 
The evaluation of the capacity of the AmB in vitro release tests to predict the in vivo 
release was explored in two parts: 
Part A. In vitro release rate constants (𝑘𝑟𝑒𝑙) (from the profiles that fitted a first-order 
release profile) were compared to 𝑘𝑟𝑒𝑙−𝑖𝑣. 
Part B. In vivo release profiles were simulated using 𝑘𝑟𝑒𝑙−𝑖𝑣, using the same dose and 
available volume as was used in the in vitro release tests to facilitate comparison with 
in vitro data. Three simulated % AmB released profiles of mean +/- 1 standard 
deviation were generated using 𝑘𝑟𝑒𝑙−𝑖𝑣, followed by calculation of AUC 0-12h.  
4.2.9. Statistical analysis 
Pareto charts, based on the DoE analysis, were constructed for the identification of 
significant factors affecting the AUC0-12h obtained from the in vitro release tests. A 
factor was significant when the standardized effect (bars) was larger than the line for 
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statistical significance level (α = 0.05) (vertical line). An independent means t – tests 
was performed to compare 2 independent means: for the continuous flow studies with 
PBS SLS 1.4 mM at low and high velocity; in the AFM studies, data were compared 
against the control sample [KRB control (centrifugation/vacuum)]; and for 𝐴𝑈𝐶0−12ℎ 
values from simulated in vivo and observed in vitro AmB release profiles. A p<0.05 
was considered significant. Additionally, the 90% confidence interval (90% CI) for 
the ratio of the averages of the measures for the observed in vitro and predicted in vivo 
ln𝐴𝑈𝐶0−12ℎ were calculated. Data analysis, creation and analysis of the design of 
experiments were performed with the statistical software Statgraphics Centurion XVII 
(USA) and the 90% CI were calculated with IBM SPSS Statistics 25 (USA). 
4.3. Results and discussion 
4.3.1. In vitro release studies of AmB from Ambisome® using sample and separate 
and continuous flow setups 
4.3.1.1. Sample and separate method 
In vitro release profiles of AmB from Ambisome® using the sample and separate 
method are shown in Figure 4.3 and their corresponding 𝐴𝑈𝐶0−12ℎ values are 




Figure 4.3. %AmB released as a function of time using the sample and separate 
method at 37°C to investigate the effects of buffer, agitation, composition including 
a) BSA concentration and b) type of synthetic surfactant and BSA 4.0% w/v presence) 
on AmB release (Mean ± SD; n = 3).  
 
Table 4.4. %AmB 𝐴𝑈𝐶0−12ℎ calculated for all the in vitro release profiles: sample 
and separate and continuous flow investigating the effect of buffers, BSA 
concentration, surfactants and agitation [for sample and separate; LA: low agitation, 
HA: high agitation. For continuous flow; LV: low velocity, HV: high velocity] (Mean 








PBS 2.0 LA - 296.04 ± 24.89 
KRB 2.0 LA - 327.34 ± 23.63 
PBS 4.0 LA - 176.35 ± 36.09 
KRB 4.0 LA - 162.14 ± 29.63 
PBS 2.0 HA - 401.98 ± 28.82 
KRB 2.0 HA - 409.86 ± 69.55 
PBS 4.0 HA - 173.78 ± 24.78 
KRB 4.0 HA - 146.79 ± 8.11 
PBS 0.0 LA SLS 1140.67 ± 0.78 
KRB 0.0 LA SLS 1112.47 ± 1.37 
PBS 4.0 LA SLS 1136.05 ± 5.95 
KRB 4.0 LA SLS 1138.21 ± 2.3 
KRB 0.0 LA Tween 80 1107.72 ± 5.25 
KRB 0.0 LA CTAB 1137.93 ± 3.23 
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PBS 0.0 HA SLS 1150 
KRB 0.0 HA SLS 1117.67 ± 8.98 
PBS 4.0 HA SLS 1135.18 ± 6.79 
KRB 4.0 HA SLS 1150 
Flow through cell apparatus 
KRB 2.0 LV - 174.38 ± 15.63 
KRB 4.0 LV - 376.23 ± 13.76 
KRB 2.0 HV - 745.35 ± 97.47 
KRB 4.0 HV - 408.91 ± 80.85 
PBS 0.0 MV SLS 442.33 ± 129.39 
PBS 0.0 HV SLS 694.36 ± 124.82 
 
In media with synthetic surfactants, the release is almost complete at the first sampling 
point (1 h) regardless of the buffer or the surfactant tested. Consequently, the statistical 
analysis of release rates could not be performed for the release profiles in synthetic 
surfactants using the sample and separate method. As it is observed in vivo that 
liposomal AmB is in circulation for more than 1 h [33], ~100% release from the 
liposomes at 1 h would not be considered a clinically relevant profile. The statistical 
analysis of 𝐴𝑈𝐶0−12h of the release profiles obtained with the sample and separate 
method (Figure 4.4a) shows that the buffer used to prepare the medium does not have 
any effect on the release, while BSA concentration and agitation had a negative and 




Figure 4.4. Pareto charts for the estimated effects of the main factors and 2 level 
interactions of the analysis of 𝐴𝑈𝐶0−12ℎ from a) sample and separate and b) 
continuous flow methods. A factor was significant when the estimated effect 
(horizontal bars) was larger than the standardized effect (vertical line). 
The interaction between BSA concentration and agitation was significant, revealing 
that even though agitation does not affect the release of AmB in media containing 
BSA 4.0% w/v, at the higher agitation in media with a lower concentration of BSA 
(2.0% w/v) affect the release as observed by the higher 𝐴𝑈𝐶0−12ℎ.The positive effect 
of agitation on the release of AmB from the liposomal formulation could be attributed 
to the increased suspension or dispersal of the liposomes and thus exposure to the 
medium, and/ or the increased mechanical stress exerted on the liposomes (i.e. 
collision with the bottle's wall or the magnetic stirrer). It is interesting that in higher 
agitation conditions the release of AmB from the liposomes in media with a lower 
BSA concentration (2.0% w/v), was higher than in the media with a higher BSA 
concentration (4.0% w/v). BSA seems to provide some kind of protective effect to the 
liposome, as the release of AmB from Ambisome® did not change significantly 
between both agitation conditions when BSA 4.0% w/v was present in the media. It 
has been reported that an increasing concentration of BSA (from 0.05 to 0.50% w/v in 
PBS) increases the permeability of liposomes as BSA is adsorbed on their surface. 
This adsorption (possibly due to hydrophobic interaction) is higher in negatively 
charged liposomes than in neutral or positively charged liposomes [35-37]. It could be 
suggested that this interaction increases the permeability of liposomes but as AmB is 
part of the structure of the liposome itself and not part of the liposome core that could 
be leaked when the permeability has been increased. Further studies for the 
characterization of this interaction of BSA with the Ambisome® liposomes would 
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provide a mechanistic understanding of the release process of AmB from the liposomal 
formulation. 
The release profiles of AmB from liposomes in PBS and KRB BSA 2.0% w/v at low 
agitation and PBS and KRB BSA 4.0% at high agitation showed first order release and 
the parameters from the first order fitting are listed in Table 4.5. 
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Table 4.5. Parameters obtained after fitting (first order equation model) of %AmB released profiles from Ambisome® in the sample and separate 









Sample and separate 
PBS 2.0 LA 0.117 ± 0.040 56.07 ± 10.04 0.93 ± 0.04 35.01 ± 2.81 
KRB 2.0 LA 0.215 ± 0.083 44.96 ± 4.88 0.94 ± 0.06 31.99 ± 9.93 
PBS 4.0 HA 0.322 ± 0.245 21.90 ± 4.37 0.85 ± 0.11 30.01 ± 7.03 
KRB 4.0 HA 0.127 ± 0.022 25.09 ± 3.50 0.86 ± 0.04 29.36 ± 3.11 
Continuous flow 
KRB 4.0 HV 0.467 ± 0.162 43.10 ± 10.56 0.86 ± 0.03 66.54 ± 7.51 
PBS SLS 1.4 mM 0.0 MV 0.725 ± 0.102 41.87 ± 12.27 0.93 ± 0.10 49.69 ± 8.84 




4.3.1.2. Continuous flow method 
In vitro release profiles of AmB from Ambisome® obtained using the continuous flow 
setup are shown in Figure 4.5 and their corresponding 𝐴𝑈𝐶0−12ℎ values are presented 
in Table 4.4.  
 
Figure 4.5. %AmB released as a function of time with the continuous flow setup at 
37°C in a) KRB to investigate the effects of BSA concentration and velocity, and b) 
in PBS SLS 1.4 mM to investigate the effect of velocity on AmB release (Mean ± SD; 
n = 3). 
 
The release of AmB from the liposomes in media incorporating synthetic surfactant 
(SLS) was slower than the one observed with the sample and separate setup. The 
slower release observed with this method could be attributed to the use of the dialysis 
membrane with this set up. 
The statistical analysis showed that the flow rate had a positive effect on the AmB 
release from the liposomes. The BSA*Flow rate interaction had a similar positive 
effect on the AmB release (as observed for the sample and separate setup studies), 
whereas the BSA concentration on its own was not a significant factor for the release 
(Figure 4.4b). The flow rates (in PBS SLS 1.4 mM) shows that 𝐴𝑈𝐶0−12ℎ is not 
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statistically similar when a high velocity is used compared to the low velocity. The 
release profiles of AmB from liposomes KRB BSA 4.0% w/v medium at high velocity 
and in PBS SLS 1.4 mM at both medium and high velocities showed first order release 
and the parameters from the first order fitting are listed in Table 4.5. 
4.3.2. AFM studies 
Figure 4.6 shows the images obtained from the AFM and Table 4.6 contains the 
parameters of the liposome characteristics measured with the AFM.  
 
Figure 4.6. AFM images to evaluate the effect of media components on Ambisome® 
liposomes. a) KRB, b) KRB BSA 4.0% w/v, c) KRB SLS 1.5 mM, d) KRB SLS 1.5 
mM BSA 4.0% w/v, e) KRB CTAB 0.2 mM and f) KRB Tween 80 10.0 µM. The 




Table 4.6. Parameters of liposomes obtained from AFM from the samples prepared 
with the media components investigated in the in vitro release studies 
Sample Diameter (nm) Surface 
Roughness (nm) 
KRB control (centrifugation/vacuum) 69.4 ± 18.9 12.9 ± 1.6 
KRB BSA 4.0% w/v 29.0 ± 2.6 4.1 ± 0.2 
KRB SLS 1.5 mM No Particles 
KRB SLS 1.5 mM BSA 4.0% w/v 100.0 ± 27.4 10.0 ± 3.1 
KRB CTAB 0.2 mM No Particles 
KRB Tween 10.0 µM 81.4 ± 7.7 11.6 ± 2.4 
 
Liposomes could not be seen on the samples from media with SLS and CTAB (Figure 
4.6c and 4.6e), probably due to quick disruption of the liposomes in the presence of 
these surfactants in the media, as revealed also from the complete AmB release at the 
first sampling point in these media with the sample and separate setup (Figure 4.3). 
Liposomes were found in the sample with Tween 80 (Figure 4.6f) as expected by the 
slightly slower release in this medium. The liposomes in the medium with Tween 80 
appear to be larger in size than the control sample, which could reflect occurrence of 
the reported mechanism of surfactant-liposome interaction, with surfactant-saturated 
vesicles and lipid-saturated micelles, which increase the size of the liposomes before 
the liposomal disruption [21-23]. The presence of BSA in the media with SLS results 
in an alteration of the interaction of the surfactant (SLS) with the liposomal structure, 
as liposomes were present in this sample, revealing the interference of the surfactant 
by BSA (Figure 4.6d) [38-40]. The liposomes in the sample with BSA and SLS were 
larger in size than those observed in the corresponding sample without SLS, possibly 
due to changes in BSA structure on interaction with SLS because of alterations in 
liposome permeability on interaction with BSA or due to aggregation. Aggregation 
can be observed in the sample with BSA only (Figure 4.6b) as in the sample with 
Tween 80, probably due to the same process described above. The diameter and 
surface roughness of the liposomes were statistically significant different to the control 
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sample [KRB control (centrifugation/vacuum)] for the samples in KRB BSA 4.0% 
w/v, KRB CTAB 0.2 mM and KRB SLS 1.5 mM, showing that the charged surfactants 
and proteins have an effect on the size and shape of the liposomes. These parameters 
(diameter and surface roughness) were not statistically significantly different 
compared to the controlled sample for the samples in KRB SLS 1.5 mM BSA 4.0 % 
w/v and KRB Tween 80, revealing that the interaction between SLS and BSA changes 
the way that these molecules interact with the liposomes and that the non-ionic 
surfactant is slightly less aggressive to the liposomes than the charged ones. 
4.3.3. PK modeling of in vivo release profiles in healthy subjects  
Observed and predicted in vivo liposomal and released AmB plasma profiles are 
shown in Figure 4.7. Table 4.7 shows the PK parameters obtained from compartmental 
modeling before and after model optimization, and the estimated value of 𝑘𝑟𝑒𝑙−𝑖𝑣.  
 
 
Figure 4.7. Observed and predicted liposomal and released AmB plasma profiles 
simulated with the optimized models. Healthy subjects data (Bekersky et al, n = 5, 
[31]), a) Liposomal AmB, b) released AmB. Blue points and line: observed data; red 









Table 4.7. PK parameters from the compartmental modeling and model optimization 
from liposomal and released AmB after administration to healthy subjects.  
  PK parameters 
Population Healthy subjects 
AmB form Free Liposomal 
V1 (L) initial 4.830 4.820 
optimized 4.830 4.820 
𝒌𝟏𝟎  (h
-1) initial 0.539 0.155 
optimized 1.052 ± 0.301 0.129 ± 0.002 
𝒌𝟏𝟐 (h
-1) 4.955 0.285 
𝒌𝟐𝟏 (h
-1) 0.737 0.538 
R2 initial 0.19 0.99 
optimized 0.92 ± 0.06 0.99 
𝒌𝒓𝒆𝒍−𝒊𝒗 (h
-1) - 0.025 ± 0.002 
 
The liposomal AmB profile for healthy subjects was explained by the model 
developed (R2 = 0.99). The model for liposomal AmB did not change after the 
optimization as the only relevant parameter is the 𝑘𝑒𝑙𝐿 which includes 𝑘𝑟𝑒𝑙−𝑖𝑣 and 𝑘10𝐿. 
The 𝑘𝑟𝑒𝑙−𝑖𝑣 value was set to be lower than 𝑘𝑒𝑙𝐿 and the difference of the value with 
𝑘𝑒𝑙𝐿 was 𝑘10𝐿. After the optimization, the elimination rate constant of released drug 
was higher than the initial value due to the presence of sodium deoxycholate in 
Fungizone®; this could suggest that released AmB is being removed from plasma more 
quickly than the AmB administered as Fungizone®. As 𝑘10 was an optimized 
parameter the decrease in the amount of drug in plasma could also be due to 
distribution to tissues, accounting for the value of 𝑘12 instead of 𝑘10. However, with 
limited data this cannot be considered as a conclusion.  
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The difference in the half – life of elimination for AmB from Fungizone® (0.17 ± 0.14 
h; calculated after poly-exponential fiting) [33] and from Ambisome® (0.66 h; 
calculated from the PK modeling, reflects the difference of the administered 
formulation. 
4.3.4. Evaluation of clinical relevance of the in vitro release tests  
4.3.4.1. Part A. Comparison of in vitro and in vivo release rate constants 
The in vitro krel (obtained from the first order fitting of the in vitro release profiles) 
and the 𝑘𝑟𝑒𝑙−𝑖𝑣  of healthy subjects (obtained from the PK modeling of liposomal and 
released plasma concentration profiles [33]) are presented in Table 4.8.  
Table 4.8. Statistical comparison of in vitro release rate constants (from the sample 
and separate and continuous flow setups) and in vivo release rate constants (estimated 
with the PK model for healthy subjects, 𝑘𝑟𝑒𝑙−𝑖𝑣  = 0.025 ± 0.002 h
-1). * = statistically 
similar [for sample and separate; LA: low agitation, HA: high agitation. For 











PBS 4.0 HA 0.322 ± 0.245 0.17* 
KRB 4.0 HA 0.127 ± 0.022 0.01 
KRB 4.0 HV 0.467 ± 0.162 0.04 
PBS SLS 1.4 mM 0.0 LV 0.725 ± 0.102 0.00 
PBS SLS 1.4 mM 0.0 HV 1.547 ± 0.523 0.00 
 
The in vitro krel are higher than the in vivo release rate. However, this analysis assumes 
a first-order release rate in vivo and is hindered by the lack of first order release in 
vitro in several of the test conditions.The in vitro 𝑘𝑟𝑒𝑙 estimated from the study in PBS 
BSA 4.0% w/v at high agitation was statistically similar to the 𝑘𝑟𝑒𝑙−𝑖𝑣 of healthy 
subjects this result needs to be interpreted with caution though as the coefficient of 
variation for the in vitro 𝑘𝑟𝑒𝑙 is 75% and the constants could be considered similar due 
to this high variability. 
141 
 
4.3.4.1. Part B. Comparison of in vivo and in vitro 𝑨𝑼𝑪𝟎−𝟏𝟐𝒉 
The 𝐴𝑈𝐶0−12ℎ of the in vitro release profiles and the in vivo simulated profile 
(obtained from the developed PK model) are presented in Table 4.9.  
Table 4.9. Statistical analysis for the comparison of in vitro 𝐴𝑈𝐶0−12ℎ (from the 
sample and separate and continuous flow setups) and in vivo simulated 
𝐴𝑈𝐶0−12ℎ(𝐴𝑈𝐶0−12ℎ = 165.18 ± 11.49 %AmB*h) [LA: low agitation, HA: high 
agitation, LV: low velocity, MV: medium velocity, HV: high velocity] (Mean ± SD; 









PBS 4.0 LA 0.70 80.20 - 138.51 
KRB 4.0 LA 0.81 77.03 - 122.87 
PBS 4.0 HA 0.65 85.87 - 127.55 
KRB 4.0 HA 0.09 79.65 - 99.27 
KRB 4.0 LV < 0.05 206.96 - 251.27 
KRB 4.0 HV < 0.05 186.82 - 320.08 
PBS SLS 1.4 mM 0.0 MV < 0.05 176.82 - 382.93 
PBS SLS 1.4 mM 0.0 HV < 0.05 323.96 - 534.58 
 
Simulated %AmB 𝐴𝑈𝐶0−12ℎ was 165.18 ± 11.49 (%AmB*h) for healthy subjects. 
The t-tests results show that for healthy subjects, the in vitro 𝐴𝑈𝐶0−12ℎ calculated 
from the %AmB released profiles obtained in media with BSA 4.0% w/v with the 
sample and separate setup were statistically similar to the in vivo 𝐴𝑈𝐶0−12ℎ. Despite 
the fact that the t-test comparisons show that some results were statistically similar, if 
the 90% CI are compared against the usual bioequivalence interval (80% - 125%) [41], 
all the 90% CI from sample and separate setup with BSA 4.0% w/v, either the lower 
or upper bound was between 80 - 125% which leave the test as inconclusive but with 




There is a lack of guidance for in vitro release of parenteral formulations. In this work, 
factors including medium components and hydrodynamics were tested to understand 
how they affect drug release from a liposomal formulation for intravenous 
administration (Ambisome®). For hydrodynamics, in both setups tested (sample and 
separate and continuous flow), an increase in the agitation/velocity resulted in 
significant increase of AmB release. The characterization of drug release from 
liposomes after the direct contact of synthetic surfactants with the liposomes (sample 
and separate method) is not possible due to fast disruption of the liposomes. The use 
of the dialysis membrane in the continuous flow setup could overcome this issue and 
allows the use of simple media with synthetic surfactants for the characterization of 
release from these formulations. The presence of proteins (BSA) is a critical factor on 
release of drugs with high protein binding (as AmB) with an increasing protein 
concentration leading to a decrease of drug release. A novel approach for the 
estimation of the in vivo release rate constant from liposomes was developed through 
PK modeling. An in vitro- in vivo relation was developed, with 𝐴𝑈𝐶0−12ℎ of in vitro 
release profiles in media with BSA 4.0% w/v with the sample and separate setup being 
statistically similar to the in vivo calculated 𝐴𝑈𝐶0−12ℎ. Establishing an in vitro- in vivo 
relation by using clinically relevant release testing and PK modeling is of high 
importance in order to make more efficient the development and the quality 
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Chapter 5: In vitro in vivo correlation for the parenteral 
liposomal formulation of Amphotericin B: Part 2: A clinically 
relevant approach with PBPK modeling 
Abstract 
In vitro release testing is a useful tool for the quality control of controlled release 
parenteral formulations, but in vitro release test which conditions that reflect or are 
able to predict the in vivo performance are advantageous. Therefore, it is important to 
investigate the factors that could affect drug release from formulations and relate them 
to the in vivo performance. In this study the effect media composition including the 
albumin presence, type of buffer and hydrodynamics (sample and separate and 
continuous flow setup) on drug release were evaluated on a liposomal Amphotericin 
B formulation (Ambisome®). A pharmacokinetic physiologically based (PBPK) 
model was developed using plasma concentration profiles from healthy subjects, in 
order to investigate the impact of each variable from the in vitro release tests on the 
prediction of the in vivo performance. It was found that albumin presence was the most 
important factor for the release of Amphotericin B from Ambisome®; both 
hydrodynamics setups (coupled with the PBPK model) gave the same degree of 
prediction of simulate the in vivo plasma concentration profiles. The PBPK model was 
extrapolated to a hypoalbuminaemic population and the Amphotericin B plasma 
concentration and its activity against fungal cells was simulated. The development of 
in vitro release tests for controlled release parenteral formulations able to predict their 
in vivo behaviour could be beneficial for the formulation development of and to assure 
the good in vivo performance of these formulations.  
 
Keywords: 







A clinically relevant in vitro release test is defined as the implication of a link between 
the in vitro release and the in vivo performance [1]. In order to establish a clinically 
relevant test, it is important to understand how the test conditions (media composition 
and hydrodynamics) affect the in vitro release from the formulation. In some cases, 
the information obtained from the in vitro release tests, is not enough to explain the in 
vivo behaviour of the formulation and the released drug and a mechanistic 
understanding of the in vivo performance is required [2]. This can be achieved by the 
use of physiologically based pharmacokinetic modeling (PBPK). The general concept 
of PBPK modeling is to mathematically describe relevant physiological, 
physicochemical, and biochemical processes that determine the pharmacokinetic 
behaviour of a compound [3-5]. PBPK modeling and simulation are currently a 
trending tendency and commercial software are available (for example, Gastro- Plus®, 
simCYP® or PK-Sim® [6]). PBPK modeling is now accepted by regulatory agencies 
[7]. The FDA have published the “Physiologically Based Pharmacokinetic Analyses 
— Format and Content (Guidance for Industry) [8]” and the EMA the “Guideline on 
the qualification and reporting of physiologically based pharmacokinetic (PBPK) 
modelling and simulation [9]”. A PBPK model can be developed considering 4 stages: 
i) setting the model equations to represent the system, ii) input data to the model; iii) 
perform the simulation, and iv) model validation (observed vs simulated data, 
parameter sensitivity analysis) [2]. A sensitivity analysis allows the identification of 
the parameters that have the greatest influence on the simulation [10, 11]. A 
biopredictive release method consists of in vitro release testing conditions that coupled 
with a mathematical modeling, are capable of predicting in vivo pharmacokinetic 
profiles [1]. The PBPK modeling could be extrapolated to simulate diseased 
populations, e.g., hypoalbuminaemic patients (plasma albumin < 25 g/L [12]), in order 
to investigate the pharmacodynamics (PD) of the drug [13]. PBPK/PD models 
integrate the movement of the drug in the body with its pharmacological activity [13]. 
In antimicrobial therapy, the pharmacological effect is the activity against infectious 
agent [14-16]. If a PBPK/PD model is used to evaluate the antimicrobial activity, the 
microbial killing is considered to be dependent on the PK profile of antimicrobial 
concentration in plasma [10, 17]. Amphotericin B (AmB) is a poorly soluble highly 
protein bound drug which is the drug of choice for the treatment of severe systemic 
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fungal disease (e.g. Candida sp., Aspergillus sp. [18, 19]) and is commerically 
available as parenteral lipid formulations (including the liposomal formulation 
Ambisome®) for intravenous administration. The development of PBPK models for 
Amphotericin B in mice and rats after the administration of Fungizone® (colloidal 
AmB) and Ambisome® have been reported [20, 21], which showed good predictive 
performance after being extrapolated to humans. For PBPK modeling of Ambisome®, 
the uptake of particles by macrophage cells in organs like the liver and spleen, were 
taken into account by using a saturable model. When this model was developed, the 
authors reported that there was no in vitro AmB release data available and they fitted 
to the model with a release rate constant of 0.0035 h-1 (in all the tissues) with an initial 
rapid release of the 8% of the dose in humans [20, 21]. AmB is administered as an 
antifungal agent to patients who can be presenting the hypoalbuminaemia condition. 
The aims of this study were i) to investigate how the presence of albumin in clinically 
relevant media containing physiological surfactants (bile salts – phospholipids, 
Category 3a media [Chapter 3]), combined with a biorelevant hydrodynamics model 
[Chapter 4], impact on the release of AmB from Ambisome®; ii) to develop a PBPK 
model to predicted plasma drug concentrations in healthy subjects and iii) coupled 
with the use of the PBPK model, guide the development of a biopredictive release test 
for the liposomal AmB formulation Ambisome® and iv) the extrapolation of the PBPK 
model to a hypoalbuminaemic population to build a PBPK/pharmacodynamics model 
to simulate the pharmacological effect of AmB on fungal cells.  
5.2. Materials and Methods 
5.2.1. Materials 
AmB analytical standard (87.8%), methanol (MeOH) high performance liquid 
chromatography (HPLC) grade, formic acid mass spectrometry grade, Sabouraud 
dextrose (SBD) broth, NaOH, MgCl2, CaCl2, NaHCO3 were obtained from Sigma 
Aldrich (Germany); AmB API powder (85%) from Cayman Chemical (USA); bovine 
serum albumin protease free powder fraction V (BSA), dimethyl sulfoxide (DMSO), 
dextrose, sodium dodecyl sulphate (SLS), Na2HPO4, NaH2PO4, KH2PO4, NaCl and 
KCl from Fisher Scientific (USA); phosphatidylcholine (PL) from egg from Lipoid 
GmbH (Ludwigshafen, Germany); sodium taurocholate (BS) from Prodotti Chimici e 
Alimentaria (Italy); Sabouraud dextrose (SBD) agar was obtained from Oxoid (UK), 
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25 mL sterile universal culture tubes were obtained from Sterilin Thermo Scientific 
(UK); 10 μL plastic loops from Microspec (UK); GF/D (pore size 2.7 μm, 25 mm 
diameter) and GF/F (pore size 0.7 μm, 25 mm diameter) filters from Whatman (UK); 
regenerated cellulose (RC) filters 0.45 µm 13 mm diameter from Cronus (UK); 
cellulose ester dialysis tubing of 300 kDa MWCO from Spectrum Labs (USA), C18 
Sep – Pak® Vac 3cc (500 mg) solid phase extraction (SPE) column from Waters (USA) 
and Ambisome® liposomal AmB formulation from Gilead (Gilead, UK). 
5.2.2. Sample treatment of AmB in release media 
The sample treatment of AmB was described previously [Chapter 4]. Briefly, the SPE 
method to separate "liposomal AmB" (AmB still entrapped in the liposome) from 
"released AmB" (AmB released from the liposome) was modified from Egger et al 
[22]. The SPE column was conditioned with methanol, followed by water. 1.0 mL of 
sample was passed through the column and the eluate is collected in a clean vial 
(liposomal AmB), the column was washed with 2.0 mL of water and collected in the 
same tube. 1.0 mL of methanol was flushed through the column to elute the AmB 
retained in the column (released AmB). In the case of samples with proteins, proteins 
were precipitated by adding 2 volumes of methanol to 1 volume of the sample 
followed by mixing in a vortex mixer, then centrifuged for 10 minutes at 12000 rpm 
and 5°C. The supernatant was filtered through a 0.45 μm RC filter before injection to 
the HPLC. 
5.2.3. Chromatographic conditions for the analysis of AmB from release media 
The chromatographic method to quantify AmB was described previously [23]. Briefly, 
AmB was quantified by HPLC analysis using a Hewlett Packard Series 1100 equipped 
with an auto sampler, temperature regulated column compartment, quaternary pump 
and diode array detector (DAD detector) (Agilent Technologies). The column was a 
C18 Waters Sunfire Column (Ireland) 150 x 46 mm 5 μm. The temperature of the 
column compartment was set at 25°C. The mobile phase consisted of formate buffer 
50 mM pH = 3.2: MeOH (27.5:72.5, v/v); the flow rate was 1 mL/min and analysis 
was performed with the DAD detector at λ = 406 nm. The UV spectrum was recorded 
from 300 to 450 nm. Quantification of AmB in samples was made based on calibration 
curves. Freshly prepared standard solutions (0.5 – 15 μg/mL) in the corresponding 
medium were prepared by appropriate dilution of a 500 μg/mL stock solution of AmB 
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analytical standard in 1:1 MeOH: DMSO v/v. The limit of detection and the limit of 
quantification were 0.12 and 0.37 μg/mL, respectively.  
5.2.4. In vitro release studies of AmB from Ambisome®  
The factors investigated for the development of the in vitro release studies were: i. the 
composition of the clinically relevant media with biorelevant surfactants (AmB 
solubility value in the media as the one observed in plasma from healthy subjects 
[Chapter 3]): type of buffer, BSA concentration and synthetic surfactants 
concentration, and ii. the hydrodynamic conditions in terms of the apparatus used i.e. 
sample and separate (bottle/stirrer) or continuous flow (flow through cell apparatus).  
Media composition was PBS BS 19.8 mM PL 7.9 mM and KRB BS 20.0 mM PL 4.0 
mM. Media preparation was previously described [Chapter 3]. Briefly, BS were 
weighed and dissolved in buffer and then PL from a stock solution of 100 mg/mL in 
dichloromethane were added. Organic solvents were evaporated with a rotary 
evaporator set at 40°C and attached to a vacuum pump. The pressure was decreased 
from 650 mbar by steps of 70 mbar every two minutes to 100 mbar, where the pressure 
was maintained for 10 minutes. If BSA was part of the medium, it was added after the 
evaporation of the organic solvents. 
5.2.4.1. Sample and separate method (bottle/stirrer setup) 
The sample and separate method was described previously [Chapter 4]. Briefly, 
Ambisome® powder (0.5 mg AmB) was placed into a 100 mL glass bottle with 30 mL 
of release medium and stirrer with a magnetic stirrer at 37°C. Release studies were 
performed based on a two level factorial design of experiments (DoE) (section 5.2.9). 
The composition of release media and agitation conditions are shown in Table 5.1, the 









Table 5.1. Levels and factors investigated with the sample and separate setup for the 
release studies of AmB from Ambisome® in clinically relevant media (category 3a 
media [Chapter 3]) 
Level BSA %w/v Buffer Agitation (rpm) 
- 1 2.0 PBS 130 (Low Agitation) 
+ 1 4.0 KRB 380 (High Agitation) 
 
The agitation rates in the bottle/stirrer setup were selected based on the linear velocity 
of the stirrer edge, which at 130 rpm (10.2 cm/s, low agitation) is comparable to the 
veins and at 380 rpm (29.5 cm/s, high agitation) to the aorta [Chapter 4]. Sampling 
times were 1, 2, 4, 6, 8, and 12 h and after sample treatment (SPE and protein 
precipitation; section 5.2.3), samples were injected to the HPLC and AmB 
concentration in the samples was calculated. All experiments were performed in 
triplicate.  
5.2.4.2. Continuous flow (flow through cell apparatus) 
The flow-through apparatus studies were described previously [Chapter 4]. Briefly, 
AmB release studies were carried out in a flow-through dissolution apparatus (Sotax 
CE7 smart connected to a Sotax piston pump CP7, Sotax, Aesch Switzerland) operated 
in the closed mode [24]. A 5mm ruby glass bead was positioned at the bottom of the 
cell (large cell: 22.6 mm diameter). The dialysis membrane was placed into the flow 
through cell apparatus dialysis adapter and Ambisome® powder (0.5 mg AmB) was 
placed into the membrane with 1 mL of the release medium. Glass fibre filters (GF/D, 
GF/F) were positioned at the top of the cell. The release studies were based on a two 
level factorial DoE, where the velocity [low velocity: 8 mL/min, high velocity: 35 
mL/min; at 8 mL/min, has linear velocity comparable to capillary linear velocities and 
at 35 mL/min, a flow rate comparable to the coronary artery [Chapter 4] and BSA 
presence (4.0% w/v) or not were the factors investigated. 36 mL of release medium 
were used in order to simulate the equivalent volume available on administration of 1 





5.2.5. Release data treatment 
The release data treatment was described previously [Chapter 4].  
Briefly, for the studies with the sample and separate method, %AmB released over 
time was calculated based on the percent of AmB still entrapped in the liposomes at 
the time of sampling (%𝐴𝑚𝐵𝑙𝑖𝑝𝑜𝑠𝑜𝑚𝑎𝑙) (Equation 5.1) to construct the calculated 
%𝐴𝑚𝐵𝑟𝑒𝑙𝑒𝑎𝑠𝑒𝑑 profile.%𝐴𝑚𝐵𝑟𝑒𝑙𝑒𝑎𝑠𝑒𝑑 = %𝐴𝑚𝐵𝑖𝑛𝑖𝑡𝑖𝑎𝑙 − %𝐴𝑚𝐵𝑙𝑖𝑝𝑜𝑠𝑜𝑚𝑎𝑙  
 (Equation 5.1)  
where %𝐴𝑚𝐵𝑖𝑛𝑖𝑡𝑖𝑎𝑙 is the mass of AmB placed into the reservoir initially (100%) and 
%𝐴𝑚𝐵𝑟𝑒𝑙𝑒𝑎𝑠𝑒𝑑 is the calculated AmB percent released. There was no correction for 
degradation for these profiles as the AmB still in the liposome cannot be subject of 
degradation. 
For the studies with the continuous flow setup the %𝐴𝑚𝐵𝑟𝑒𝑙𝑒𝑎𝑠𝑒𝑑(𝑜𝑏𝑠) over time was 
corrected for degradation using Equation 5.2 to construct the calculated 
%𝐴𝑚𝐵𝑟𝑒𝑙𝑒𝑎𝑠𝑒𝑑 profile. 
%𝐴𝑚𝐵𝑟𝑒𝑙𝑒𝑎𝑠𝑒𝑑 =  %𝐴𝑚𝐵𝑟𝑒𝑙𝑒𝑎𝑠𝑒𝑑(𝑜𝑏𝑠) + 𝑘𝑑𝑒𝑔 ∗ 𝐴𝑈𝐶0−𝑡  (Equation 5.2)  
where %𝐴𝑚𝐵𝑟𝑒𝑙𝑒𝑎𝑠𝑒𝑑 is the corrected AmB percent released accounting for 
degradation, %𝐴𝑚𝐵𝑟𝑒𝑙𝑒𝑎𝑠𝑒𝑑(𝑜𝑏𝑠) is the AmB percent released at time t, 𝐴𝑈𝐶0−𝑡 is the 
Area Under the Curve of the observed concentration – time curve from time 0 to time 
𝑡 and 𝑘𝑑𝑒𝑔 is the degradation rate constant obtained from the degradation experiments 
[Chapter 3]. 
AmB release rate constant (𝑘𝑟𝑒𝑙) from Ambisome
® was obtained from first order 
fitting of calculated %𝐴𝑚𝐵𝑟𝑒𝑙𝑒𝑎𝑠𝑒𝑑 individual profiles (Equation 5.3) and mean and 
standard deviation values were calculated (GraphPad Prism 7, GraphPad Software, 
Inc, USA). 
%𝐴𝑚𝐵𝑟𝑒𝑙𝑒𝑎𝑠𝑒𝑑 = %𝐴𝑚𝐵𝑟𝑒𝑙𝑒𝑎𝑠𝑒𝑑𝑚𝑎𝑥 ∗ (1 − 𝑒
−𝑘𝑟𝑒𝑙𝑡) (Equation 5.3),  





5.2.6. Atomic Force Microscopy (AFM) studies 
To further investigate the effect of the clinically relevant media components (BS, PL 
and BSA) on the liposomes, AFM studies were performed. The AFM studies’ 
methodology has been described previously [Chapter 4]. Ambisome® liposomes were 
incubated in KRB BS 20.0mM PL 4.0 mM BSA 4.0% w/v (for 30 minutes) and in 
KRB BS 20.0mM PL 4.0 mM (for 5 minutes; a shorter period of incubation was set in 
order to reflect the fast release of AmB from the liposomes observed in the absence of 
BSA). After the incubation time, samples were centrifuged for 30 minutes at 13300 
rpm in an Eppendorf centrifuge, the supernatant was discarded and the pellet was dried 
under vacuum. The pellets were diluted with 1 mL of HPLC water, and then 10 µL of 
the lipid solution was placed on a freshly cleaved mica surface (1.5 cm × 1.5 cm; 
G250-2 Mica sheets 1″ × 1″ × 0.006″; Agar Scientific Ltd., Essex, UK). The sample 
was then air-dried for ∼30 min and imaged immediately by scanning the mica surface 
in air under ambient conditions using a Bruker MultiMode 8 Scanning Probe 
Microscope (Digital Instruments, Santa Barbara, CA, USA) operated on Peak Force 
QNM mode. The AFM measurements were obtained using ScanAsyst-air probes; the 
spring constant was calibrated by thermal tune (Nominal 0.4 N m−1) and the deflection 
sensitivity calibrated using a silica wafer. AFM scans were acquired at a resolution of 
512 × 512 pixels at scan rate of 1 Hz, and produced topographic images of the samples 
in which the brightness of features increases as a function of height. The surface 
roughness (Ra) of each substrate was determined by using Nanoscope Analysis’ 
algorithm to analyse several scans of the surface from different locations (n = 20). 
AFM images were collected from random spot surface sampling (at least four areas).  
5.2.7. PBPK modeling for Ambisome® administration to healthy subjects 
5.2.7.1 Data for PBPK modeling.  
Published data of plasma concentration profiles from a population of 5 healthy 
subjects (4 males, 1 female; ages from 33 to 65 years; height from 1.61 to 1.68 m; and 
weight from 68 to 86 kg) infused for 2 h with 2.0 mg/kg of Ambisome® where the 
"liposomal AmB" and "released AmB" were quantified [25, 26], were digitalized with 
Webplot digitalizer 3.8 software. 
"Liposomal AmB" and "released AmB" distribution, clearance, protein binding; and 
physicochemical properties are shown in Table 5.2. 
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Table 5.2. PK-Sim model set up: physicochemical properties, distribution and clearance parameters of "released AmB" and "liposomal AmB" 
(Ambisome®) after administration to healthy subjects. 
"Released AmB" 
Molecular weight (g/mol) 924 [27, 28] 
log P 0.80 [27], 0.94 [29], 1.84[29], 2.14 [29]  
clog P - 2.33 [27], - 0.66 [27], 1.16 [30] 
pka acidic 5.5 [28], basic 10.0 [28] 
Solubility at pH = 7 0.09 µg/mL [31], 1.38 µg/mL [32], 6.00 µg/mL [33] 
fraction unbound (albumin) 0.05 [26] 
Distribution volume 2340 ± 202 mL/kg [25] 
Cl renal 0.07 ± 0.01 mL/min/kg [25]. GFR fraction = 0.875 
Cl biliary 0.09 ± 0.02 mL/min/kg [25]. kbil = 0.002 h
-1 
Binding partners 
alfa 1 acid glycoprotein (AAG1), EST expression [25], kdiss = 1.07 – 2.44 x 10
-6 M-1  (approximation from 
unbound fraction) [25] 
beta lipoprotein (APOB), EST expression, kdiss = 4 x 10





Distribution volume 1628 ± 876 mL/kg [25] 
Cl renal 0.01 ± 0.00 mL/min/kg [25], GFR fraction = 0.125 
Cl biliary 0.01 ± 0.00 mL/min/kg [25], kbil = 0.0003 h
-1 
Assumptions for the model, considering the "liposomal AmB" as a molecule 
Molecular weight (g/mol) 924 
Radius (solute) 80 nm [35] 
log P Parameter to identify, starting value 0.8 
pka Neutral 
Solubility at pH = 7 
290 mg/mL [calculated from the total amount of powder in a formulation vial (14.5 g), dissolved in 50 mL 
of water] 




Metabolizing enzymes -> Intrinsic clearance First order ->  
Relative expression -> Intracellular -> Endosomal     
                                                Plasma    100% 
    Liver periportal  100% 
    Liver pericentral             100% 




The PK parameters (distribution, clearance and protein binding) for "released AmB", 
were the ones reported after the administration of the colloidal AmB formulation 
Fungizone® as reported by Kagan et al [21] (Table 5.2). Protein binding is 
characterized by kdiss (equilibrium dissociation constant). The nominal glomerular 
filtration rate (GFR) for AmB is 0.08 mL/min/kg as calculated with equation 5.4, 
based on a fraction unbound to albumin of 0.05. This value was used to calculate the 
GFR fraction for the "liposomal AmB" and "released AmB". 
𝑁𝑜𝑚𝑖𝑚𝑎𝑙 𝐺𝐹𝑅 =  𝑓𝑟𝑎𝑐𝑡𝑖𝑜𝑛 𝑢𝑛𝑏𝑜𝑢𝑛𝑑 (𝑎𝑙𝑏𝑢𝑚𝑖𝑛) ∗ (120 𝑚𝐿/𝑚𝑖𝑛) ∗ (1/73 𝑘𝑔)
 Eq 5.4. 
Elimination rate constant of biliary elimination was calculated using Eq 5.5. 
𝑘𝑏𝑖𝑙 = (𝐶𝑙𝑏𝑖𝑙𝑖𝑎𝑟𝑦/𝑑𝑖𝑠𝑡𝑟𝑖𝑏𝑢𝑡𝑢𝑖𝑜𝑛 𝑣𝑜𝑙𝑢𝑚𝑒)(60 𝑚𝑖𝑛/1 ℎ) Eq 5.5. 
For the development of the model, "liposomal AmB" was assumed to behave as a 
molecule as the concentration of AmB is what is quantified in the in vivo studies and 
not the concentration or amount of liposomes. 
An "immune" enzyme was added for the "liposomal AmB" to account for the removal 
of circulation of the "liposomal AmB" by the macrophages of the immune system. The 
enzyme was set to be located in the plasma, liver and spleen. The fraction unbound 
value for the "liposomal AmB" was hypothesized to be smaller than 0.95 based on the 
reported interaction between albumin and liposomes [36-38]. All the other parameters 
were left as software's default values.  
5.2.7.2. Workflow for PBPK modeling for Ambisome® administration to healthy 
subjects 
The workflow for the PBPK modeling to describe the pharmacokinetics of "liposomal 
AmB" and "released AmB" in a healthy individual after the administration of the 





Figure 5.1. Workflow for the PBPK modeling of "liposomal AmB" and "released AmB" after the administration of Ambisome® to healthy subjects. 
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PBPK modeling was performed with PKSim® 7.2.1 (Bayer, Germany) and MoBi® 7.2 
(Bayer, Germany). The five parameters listed in Figure 5.1 were optimized 
simultaneously with the MoBi® built in function "Parameter identification" using an 
algorithm based on Monte Carlo methods and the default software setup (the 
Parameter identification tool varies selected input parameters in a given range to 
identify the best values to obtain output simulated curves similar to the observed 
curves). The in vivo release of AmB from liposome was set to occur only in plasma 
(𝑘𝑟𝑒𝑙−𝑖𝑣.only in plasma of venous blood). 
Comparing the developed PBPK model in this study with the one reported by Kagan 
et al [21], there were some differences: i) this model was developed in order to link 
the in vitro release data to the observed plasma concentration data while Kagan and 
coworkers developed their model to have a better understanding of AmB PK in order 
to improve the dosing; ii) the release of AmB took place in all of the compartments 
[21] while in this study, the release was only in plasma. 
Sensitivity analysis was performed on all the parameters of the model (PK data and 
physicochemical properties of "liposomal AmB" and "released AmB") except for the 
molecular weight and the pka values of "released AmB". The parameters and the range 
















Table 5.3. Parameters and the range in which the parameters were investigated in the 
sensitivity analysis of the validated PBPK model of Ambisome® administration. 
Parameter Abbreviation Interval tested 
log P ("liposomal AmB") logP (lip) 0 – 2 (log units) 
log P ("released AmB") logP (rel) 2.24 – 4.24 (log units) 
Aqueous solubility ("liposomal 
AmB") 
Sol (lip) 
90 – 490 (μg/mL) 
Aqueous solubility ("released 
AmB") 
Sol (rel) 
0.01 – 6.00 (μg/mL)  
Radius solute ("liposomal AmB") Rad (lip) 40 – 120 (nm) 
Specific biliary clearance 
("liposomal AmB") 
Bil (lip) 
0.0001 – 0.0005 (h–1) 
Specific biliary clearance 
("released AmB") 
Bil (rel) 
0.001 – 0.003 (h–1) 
GFR ("liposomal AmB") GFR (lip) 0 – 1 (fraction) 
GFR ("released AmB") GFR (rel) 0 – 1 (fraction) 
"Immune enzyme" specific 
clearance 
Imm 
1.57 – 3.57 (h–1) 
APOB1 𝑘𝑑𝑖𝑠𝑠 APOB1 2 – 6 (μmol/L) 
AAG1 𝑘𝑑𝑖𝑠𝑠 AAG1 0.21 – 0.63 (μmol/L) 
𝑘𝑟𝑒𝑙−𝑖𝑣 krel 0.114 - 3.539 (h
–1) 
Unbound fraction ("liposomal 
AmB") 
fU (lip) 
0.05 – 0.95 (fraction) 
Unbound fraction ("released 
AmB") 
fU (rel) 




The range were selected as follows: logP of "liposomal AmB" and "released AmB": ± 
1 log unit of the optimized value, immune enzyme of "liposomal AmB": ± 1 h–1 of the 
optimized value, aqueous solubility of "released AmB": the range was selected to 
cover the solubility values reported in the literature [31, 33], aqueous solubility of 
"liposomal AmB": ± 200 µg/mL in order to cover a wide range as the value was based 
on an assumption (Table 5.2); for radius solute ("liposomal AmB"), biliary clearance 
("liposomal AmB" and "released AmB"), 𝑘𝑑𝑖𝑠𝑠 of APOB and AAG1 the interval was 
± 50% of the literature value (Table 5.2 and 5.3). GFR fraction ("liposomal AmB" and 
"released AmB") was investigated from 0 to 1; and the unbound to protein fraction 
("liposomal AmB" and "released AmB") from 0.05 to 0.95. 𝑘𝑟𝑒𝑙−𝑖𝑣 was investigated 
in the interval of the 𝑘𝑟𝑒𝑙 found in the in vitro tests (Table 5.3). 𝐴𝑈𝐶0−24ℎ of both 
liposomal and released AmB was used as response to evaluate the effect of the 
parameters investigated. Sensitivity analysis was performed with the MoBi Toolbox 
for R esqLABS version 7.2.1 (esq LABS, Germany). All the intervals tested, were 
normalized to 0 – 1 for clarity of presentation. 
After the sensitivity analysis, the model was applied to the population described in 
section 5.2.7.1. The variability (standard deviation) for the parameters input into the 
model was as described in Table 5.2. As the values of 𝑘𝑟𝑒𝑙−𝑖𝑣 and specific clearance 
for the immune removal "enzyme" were obtained by parameter identification and there 
are no reported values for their variability, 20% of the identified value was used as 
standard deviation. 
5.2.7.3. Evaluation of the in vitro tests using PBPK modeling 
The in vitro 𝑘𝑟𝑒𝑙 (Mean ± SD) obtained from the in vitro release profiles of AmB from 
Ambisome® were input to the validated PBPK model in order to predict the observed 
in vivo AmB ("liposomal AmB" and "released AmB") plasma concentration profiles. 
The 𝐴𝑈𝐶0−24ℎ was calculated from the predicted "liposomal AmB" and "released 
AmB" plasma concentration profiles 
5.2.8. PBPK-PD model for the pharmacological activity of AmB against Candida 
albicans 
The effect of AmB on Candida albicans (C. albicans) was investigated in order to 
develop a PBPK-PD model: i. for a patient population receiving Ambisome® with a 
reduced albumin plasma concentration (hypalbuminaemia: albumin < 25 mg/mL), and 
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ii. for a healthy population receiving Ambisome® with normal concentration of 
albumin. 
5.2.8.1. Quantification of C. albicans 
The culture and quantification of C. albicans was described previously [23]. A single 
colony culture was started in a tube with 5 mL of SBD broth and incubated overnight 
at 37°C in a shaking incubator; the optical density was measured at 600 nm (OD600). 
The colony forming units (CFU) were determined by preparing serial dilutions and the 
suspensions were plated on SBD agar plates, incubated overnight at 37°C; the number 
of colonies were counted and related to the OD600 of the culture. 
5.2.8.2. Time killing experiments 
Time killing experiments were performed with 105 CFU/mL of C. albicans using 
different AmB final concentrations (0.00, 0.75, 1.50 and 3.00 µg/mL) in the presence 
of BSA 2.0% and 4.0% w/v in KRB. The percent of CFUs remaining at each time 
point were used for curve fitting to the exponential decay equation to obtain the killing 
rate constant for each concentration tested (Eq 5.6).  
%𝐶𝐹𝑈 = %𝐶𝐹𝑈𝑚𝑎𝑥 ∗ 𝑒
−𝑘𝑘𝑖𝑙𝑙𝑡 Eq 5.6. 
where %𝐶𝐹𝑈 are the percent of CFU at time t, %𝐶𝐹𝑈𝑚𝑎𝑥 is the maximum percent of 
CFU, 𝑘𝑘𝑖𝑙𝑙 is the time killing rate constant and 𝑡 is time. 
A linear relation was found between 𝑘𝑘𝑖𝑙𝑙 and AmB concentration and it was used in 
the PBPK-PD model. 
5.2.8.3 PBPK-PD modeling 




Figure 5.2. Workflow for the PBPK-PD modeling of the liposomal and released AmB 
after the administration of Ambisome® l to a hypoalbuminaemic population in order 
to simulate the pharmacological activity of the released AmB on C. albicans. 
To simulate the patient population (hypoalbuminaemic), the protein content was 
halved in the validated PBPK model for the healthy subject and the rest of the 
parameters remained unchanged. The "released AmB" concentration was used to 
calculate the 𝑘𝑘𝑖𝑙𝑙 for the 24 h time course to simulate the "released AmB" activity 
against C. albicans which was set to be at a concentration of 105 CFU/mL at time zero. 
The C. albicans rate growth constant (𝑘𝑔𝑟𝑜𝑤𝑡ℎ) was obtained from the control time 
killing experiment (0.00 µg/mL AmB). 
5.2.9. Statistical analysis 
The statistical analysis was described previously [Chapter 4]. Pareto charts, based on 
the DoE analysis, were performed for the identification of significant effects from the 
in vitro release tests. A factor was significant when the standardized effect (bars) was 
larger than the line for statistical significance level (α = 0.05) (vertical line). An 
independent means t – test was performed to compare 2 independent means: in the 
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AFM studies, size and surface roughness were compared against the control sample. 
A p<0.05 was considered statistically significant. Due to the lack of individual 
observed data of plasma concentration profiles, the PK parameters obtained with the 
in vitro 𝑘𝑟𝑒𝑙 were compared against the PK parameters obtained from the simulation 
of the PBPK validated model. 
Additionally, the 90% confidence interval (90% CI) for the ratio of the averages of the 
measures for the observed in vitro and predicted in vivo ln𝐴𝑈𝐶0−24ℎ were calculated. 
As recommended by the FDA guidance, both "liposomal AmB" and "released AmB" 
were evaluated [39]. Data analysis, creation and analysis of DoE were performed with 
the statistical software Statgraphics Centurion XVII (USA) and the 90% CI were 
calculated with IBM SPSS Statistics 25 (USA).  
5.3. Results and discussion 
5.3.1. In vitro release testing of Ambisome® in category 3a media 
In vitro release profiles of AmB from Ambisome® in both hydrodynamic setups are 
shown in Figure 5.3 and parameters obtained after fitting to the first order equation 





Figure 5.3. %AmB released with the a) sample and separate and the b) continuous 
flow setup at 37 °C to investigate the effect of the type of buffer, the BSA 4.0% w/v 
presence and the hydrodynamics in clinically relevant media with BS – PL. (Mean ± 




Table 5.4. Parameters obtained after fitting (Equation 5.3) of %AmB released profiles from Ambisome® with the sample and separate setup and 




Surfactant concentrations Agitation/velocity 𝒌𝒓𝒆𝒍 (h
-1
) %𝑨𝒎𝑩𝒓𝒆𝒍𝒆𝒂𝒔𝒆𝒅𝒎𝒂𝒙 
Sample and separate 
PBS 0.0 BS 19.8 mM PL 7.9 mM LA 1.425 ± 0.101 96.258 ± 0.101 
PBS 4.0 BS 19.8 mM PL 7.9 mM LA 0.701 ± 0.060 78.573 ± 2.548 
KRB 0.0 BS 20.0 mM PL 4.0 mM LA 3.034 ± 0.106 99.201 ± 0.321 
KRB 4.0 BS 20.0 mM PL 4.0 mM LA 0.621 ± 0.192 81.662 ± 2.931 
PBS 0.0 BS 19.8 mM PL 7.9 mM HA 2.437 ± 0.129 98.953 ± 0.158 
PBS 4.0 BS 19.8 mM PL 7.9 mM HA 0.410 ± 0.052 73.031 ± 6.013 
KRB 0.0 BS 20.0 mM PL 4.0 mM HA 2.747 ± 0.046 99.146 ± 0.072 
KRB 4.0 BS 20.0 mM PL 4.0 mM HA 0.896 ± 0.041 88.141 ± 2.480 
Continuous flow 
KRB 0.0 BS 20.0 mM PL 4.0 mM LV 0.305 ± 0.071 49.181 ± 17.119 
168 
 
KRB 4.0 BS 20.0 mM PL 4.0 mM LV 0.467 ± 0.162 43.101 ± 10.563 
KRB 0.0 BS 20.0 mM PL 4.0 mM HV 1.364 ± 1.890 60.416 ± 4.593 




For the sample and separate setup, the statistical analysis (Figure 5.4a) showed that 
the buffer was a significant factor on %𝐴𝑚𝐵𝑟𝑒𝑙𝑒𝑎𝑠𝑒𝑑𝑚𝑎𝑥 with a higher release in 
KRB, the presence of BSA 4.0% w/v had a significant negative effect and the 
interaction between buffer and BSA was significant as the amount released in KRB 
with BSA is slightly higher than in PBS with BSA while in media without BSA there 
is no difference. The release rate constant was affected in the same way as 
%𝐴𝑚𝐵𝑟𝑒𝑙𝑒𝑎𝑠𝑒𝑑𝑚𝑎𝑥 but the interaction between buffer and BSA showed that the 
release rate is faster in KRB than in PBS without BSA and there is not a statistical 
significant difference in KRB and PBS with BSA. For the continuous flow setup 
(Figure 5.4b), the flow rate was the only significant factor on AmB release from the 
liposomes, with a positive effect on the 𝐴𝑈𝐶0−12ℎ. 
 
 
Figure 5.4. Pareto charts for the estimated effects of the main factors and 2 level 
interactions of the analysis of a) %𝐴𝑚𝐵𝑟𝑒𝑙𝑒𝑎𝑠𝑒𝑑𝑚𝑎𝑥 and 𝑘𝑟𝑒𝑙 from the sample and 
separate setup and b) the 𝐴𝑈𝐶0−12ℎ from the continuous flow method. A factor was 
significant when the estimated effect (horizontal bars) was larger than the standardized 




5.3.2. AFM studies 
Figure 5.5 shows the images obtained from the AFM and Table 5.5 contains the 
parameters of the liposome characteristics measured with the AFM.  
 
Figure 5.5. AFM images to evaluate the effect of media components on Ambisome® 
liposomes. a ) KRB BS 20.0 mM PL 4.0 mM, b) KRB BS 20.0 mM PL 4.0 mM BSA 
4.0% w/v. The scale bar represents 200 nm. 
 
Diameter and surface roughness of the liposomal structures in samples from KRB BS 
20.0 mM PL 4.0 mM are significantly higher than the control sample; liposomes could 
be merging with each other or the inclusion of BS PL could alter the structure of the 
liposome resulting in a higher size before the disruption. Liposomes were not visible 
in the sample of from KRB BS 20.0 mM PL 4.0 mM BSA 4.0% w/v, probably due to 




Table 5.5. Properties of liposomes obtained from atomic force microscopy from the 
samples prepared in media with BS PL in the presence and absence of BSA. Mean ± 







KRB control (centrifugation/vacuum) 69.4 ± 18.9 12.9 ± 1.6 
KRB BS 20.0 mM PL 4.0 mM 130.0 ± 13.0 10.1 ± 2.7 
KRB BS 20.0 mM PL 4.0 mM BSA 4.0% w/v No Particles 
 
5.3.3. PBPK modeling of Ambisome® administered to healthy subjects 
The simulated plasma concentration profiles obtained with the validated PBPK model 
for the administration of Ambisome® to healthy subjects are shown in Figure 5.6.  
 
Figure 5.6. Observed and simulated (PBPK model) plasma concentration profiles of 
"liposomal AmB" and "released AmB" after the administration of Ambisome® to 
healthy subjects [25, 26].  
 
Using the parameter identification method, the values for the parameters investigated 
were: 𝑘𝑟𝑒𝑙−𝑖𝑣 = 0.60 h
-1, logP (released AmB) = 3.24, logP (liposomal AmB) = 1.0, 
Specific clearance for the immune removal "enzyme" = 2.57 h-1 and AAG1 𝑘𝑑𝑖𝑠𝑠 = 
0.42 µmol/L. The logP and clogP values reported in the literature, are between -2.33 
172 
 
to 2.14 (Table 5.2) providing a wide interval for the actual value. The value obtained 
from parameter identification fitting was 3.24 which could be supported due to the 
dispersion of the values previously reported (Table 5.2). 
The PBPK model described closely the average observed data for "liposomal AmB" 
and "released AmB" (%.𝐴𝑈𝐶0−24ℎ predicted/𝐴𝑈𝐶0−24ℎ observed = 94% and 101%, 
respectively). Comparing the developed PBPK model in this study with the one 
reported by Kagan et al [21], the main difference was the 𝑘𝑟𝑒𝑙−𝑖𝑣 from this model was 
faster: 0.60 h-1 > 0.0035 h-1 [21] and there was no initial rapid release of the 8% of the 
dose. It could be due to that the release of AmB took place in all of the compartments 
[21] while in this study; the release was only in plasma. 
The sensitivity analysis is shown in Figure 5.7.  
 
 
Figure 5.7. Sensitivity analysis of PBPK model parameters on the "liposomal AmB" 
and "released AmB" 𝐴𝑈𝐶0−24ℎ obtained from simulated plasma concentrations in 
healthy subjects. The black line is the 𝐴𝑈𝐶0−24ℎ obtained from the validated PBPK 
model for healthy subjects. 
 
Parameters such as aqueous solubility ("liposomal AmB" and "released AmB"), solute 
radius ("liposomal AmB"), specific biliary clearance ("liposomal AmB" and "released 
AmB"), 𝑘𝑑𝑖𝑠𝑠 for AAG1 and APOB ("released AmB"), and the GFR for "released 
AmB" did not have a significant impact on the 𝐴𝑈𝐶0−24ℎ of "liposomal AmB" and 
"released AmB". For the "liposomal AmB", the fraction unbound to proteins had the 
greatest impact on the model. It can be observed how the "liposomal AmB" in plasma 
decreases as the fraction unbound increases, leading to a decreased on "released 
AmB", as there will be less "liposomal AmB" available in plasma to release drug.  
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𝑘𝑟𝑒𝑙−𝑖𝑣 had a high impact on both "liposomal AmB" and "released AmB" (Figure 5.7), 
with a higher release rate constant leading to an increase of the "released AmB" and a 
decrease of the "liposomal AmB". For "released AmB", logP is the factor with the 
highest effect on  𝐴𝑈𝐶0−24ℎ. 
5.3.4. Evaluation of the in vitro release profiles using the PBPK model 
The predictability of the in vitro release tests is presented in Figure 5.8 for both 
"liposomal AmB" and "released AmB".  
 
Figure 5.8. 𝐴𝑈𝐶0−24ℎ calculated from simulated plasma concentration profiles with 
with the 𝑘𝑟𝑒𝑙 from the in vitro release profiles against the 𝐴𝑈𝐶0−24ℎ obtained from the 
validated PBPK model for "liposomal AmB" and "released AmB". n = 5 subjects for 
each population. 
 
For the "liposomal AmB", the 𝐴𝑈𝐶0−24ℎ obtained with the in vitro release profiles 
where BSA was present in the media were similar to the 𝐴𝑈𝐶0−24ℎ obtained from the 
validated PBPK model, regardless of the type of the buffer or the hydrodynamic 
conditions. The 𝐴𝑈𝐶0−24ℎ values were only similar for a medium without BSA in the 
low velocity setup (Figure 5.8). For the "released AmB", the 𝐴𝑈𝐶0−24ℎ obtained with 
the in vitro release profiles in media with BSA were close to attaining similarity to the 
in vivo profiles, as all the tests (except KRB BS PL BSA low agitation) revealed one 
extreme of the 90% CI between 80 – 125%. It can be noticed that the tests performed 
with the continuous flow setup under-predicted the plasma concentration of the 
"released AmB". An increasing flow rate leads to a higher drug release (Figure 5.4) 
thus further exploration of flow rate effect could be conducted to identify the flow rate 
resulting in release profiles suitable for simulation of in vivo release. The model 
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developed is suitable for the evaluation of the in vitro release tests and could support 
the development of a biopredictive in vitro release test. It has to be noted that for the 
prediction of the plasma concentration of "liposomal AmB" and "released AmB", the 
presence of BSA was a critical factor, thus, information on the exact mechanism of 
the protein binding to the liposomes could further improve the model developed.  
5.3.5. PBPK – PD modeling for the patient (hypoalbuminaemic) population. 
Parameters obtained after fitting to the exponential decay equation model for the time 
killing experiments are presented in Table 5.6.  
Table 5.6. Parameters obtained after fitting (Equation 5.6) of CFU time profiles from 
time killing experiments in KRB BSA 2 and 4% w/v using different concentrations of 






–1) R2 AIC 
2.0 
0.75 105.1 ± 5.23 0.33 ± 0.03 0.86 ± 0.02 52.88 ± 0.3 
1.50 110.65 ± 4.17 0.54 ± 0.03 0.93 ± 0.05 47.16 ± 6.17 
3.00 110.6 ± 5.37 0.77 ± 0.11 0.92 ± 0.05 48.00 ± 6.43 
4.0 
0.75 101.75 ± 4.6 0.11 ± 0.01 0.89 ± 0.01 47.25 ± 2.38 
1.50 123.8 ± 10.04 0.17 ± 0.03 0.84 ± 0.07 54.71 ± 5.18 
3.00 107.65 ± 6.15 0.37 ± 0.01 0.90 ± 0.00 50.27 ± 1.06 
 
The simulated plasma concentration profiles for "liposomal AmB" and "released 
AmB" in the extrapolated hypoalbuminaemic population and the healthy subjects' 
population are presented in Figure 5.9a. It can be observed that both "liposomal AmB" 
and "released AmB" are in a lower concentration as a consequence of the decrease of 
the amount of proteins present. It could be hypothesized that the unbound "liposomal 
AmB" and "released AmB" are distributing to tissues leading to a lower concentration 





Figure 5.9. PBPK-PD model for a hypoalbuminaemic population (plasma protein 
fraction 0.5; healthy subjects: plasma protein fraction 1.0) and its pharmacodynamic 
effect on fungal cells. a) Simulated plasma concentration profiles of "liposomal AmB" 
and "released AmB" from the validated PBPK model for healthy subjects and the 
hypoalbuminaemic population, b) simulation of a dose administered to patients 
receiving Ambisome®, c) simulated 𝑘𝑘𝑖𝑙𝑙 (corresponding to the simulated plasma 
concentration profile of Figure 5.9b), and d) effect of the administration of 
Ambisome® on the growth of Candida albicans. 
 
Figure 5.9b shows the simulated plasma concentration profiles for a typical 
administration of Ambisome® to a patient with a systemic fungal infection (300 mg, 
infusion 4 h) in the simulated hypoalbumianemic patient and in a subject with normal 
albumin levels. A linear relationship between the AmB concentration and the time 
killing rate coefficient was found for experiments with BSA 2.0 and 4.0% w/v, (Eq 
5.7 and eq. 5.8, respectively) and used in the PBPK-PD model to simulate the killing 
of C. albicans (Figure 5.9c). 
𝑡𝑖𝑚𝑒 𝑘𝑖𝑙𝑙𝑖𝑛𝑔 𝑟𝑎𝑡𝑒 𝑐𝑜𝑒𝑓𝑓𝑖𝑐𝑖𝑒𝑛𝑡 (ℎ−1) = 0.1923(𝑚𝐿 ∗ ℎ−1) ⁄ 𝜇𝑔 + 0.2102 ℎ−1  Eq 
5.7. 
𝑡𝑖𝑚𝑒 𝑘𝑖𝑙𝑙𝑖𝑛𝑔 𝑟𝑎𝑡𝑒 𝑐𝑜𝑒𝑓𝑓𝑖𝑐𝑖𝑒𝑛𝑡 (ℎ−1) = 0.1167 (𝑚𝐿 ∗ ℎ−1) ⁄ 𝜇𝑔 + 0.014 ℎ−1  Eq 
5.8. 
It can be observed how the growth of the fungal cells is reduced by the administration 
of Ambisome® (Figure 5.9d) with a higher effect in the simulated hypoalbuminaemic 
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patient than in the subject with normal albumin levels. From the time killing studies 
and previous data [23], a higher fungicidal effect is reached with a lower AmB 
concentration in the presence of BSA 2.0% w/v as there is more unbound drug able to 
exert its pharmacological effect. It has to be noted that only the effect of released AmB 
is evaluated in this PBPK-PD model. The humoral and cellular immune responses and 
the effect that the liposomal AmB could have on C. albicans are not considered. A 
number of 105 CFU/mL were used to simulate the effect of AmB in vivo as this was 
the concentration of the fungal cell suspensions used in the time killing experiments. 
It has been reported that a concentration of 100 – 1000 CFU/mL are found in cultures 
of blood from patients with systemic fungal infection [40, 41]. The PBPK-PD analysis 
could be further improved by using the adequate number of CFU quantified in plasma 
from infected patients to evaluate the response of the humoral immune response and 
not only the effect of the protein content. In plasma from healthy subjects the fungal 
cells did not grow (data not shown), thus, the results of the PBPK-PD model for the 
healthy subject must be only considered as an exercise for comparative purposes. For 
this model, only the changes in the albumin levels were considered, leaving aside the 
physiological characteristics of septic or critically ill patients. In order to improve the 
model, the change in the activity of the immune enzyme should be adjusted to the 
patients' population as the immune system might be compromised, and the  𝑘𝑟𝑒𝑙−𝑖𝑣, 
which the in vitro tests showed to be dependent on the albumin concentration, should 
be adjusted too. This approach reveals the potential of the use of in vitro release data 
and suitable microbiology data in combination with a PBPK-PD model in order to 
guide parenteral formulation development based on pharmacodynamics and 
therapeutic outcomes. 
5.4. Conclusions 
The literature available for in vitro release testing of controlled release parenteral 
formulations is limited. The evaluation of the factors that can affect the release from 
these formulations and the development of in vitro release tests that are able to predict 
the in vivo performance are of high importance. In this work, the development of a 
clinically relevant in vitro release test for the liposomal formulation of AmB 
(Ambisome®) was investigated. A PBPK model was developed for the administration 
of Ambisome® to healthy subjects, which was used to evaluate the critical factors for 
the AmB release from the liposomes and the in vivo predictability of the in vitro release 
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tests. The presence of BSA in the media was the most critical factor on the AmB 
release, and the in vitro release profiles from tests with BSA in the medium were 
biopredictive. Successful predictions of the “liposomal AmB” and the “released 
AmB” plasma concentration profile were obtained with both hydrodynamic setups 
tested (sample and separate method and continuous flow method). A PBPK-PD model 
of the activity of AmB on fungal cells was developed based on the predicted "released 
AmB" plasma concentration profile in a hypoalbuminaemic population in order to 
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Conclusions and future directions 
 
Conclusions 
In vitro release tests are mainly designed to characterize the release of the drug from 
a formulation and hopefully, predict the in vivo behaviour. Currently, for in vitro 
release tests for parenterals, there are no guidelines from the regulatory agencies (FDA 
or EMA) where well defined characteristics and specifications are provided. The 
investigation of the variables that might influence drug release (both release medium 
and hydrodynamics) from these formulations would be the first step in order to 
develop compendial and biopredictive in vitro release tests.  
Towards the development of clinically relevant in vitro release testing for controlled 
released parenteral formulations, three steps were followed: i) development of suitable 
release media, ii) in vitro release testing of a controlled released parenteral formulation 
administered intravenously, and iii) PK and PBPK modeling in order to relate the in 
vitro data with observed in vivo data. 
Media with different albumin (BSA) concentration were developed using KRB 
(Chapter 2). It was found that BSA was a critical factor for the solubility, degradation 
rate constant, dissolution and pharmacological activity of a poorly soluble, highly 
protein bound drug (AmB as model drug) in a concentration dependent manner. The 
importance of incorporating BSA as a medium component for the in vitro release 
testing of these types of drugs in a suitable concentration for the population that is 
attempting to simulate (healthy subjects, hypoalbuminaemic subjects) was revealed. 
After measuring the AmB solubility in plasma (clinically relevant solubility value), 
more complex media were developed. Media with BSA (Chapter 2) and media with 
biorelevant plasma components in biorelevant concentrations were not clinically 
relevant. Clinically relevant media were developed with biorelevant and synthetic 
surfactants. When BSA was added to the media, a decrease on the surfactants' activity 
was observed.  
With the developed media (Chapter 2 and 3), the in vitro release of AmB from a 
liposomal formulation (Ambisome®) was investigated in two setups: sample and 
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separate and continuous flow. It was found that BSA was the most significant factor 
for the release of AmB from Ambisome® liposomes. The presence of BSA was found 
to slow and decrease the in vitro release (Chapter 4 and 5). 
A PK and a PBPK model were developed to characterise the PK of the liposomal and 
released AmB in healthy subjects in order to relate them to the in vitro release profiles 
(Chapter 4 and 5). The in vitro release profiles were linked with the modeling in order 
to predict the in vivo release. An in vitro- in vivo relation was developed, with the in 
vitro release profiles in category 1 media with BSA 4.0% w/v with the sample and 
separate setup. The in vitro release profiles from tests with category 3a media with 
BSA were biopredictive. Successful predictions of the liposomal AmB and the 
released AmB plasma concentration profile were obtained with both hydrodynamic 
setups. 
Summarizing, in this project are presented the steps suggested in order to develop an 
in vitro clinically relevant release test for an intravenous parenteral formulations, 




In this project a clinically relevant in vitro test for a controlled release parenteral 
formulation (intravenously administered) was developed but there were some 
limitations. As this was the first step for the investigation and development of 
clinically relevant media and release testing for these formulations, only the conditions 
of healthy subjects in fasted state with relevant changes of albumin concentration were 
simulated. 
In future studies, the effect of the prandial state on the release from these formulations 
could be explored. The physiological changes that occur after the meal ingestion 
include changes in the composition of plasma (increased concentration of 
phospholipids, bile salts) and increase of the flow rate (increase in the heart beat rate 
leads to increase of the blood flow to the gastrointestinal tract). Based on the findings 
of the current project, alteration of the performance of the formulation in the fed state 
would be expected. 
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The human PK data for this formulation, and in general for the AmB formulations, is 
scarce. Plasma concentration of AmB after administration of an AmB formulation is 
often quantified as total AmB and not as formulation-bound AmB and released AmB; 
this affects the development of an accurate PK or PBPK model. There are studies 
where both species are quantified in patients but the data sets are from only just one 
patient and it could not be used for a robust analysis. The in vitro release profiles in 
the sample and separate setup were successful in predicting the in vivo release. The 
drawback of this setup is that it is not performed in a compendial apparatus and it 
might not be suitable for routinely or quality control analysis. Future experiments 
could be designed in order to translate the hydrodynamics from the bottle/stirrer setup 
to a compendial apparatus (paddle, mini paddle apparatus). 
As BSA plays an important role in the release of drug and interferes with release media 
components, more studies to confirm these interactions are needed. Studies confirming 
the interaction between AmB, surfactants and liposomes with BSA could reveal how 
the interaction takes place and update the in vitro tests. Also, microscopy time-
dependent studies to show the changes in the liposomes occurring during the release 
would be beneficial to understand the mechanism of AmB release from the liposomes. 
The PD model developed was only a demonstration of how the PBPK model could be 
used to predict the PD effect of the released drug. In order to get meaningful in vitro 
data for its incorporation to the model, the tests should be performed simulating 
closely the conditions patients receiving AmB therapy.  
The causes of hypoalbunaemia should be considered for the development of the PBPK 
model. For example, in case of infection, damage to the endothelium could lead to 
leakage of the liposomes to the lymphatic system. In patients with fungal infection, 
oncology patients or patients with a transplant, the response of the immune system 
needs to be taken into account in the model. 
The MIC, MFC and time killing determinations in plasma from patients receiving 
AmB would be more suitable than only using a simulated plasma medium as there are 
more plasma components that could slow or reduce the proliferation of fungal cells. 
Working into more depth in these topics, the in vitro release test would increase their 
prediction capability, the outcome would be improved and their applications 
expanded. 
